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ABSTRACT 
 
 Hydroxyamino acid motifs are well-represented structures in natural products and 
pharmaceuticals, and are widely employed as synthetic building blocks in organic synthesis. In 
nature, such compounds are often synthesized via enzymatic C-H oxidation of simple amino acid 
precursors. Inspired by such processes, small molecule catalysts have been developed to perform 
a variety of C-H oxidation reactions, which have increased the efficiency of synthetic routes and 
allowed for late-stage diversification of complex molecules. This work describes the 
development and application of two transition metal catalyzed C-H oxidation reactions for the 
synthesis and diversification of hydroxyamino acids and related molecules.  
 α-Hydroxy-β-amino acids are an important subclass of the hydroxyamino acid family, 
examples of which are found in pharmaceutical agents including taxol and bestatin. Current 
synthetic methods for the construction of these molecules often rely on the use of pre-oxidized 
fragments or harsh reagents. This work reports the merging of Brønsted acid catalysis with 
Pd(II)/bis-sulfoxide catalyzed allylic C-H oxidation to achieve the synthesis of vinyl-
oxazolidinones from simple homoallylic, N-Boc protected amines. It is shown that utilization of 
dibutylphosphate as a co-catalyst with a Pd(II)/bis-sulfoxide catalyst produces optimal reactivity, 
affording anti-vinyl-oxazolidinones. These products are versatile synthetic intermediates, and 
their synthetic derivatization into α-hydroxy-β-amino acids as well as intermediates to amino 
sugars is demonstrated. Furthermore, the high functional group tolerance of the reaction enabled 
late-stage cyclization on a leucine-β-allylglycine dipeptide substrate to install a vinyl 
oxazolidinone moiety. Mechanistic investigations into the role of the dibutylphosphate co-
catalyst revealed that it may play multiple roles beyond promoting formation of a cationic π-
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allylPd intermediate, including serving as an anionic ligand to palladium capable of performing 
allylic C-H cleavage.  
 Natural products of nonribosomal peptide synthetase (NRPS) origin posses complex 
topologies and diverse functional group arrays that lead to varied and impressive therapeutic 
potential. The structural diversity achieved among these natural products is due in large part to a 
biosynthetic strategy that employs pre- and post-assembly oxidative modifications of individual 
amino acid building blocks and fully assembled peptide chains, exemplified in the biosynthesis 
of vancomycin. In many cases, diversification is achieved via enzymatic hydroxylation of amino 
acids to form unnatural amino acids that are incorporated into a larger peptide structure, or are 
intermediates for further diversification of an amino acid. Here we report a strategy inspired by 
the elegant approach of NRPS biosynthetic systems, wherein small molecule iron catalysts 
Fe(PDP) and Fe(CF3PDP) enable the oxidative diversification of amino acids and peptides. In 
particular, a highly chemoselective hydroxylation at C5 of proline residues produces the versatile 
5-hydroxyproline derivative, enabling further transformations to rapidly diversify amino acid and 
proline-containing peptide structures. In total, four chiral pool amino acids (proline, valine, 
leucine, and norvaline) are rapidly converted to twenty-one unnatural amino acid residues 
representing seven distinct functional group classes, and a single proline-containing tripeptide is 
transformed into eight sequences spanning five distinct functional group classes. Finally, the 
high efficiency and chemoselectivity of the iron catalyst is demonstrated by the chemoselective, 
late-stage transformation of a proline residue pentapeptide macrocycle to an unnatural residue.  
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CHAPTER 1: 
 
N-BOC AMINES TO OXAZOLIDINONES VIA PD(II)/BIS-SULFOXIDE/BRØNSTED 
ACID CO-CATALYZED ALLYLIC C-H OXIDATIONa 
 
1.1 INTRODUCTION 
  Chief among the challenges facing chemical synthesis in the coming years is the 
advancement of synthetic methods enabling more efficient access to important structural units 
that appear as components in natural products and pharmaceuticals. A powerful strategy that has 
recently emerged is the direct functionalization of C-H bonds to install target functional groups 
at the correct site and with the appropriate oxidation state and stereochemistry.1, 2 In contrast to 
traditional synthetic methods which rely on the use of pre-oxidized fragments, often requiring 
protection and deprotection steps and functional group manipulations throughout a synthetic 
sequence, the direct C-H functionalization approach has the potential to bypass these 
cumbersome steps by taking a minimally oxidized hydrocarbon precursor and installing the 
functional group of interest at the correct oxidation state in a single step.3 In 2005, White and 
Chen disclosed Pd(II)/bis-sulfoxide catalyst 1 for the branched-selective allylic C-H 
acetoxylation reaction.4 Since this seminal report, catalyst 1 has been demonstrated to be a 
general solution for the direct allylic C-H functionalization of hydrocarbons possessing a 
terminal alkene unit, enabling allylic C-H oxidation,4-7 amination,8-13 alkylation,14-16 
fluorination,17 and dehydrogenative processes18 to form a wide range of linear and branched 
products with high regioselectivity and stereoselectivity (E/Z or syn/anti, Figure 1).   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a This chapter and the figures herein are adapted from Osberger, T. J. and White, M. C. J. Am. Chem. Soc. 2014, 
136, 11176-11181. Permission for the inclusion of this work has been granted by the copyright holder. 
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Figure 1. Pd(II)/Bis-sulfoxide Serial Ligand Catalysis for Allylic C-H Functionalization 
 
The success of Pd(II)/bis-sulfoxide catalyst 1 relates to its underlying mechanism, termed 
serial ligand catalysis, which is generally operative in the allylic C-H functionalization reactions 
for which 1 is employed (Figure 1, right).  In serial ligand catalysis, 1 coordinates the terminal 
olefin substrate and effects allylic C-H cleavage to produce a π-allylPd intermediate I, which 
then undergoes a nucleophilic functionalization step promoted by a second ligand, usually 1,4-
benzoquinone, to afford the product of allylic functionalization and Pd(0).  Reoxidation of Pd(0) 
to Pd(II) mediated by 1,4-benzoquinone and the acid generated during the reaction19-21 reforms 1 
to complete the catalytic cycle. The ligand environment surrounding Pd under this regime 
consists of exchanging, weakly coordinating ligands that are able to promote separate steps in the 
catalytic cycle. This concept benefits from its ability to be tuned to a degree, as strategies have 
been developed to activate the π-allylPd electrophile by enhancing its electrophilicity. For 
example, Lewis acid additives have been shown to promote a number of transformations with 1; 
this promotion effect is proposed to be modulated through benzoquinone binding to the π-allylPd 
intermediate.5 On the other hand, due to the fluxional ligand environment, C-H functionalization 
reactions with 1 are generally constrained to the use of acidic (pKa <5), protic pronucleophiles 
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that become activated toward attack when deprotonated (often in equilibrium concentrations) as 
their conjugate bases. Thus, increasing the concentration of conjugate base in solution has 
become an excellent strategy for nucleophile activation in reactions using catalyst 1, either by 
increasing the acidity of the nucleophile11 or by the addition of catalytic amounts of a Brønsted 
base.10	  	  
Figure 2. Synthesis of Amino Alcohol Motifs with Catalyst 1 
 
 However, there are cases where an aprotic pronucleophile may be preferable to its protic 
counterpart due to ease of preparation and stability, and thus the use of aprotic surrogates in an 
allylic C-H functionalization reaction with 1 warranted investigation. In particular, we were 
interested in developing an allylic C-H oxidation with catalyst 1 to form oxazolidinone 
structures, which are valuable pharmacophores and versatile synthetic precursors to many 
valuable molecular motifs, including amino sugars and hydroxyamino acids.  We had previously 
developed the synthesis of a related oxazolidinone via allylic C-H amination with 1 using an 
acidic, protic N-tosylcarbamate pronucleophile8 (Figure 2, top right). However, the products 
formed in this amination reaction were an isomeric N/O motif of our desired oxazolidinone, and 
the only allylic C-H functionalization developed to date to form the desired N/O isomer gave 
difficult-to-modify 2-amino-oxazoline products (Figure 2, top left).22 We considered that our 
desired transformation may be possible using a N-(tert-butoxycarbonyl)amine (Boc) group as a 
Previous work:
This work:
cat. 1
C—N
R
X
O
NHNs
S S
OO
Ph Ph
Pd(OAc)2
Pd(OAc)2
S S
OO
Ph Ph
X = O, NH
R
O
O
NNs
R
N
NHNs
O
C—O
cat. 1
AgOTf cat.
R
NHBoc
P
O
OBu
OBu
HO
cat. 1
C—O
R
HN
O
O
R
HN
O
OH
carbamic acid
N-Boc amine
R
HN
O
Ot-Bu
N-Boc amine
~
cat.DBP
	   4 
surrogate for the unstable carbamic acid (Figure 2, bottom).  In addition to being a readily 
accessible, common protecting group for amines, the N-Boc group has also been demonstrated to 
be a competent aprotic nucleophile in the functionalization of iodonium electrophiles.23 Thus, we 
undertook the challenge of discovering an activation mode to generate a sufficiently electrophilic 
π-allylPd intermediate that could be functionalized, while maintaining efficient catalytic 
turnover. 
 Brønsted acid catalysis is a well-established, powerful strategy for electrophile 
activation,24-29 and holds tremendous potential for cooperative catalysis with transition metal and 
organometallic systems.  For example, phosphoric acids have recently been employed as co-
catalysts with Pd30, 31 and Ir32 in allylic functionalization and C-H activation/rearrangement 
reactions.  We reasoned that a Brønsted acid promotion strategy may be an effective means of 
electrophile activation that is compatible with the acidic, oxidative conditions and fluxional 
ligand environment required for efficient reactivity with Pd(II)/bis-sulfoxide catalyst 1.   
1.2 RESULTS AND DISCUSSION 
1.2.1 Reaction Optimization 
 We commenced our studies by investigating the reactivity of homoallylic, Boc-protected 
amine 2a with catalyst 1 and stoichiometric 1,4-benzoquinone oxidant under reaction conditions 
adapted from our previous allylic C-H amination and acetoxylation procedures, and observed 
low overall conversion and poor yield of desired product 3a (Table 1, entry 1).  We hypothesized 
that an acid additive may activate the π-allylPd species through one or more of several potential 
mechanisms, including protonation of anionic ligands on Pd, promoting breakdown of the N-Boc 
pronucleophile, or serving as a proton source for reoxidation of Pd(0) to Pd(II).19 We first 
explored carboxylic acids, which have been shown to be useful and compatible additives with 
	   5 
catalyst 1 in previous allylic C-H functionalization reactions.  When 1.5 equivalents of acetic 
acid was employed, we observed a substantial increase in reactivity, obtaining 3a in 40% yield 
and excellent diastereoselectivity (entry 2).  We next evaluated carboxylic acids with lower pKa 
values and observed an increase in overall reactivity (e.g. Benzoic acid, entry 3); however, 
further increasing the acidity led to significant levels of competing intermolecular esterification 
in the cases of nitrobenzoic acid derivatives (entries 4 and 5); in fact, with ortho-nitrobenzoic 
acid additive, 78% overall conversion was observed, with only 27% yield 3a and 51% linear 
ester 2ac as the major product.  We hypothesized that an acid with similar acidity but a less 
nucleophilic conjugate base may more effectively promote reactivity while minimizing linear 
functionalization.  Dibutylphosphate (DBP), a phosphoric acid with a pKa similar to ortho-
nitrobenzoic acid (pKa = 1.72, 2.17, respectively) afforded a promising yield of 3a (54%, entry 
6), with no observed linear allylic functionalization byproducts. Use of the more acidic 
phosphoric acid diphenylphosphate gave diminished yields (42%, entry 7). We explored the 
loading of DBP and found 50 mol% to be optimal and highly scalable (63%, entry 8, 59% on 
gram scale, entry 9), whereas lower loadings of DBP (e.g. 20 mol%, entry 10) resulted in lower 
conversion. We explored iterative addition of DBP (3 x 17 mol% at 0 h, 1.5 h, and 3 h, entry 11) 
and observed a slight increase in reactivity, but found this protocol to be helpful in the case of 
lower-converting substrates, possibly by lengthening the catalyst lifetime. Deletion of catalyst 1 
under the optimal conditions led to no product formation and 97% recovered starting material 
(entry 12). Furthermore, substituting the bulky 2,6-dimethylbenzoquinone for 1,4-benzoquinone 
resulted in low conversion and isolation of no 3a, suggesting that the functionalization step of 
this reaction is quinone-dependent (entry 13).  
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Table 1.  Reaction Development 
 
 We further examined alternative modes of promotion of this reaction, including Lewis 
acid additives, which have been shown to promote allylic C-H functionalization under Pd(II)/bis-
sulfoxide catalysis with protic pro-nucleophiles. The oxophilic Lewis acid Cr(salen)Cl was not 
an effective promoter, resulting in low conversion and recovered starting material (entry 14).  
The azaphilic Lewis acids AgOTf and B(C6F5)3, both hypothesized to increase the 
electrophilicity of the π-allylPd intermediate, were less effective than  acids in this reaction.  
These results are consistent with our hypothesis that an exogenous source of proton is required 
for catalyst regeneration when employing aprotic pro-nucleophiles.  Finally, copper (II) triflate 
was an effective promoter of reactivity; however, even after significant exploration, yields and 
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diastereoselectivities of 3a were modest. Additionally, significant amounts of olefin 
isomerization were observed when AgOTf, B(C6F5)3, or Cu(OTf)2 were employed.   
1.2.2. Exploration of Reaction Scope   
Table 2. Substrate Scope of Allylic C-H Oxidation Reaction 
 
Having identified the optimal conditions for reactivity, we examined the substrate scope 
of the reaction (Table 2).  A variety of N-Boc homoallylic amine substrates could be prepared 
using a carboxylic acid alkylation33 / Curtius rearrangement34 approach or Ellman’s sulfinamine 
auxiliary.35 Substrates possessing a branching element adjacent to the amine center afforded 
good yields of oxazolidinones as single diastereomers (3b, 3c, 3d).  As the steric bulk was 
moved away from the amine center, the diastereoselectivity of the reaction decreased but 
remained synthetically useful, as isobutyl (3e) and methyl (3f) substitution gave 7:1 and 4:1 dr, 
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respectively. The generally high diastereoselectivity is rare among allylic C-H oxidation 
processes, and may be a consequence of the conformational rigidity of the carbamate tether due 
to amide A(1,3) strain. We examined the compatibility of oxygen- and nitrogen-containing 
functional groups (e.g., ethers, esters, and amides), and found them to be well-tolerated, 
furnishing polyoxidized motifs with functional group handles for further elaboration (3g, 3h, 3i, 
3j). Significantly, acid-labile functional groups such as primary silyl ethers, tert-butyl esters, and 
even a distal Boc-amino group were all stable under these mildly acidic conditions.   
Aryl substitution at the homoallylic position provided product in good yield and 
diastereoselectivity (3k). Previous allylic C-H functionalization reactions utilizing catalyst 1 with 
similar substrates did not tolerate this type of substitution. Benzyl-substituted amines furnished 
the desired products with good yields as single diastereomers (3l, 3p). Significantly, substrate 
2m, which contains an indole group, proceeded intact through the acidic, oxidative conditions to 
afford product 3m. Indoles have been reported previously to undergo oxidation on the ring with 
Pd(II) salts under acidic conditions.36   
We investigated the tolerance of sterically congested amine-bearing carbons in this 
reaction. Because stereocontrolled methods for the synthesis of β,β-disubstituted amino alcohols 
motifs are scarce,37 we sought to probe whether our reaction could fill this methodological gap.  
Gratifyingly, the reaction was demonstrated to be tolerant of such highly substituted carbon 
centers, providing oxazolidinones 3n, 3o, and 3p in good yields and acceptable 
diastereoselectivity.  
1.2.3. Synthetic Applications 
The oxazolidinone ring is recognized as a valuable pharmacophore, appearing in 
pharmaceuticals such as Zyvox.38 However, the vinyl-oxazolidinone products produced in this 
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reaction are equally valuable for their synthetic versatility. The general framework of this 
compound has been transformed to numerous structural types, including α-hydroxy-β-amino 
acids, through simple transformations. In particular, the α-hydroxy-β-amino acid compounds are 
highly prevalent, and can be found in the clinically utilized compounds Taxol, Bestatin, and 
Amastatin (Figure 3A).39 Product 3a can be readily transformed into syn-3-amino-2-hydroxy-4-
phenylbutyric acid (AHPBA, 4), which is a component of the aminopeptidase inhibitor 
Bestatin,40 via a sequence of olefin oxidation and oxazolidinone hydrolysis to the free amino 
alcohol (Figure 3B).  
Figure 3.  Synthetic Applications Toward Hydroxyamino Acid Motifs 
 
We questioned whether the high functional group tolerance of our reaction could enable 
the direct C-H oxidation of a preassembled peptide containing a N-Boc-β-allylglycine residue. 
Thus, we synthesized leucine-β-allyglycine dipeptide 5, and subjected it to the allylic C-H 
oxidation reaction conditions (Figure 3C). In the event, we observed a 57% yield of 
oxazolidinone 6 as a 6:1 mixture of diastereomers, demonstrating the effectiveness of this 
reaction to effect a late-stage allylic C-H oxidation in a more complex setting.  
An additional powerful feature of our allylic C-H oxidation reaction is its predictably 
high diastereo- and site-selectivity. Taking advantage of this aspect, we envisioned coupling this 
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reactivity in parallel with our previously reported allylic C-H amination to function as a 
regiodivergent synthetic transform for the synthesis of oxazolidinones and 1,2-amino alcohols 
starting from a common aldehyde precursor (Figure 4). To demonstrate this, we began with 
aldehyde (-)-7, derived from commercially available (L)-ethyl lactate. Conversion of 7 to 
homoallylic Boc-amine 8 was achieved via a short sequence of condensation with Ellman’s 
sulfinamine auxiliary, Grignard addition, and exchange of the Ellman sulfinamine to a Boc 
group. Cyclization of this intermediate via 1/DBP catalyzed C-H oxidation proceeded efficiently, 
affording oxazolidinone 9. A sequence of methylation of the oxazolidinone nitrogen and 
Figure 4. Regiodivergent Synthesis of Amino Sugars 
 
hydroboration/oxidation of the terminal olefin yielded 10, a known synthetic intermediate to 
perosamine,41, 42 an amino sugar found in the natural product pyrrolosporin A.43 Alternatively, 
also beginning from aldehyde 7, rapid conversion to N-tosylcarbamate substrate and subsequent 
allylic C-H amination with catalyst 1 affords the related oxazolidinone product, which is a 
known intermediate to the amino sugar N-acetyl-O-methyl acosamine, found in epirubicin.44  
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1.2.4. Mechanistic Studies 
Having established the reactivity and synthetic utility of our reaction catalyzed by Pd/bis-
sulfoxide and dibutylphosphate, we set out to investigate the mechanism by which the 
substoichiometric amounts of dibutylphosphate promote allylic C-H functionalization with N-
Boc amines.  One plausible hypothesis was that the mild acid promoted loss of tert-butyl cation 
from the Boc group, forming a transient carbamic acid species that functionalizes the pi-allylPd 
intermediate. However, several pieces of evidence suggested that this was not the case.  First, we 
observed preservation of distal Boc groups (Table 2, 3j and 3m) under the reaction conditions.  
Second, deletion of catalyst 1 or use of 2,5-dimethylbenzoquinone (Table 1, entries 12 and 13), 
also indicated that under the reaction conditions starting material was largely recovered (>90% 
rsm in both experiments). Thus, it appeared unlikely that the reaction proceeded through simple 
acid-mediated decomposition of the Boc group.   
Figure 5. Exploration of DBP as a Nucleophilic Catalyst 
 
A second possibility was that the phosphate anion—generated in equilibrium amounts 
with acetate—acts as a nucleophilic catalyst45-47 to form a transient allylic phosphate48 by 
intermolecular π-allylPd substitution.  The allylic phosphate may then undergo intramolecular 
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displacement by the carbamate to form oxazolidinone product and regenerate the phosphate 
catalyst (Figure 5A).  To test this possibility, allylic phosphate 11 was synthesized and subjected 
to the standard reaction conditions, resulting in moderate conversion to oxazoldinone 3c (Figure 
5B).  Additionally, a competition experiment between 11 and terminal olefin substrate 2a was 
performed and demonstrated preferential reactivity of the terminal olefin (Figure 5C).  Initial rate 
studies on 11 versus 2c were consistent demonstrated a faster reaction rate for the terminal 
olefin, which converted roughly twofold faster than the putative allylic phosphate intermediate.  
Finally, allylic phosphate products of type 11 were not observed in crude reaction mixtures 
(Figure 5D).  In view of these results, we ruled out this mechanistic scenario as a major reaction 
pathway.   
Figure 6. In Situ Formation and Study of Pd(II)(bis-sulfoxide)(phosphate) Complex 
 
 A final intriguing hypothesis was that dibutylphosphate acts as an acid co-catalyst to 
generate an electrophilic π-allylPd intermediate highly activated toward nucleophilic attack.  We 
tested this hypothesis by in situ generation of a Pd(II)/bis-sulfoxide/phosphate complex from 
Pd(II)Cl2(bis-sulfoxide) complex 12 and silver dibenzylphosphate under otherwise identical 
reaction conditions (Figure 6A).  We observed comparable catalytic reactivity and selectivity 
compared to the standard conditions using acetate catalyst 1. An Additional experiment 
demonstrated that the role of dibutyl phosphate extends beyond generation of a Pd(II)/phosphate 
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complex; removal of phosphate from the reaction results in dramatically reduced yields of 
oxazolidinone product (Figure 6B).  This may be due to the requirement for an acid to assist in 
catalyst regeneration.  Importantly, a control experiment confirmed the requirement for an 
acetate or phosphate anion for Pd to observe any expected reactivity (Figure 6C).  Finally, we 
probed the C-H cleavage step of the reaction using the in situ preparation of the Pd(II)/bis-
sulfoxide/phosphate complex under mock catalytic conditions with 1-undecene, and observed 
robust C-H cleavage activity by isolation of the (allyl)PdCl dimer after trapping with chloride ion 
(Figure 6C).  These results demonstrate for the first time that a non-carboxylate counterion on 
Pd(II)/bis-sulfoxide can effect allylic C-H cleavage.   
Figure 7. Plausible Catalytic Cycle 
 
 Consistent with these studies, we present a plausible catalytic cycle for the Pd(II)/bis-
sulfoxide/phosphate co-catalyzed allylic C-H oxidation.  First, catalyst 1 may undergo 
equilibrium acetate/phosphate exchange to form an intermediate (A) having acetate and/or 
phosphate ligands.  Intermediate A binds substrate and performs C-H cleavage, producing π-
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Loss of the tert-butyl group during functionalization may occur via loss of isobutylene gas, 
concomitantly generating a second equivalent of proton and/or by loss of tert-butyl cation and 
subsequent trapping by DBP or acetate, forming t-Bu-X products.49, 50 We have observed (n-
BuO)2P(=O)(Ot-Bu) in crude reaction mixtures, suggesting that this pathway is operating to 
some degree. Finally, proton assisted reoxidation of Pd(0) to Pd(II) by BQ reforms A and 
dihydroquinone (DHQ), completing the catalytic cycle.   
1.3 CONCLUSIONS 
We have developed a Pd(II)/bis-sulfoxide/phosphoric acid catalyzed intramolecular 
allylic C-H oxidation of simple homoallylic, Boc-protected amine substrates to furnish anti-vinyl 
oxazolidinones.  The reaction disclosed herein allows for direct access to these important 
heterocycles with outstanding stereoselectivities and novel regioselectivities.  Mechanistic 
studies suggest the in situ generation of a Pd(II)/bis-sulfoxide/phosphate complex that is capable 
of promoting both C-H cleavage and π-allylPd functionalization with a weak, aprotic N-Boc 
amine pro-nucleophile.  These findings have important implications for effecting asymmetric 
induction under this general allylic C-H oxidation manifold.   
1.4 EXPERIMENTAL SECTION 
I.  General Methods. 
Materials. Catalyst 1 was obtained as a gift from TCI America and Sigma Aldrich Co., and used 
as received.  The catalyst was stored in a dessicator over DriRite at 0°C.  Prior to use catalyst 1 
was warmed to room temperature and weighed out in air. Dibutyl phosphate and benzoquinone 
were purchased from Sigma Aldrich and used as received.  1,4-dioxane was purified prior to use 
by passage through a bed of activated alumina (Glass Contour, Laguna Beach, California).   
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Experimental Procedures.  All allylic oxidation reactions were carried out under air with 
magnetic stirring, with no precautions taken to exclude moisture.  All other reactions were 
conducted in flame-dried glassware with magnetic stirring under an inert atmosphere of dry 
nitrogen or argon, unless otherwise noted.  Thin-layer chromatography was conducted with E. 
Merck silica gel 60 F254 precoated plates (0.25 mm) and visualized with KMnO4 and UV.  Flash 
column chromatography was performed as described by Still et al. using EM reagent silica gel 60 
(230-400 mesh). 51 
Structural Analysis.  1H NMR spectra were recorded on a Varian Unity-500 (500 MHz) or 
Varian Unity Inova-500 (500 MHz) spectrometer, using solvent as an internal standard (CDCl3 at 
7.26 ppm).  Data are reported as: s=singlet, d=doublet, t=triplet, q=quartet, pent=pentet, 
oct=octet, m=multiplet, br=broad, app=apparent; coupling constants in Hz; integration.  Proton-
decoupled 13C NMR spectra were recorded on a Varian Unity 500 (125 MHz) spectrometer and 
are reported in ppm using solvent as internal standard (CDCl3 at 77.16 ppm).  High resolution 
mass spectrometry (HRMS) was performed at the Unversity of Illinois Mass Spectrometry 
Laboratory (Dr. Furong Sun, Director) using a Waters Q-TOF Ultima ESI spectrometer.  Infrared 
(IR) spectra were recorded as thin films on NaCl plates on a Perkin-Elmer Spectrum BX FT-IR 
and are reported in wavenumbers (cm-1).  Optical rotations were obtained using a JASCO DIP-
360 digital polarimeter (cell dimensions: 3.5 x 50 mm) and are reported as follows [α]DT/°C 
concentration (c = g / 100 mL, solvent).   
Synthesis of Substrates.   Homoallylic Boc-protected amine substrates (±)-2a, b, c, d, e, f, k, l, 
and n were prepared in racemic form using a general carboxylic acid alkylation33 / Curtius 
rearrangement34 strategy.  Substrates (+)-8, (+)2m, and (+)-2j were prepared in enantioenriched 
form using Ellman’s sulfinamine auxiliary,35 and 2o and 2p were prepared in racemic form 
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utilizing racemic sulfinamine.  For an example procedure, see the synthesis of (+)-8 below. β-
amino acid type substrates (-)-2g and (-)-5 were prepared via Evans’ oxazolidinone auxiliary 
alkylation52, 53 methods, and (±)-2h was prepared in racemic form using 2-oxazolidinone as the 
auxiliary. Substrate (±)-2i was synthesized using standard methods from dl-allylglycine. General 
synthetic routes are summarized below. 
Figure 8. Substrate Synthesis 
 
Representative two-step alkylation / Curtius rearrangement of carboxylic acids.  Synthesis 
of tert-butyl (2-methylhex-5-en-3-yl)carbamate (2b). 
Alkylation.  A flame-dried round bottom flask equipped with a magnetic stir bar under nitrogen 
atmosphere was charged with isovaleric acid (1.10 mL, 1.0 eq, 10.0 mmol) in THF (17 mL), and 
cooled to -78 °C. Freshly prepared lithium diispropylamide solution (22.0 mL, 1.0M, 2.2 equiv., 
22.0 mmol) was added slowly dropwise to the stirring mixture, followed immediately by DMPU 
as one addition (2.40 mL, 2.0 equiv., 20.0 mmol).  The mixture was warmed to RT and stirred 
for 30 min.  Then, the mixture was cooled to 0 °C, and allyl bromide (0.952 mL, 1.1 equiv., 11.0 
mmol) was added dropwise. The reaction was warmed to rt and stirred for 1h.  When complete, 
the reaction was quenched at 0 °C with 10% aq. HCl.  The mixture was transferred to a 
separatory funnel, and the aqueous layer extracted with EtOAc (3x 20 mL).  The combined 
organics were washed with 10% aq. HCl (2x 20 mL), dried over MgSO4, filtered over a plug of 
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Celite, and concentrated via rotary evaporation.  The crude mixture (1.52 g) was taken on to the 
Curtius rearrangement step without further purification. 
Curtius Rearrangement.  To a flame dried round bottom flask equipped with a magnetic stir bar 
was added crude material from the alkylation step (1.52 g, approx. 7.6 mmol), 
tetrabutylammonium bromide (355 mg, 0.15 equiv., 1.1 mmol), ZnCl2 (34.1 mg, 0.033 equiv., 
0.25 mmol), sodium azide (3.59 g, 7.0 equiv., 55.2 mmol), and di-tert-butyl dicarbonate (1.83 g, 
1.1 equiv., 8.4 mmol).  The mixture was dissolved in THF (25 mL) and stirred at 60 °C for 16h.  
When complete, the mixture was cooled to rt and then 10% aq. NaNO2 solution was added and 
stirred for 30 min. The mixture was transferred to a separatory funnel and the aqueous layer 
extracted with EtOAc (3x 25 mL).  The combined organic layers were washed with sat. aq. 
NH4Cl (2x 25 mL), sat. NaHCO3 (2x 25 mL), and brine (25 mL), dried over MgSO4, filtered 
over a plug of Celite, and concentrated via rotary evaporation.  Column chromatography (5% 
EtOAc / Hexanes) yielded the title compound 2b (556.7 mg, 34% over 2 steps).  
II.  Substrate Characterization Data. 
 
 (±)-tert-butyl (1-phenylpent-4-en-2-yl)carbamate (2a): 
1H NMR (500MHz, CDCl3) δ 7.31-7.19 (m, 5H), 5.81 (m, 1H), 5.09 (m, 2H), 4.43 (m, 1H), 3.91 
(m, 1H), 2.83-2.73 (m, 2H), 2.26 (m, 1H), 2.11 (m, 1H), 1.41 (s, 9H).  
13C NMR (125MHz, CDCl3) δ 28.7, 38.4, 40.8, 51.4, 79.4, 118.2, 128.7, 129.8, 134.8, 138.4, 
155.7. 
IR (film, cm-1): 3352, 2977, 2929, 1701, 1498, 1365, 1171. 
HN Ot-Bu
O
(±)-2a
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HRMS (ESI) m/z calc’d for C16H24NO2 [M + H]+: 262.1807, found: 262.1811. 
 
 
 (±)-tert-butyl (2,2-dimethylhex-5-en-3-yl)carbamate (2b): 
1H NMR (500 MHz, CDCl3) δ 5.81-5.72 (m, 1H), 5.03-4.98 (m, 2H), 4.24 (d, J=10 Hz, 1H), 
3.42 (td, J=3, 11Hz, 1H), 2.40-2.36 (m, 1H), 1.88-1.79 (m, 1H), 1.39 (s, 9H), 0.88 (s, 9H).  At 
RT, this compound appears as a ~7:1 mixture of rotamers. Peaks corresponding to the minor 
rotamer are present at: δ4.10 (m, 1H), 3.27 (m, 1H), 1.42 (s, 9H). 
13C NMR (125 MHz, CDCl3) δ 156.3, 136.3, 116.6, 78.9, 58.6, 35.4, 34.9, 28.6, 26.6.   
IR (film, cm-1): 3349, 2966, 1703, 1504, 1365, 1250, 1174.   
HRMS (ESI) m/z calc’d for C13H26NO2 [m + H]+: 228.1964, found: 228.1969.  
 
 
(±)-tert-butyl-(2-methylhex-5-en-3-yl)carbamate (2c): 
1H NMR (500MHz, CDCl3) δ 5.77 (ddt, J=17.2, 10.1, 7.2Hz 1H), 5.06 (2H, m), 4.32 (1H, br d, J 
= 8 Hz), 3.50 (1H, m), 2.25 (dt, J=11.9, 5.6Hz, 1H), 2.10 (dt, J=14.8, 7.8Hz, 1H), 1.73 (1H, m), 
1.43 (9H, s), 0.92 (3H, d, J = 7 Hz), 0.88 (3H, d, J = 6.5 Hz). 
13C NMR (125MHz, CDCl3) δ 18.1, 19.6, 28.8, 31.8, 37.3, 55.4, 79.2, 117.5, 126.5, 135.5, 156.2. 
IR (film, cm-1): 3344, 2964, 2933, 2875, 1703, 1693, 1523, 1365, 1247. 
HN Ot-Bu
O
(±)-2b
HN Ot-Bu
O
(±)-2c
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HRMS (ESI) m/z calc’d for C12H24NO2 [m + H]+: 214.1807, found: 214.1816. 
 
 (±)-tert-butyl (1-cyclohexylbut-3-en-1-yl)carbamate (2d):  
1H NMR (500MHz, CDCl3) δ 5.76 (ddt, J=17.2, 10.2, 7.1Hz), 5.05 (m, 2H), 4.33 (d, J= 9.0 Hz), 
3.49 (m, 1H), 2.26 (dt, J=11.9, 5.6Hz, 1H), 2.11 (dt, J=14.7, 7.7Hz, 1H), 1.75-1.63 (m, 6H), 1.42 
(s, 9H), 1.35-0.91 (m, 5H).   
13C NMR (125MHz, CDCl3) δ 26.5, 26.7, 28.8, 30.7, 37.1, 41.8, 54.8, 79.2, 117.5, 135.4, 156.2. 
IR (film, cm-1): 3282, 2912, 2852, 2356, 1675, 1536, 1448, 1363, 1270, 1176. 
HRMS (ESI) m/z calc’d for C15H28NO2 [m+H]+: 254.2120, found: 254.2119. 
 
 tert-butyl (6-methylhept-1-en-4-yl)carbamate (2e): 
1H NMR (500MHz, CDCl3) δ 5.75 (m, 1H), 5.04 (m, 2H), 4.28 (m, 1H), 3.70 (m, 1H), 2.24-2.11 
(m, 2H), 1.64 (m, 1H), 1.41 (s, 9H), 1.24 (app t, J= 7.0 Hz, 2H), 0.89 (app. d, J= 6.5 Hz, 6H).  
13C NMR (125MHz, CDCl3) δ 22.5, 23.3, 25.1, 28.6, 40.3, 44.2, 48.4, 79.1, 117.8, 134.8, 155.7. 
IR (film, cm-1): 3338, 2958, 2871, 1691, 1523, 1265, 1174. 
HRMS (ESI) m/z calc’d for C13H26NO2 [m+H]+: 228.1964, found: 228.1966. 
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 (±)-tert-butyl pent-4-en-2-ylcarbamate (2f): 
1H NMR (500 MHz, CDCl3) δ 5.82-5.73 (m, 1H), 5.09-5.06 (m, 2H), 4.37 (br s, 1H), 3.72 (br s, 
1H), 2.24-2.15 (m, 2H), 1.44 (s, 9H), 1.12 (d, J=6.5 Hz).   
13C NMR (125 MHz, CDCl3) δ  155.5, 134.7, 117.8, 79.2, 46.1, 41.5, 28.6, 20.7.   
IR (film, cm-1): 3338, 2977, 1691, 1523, 1174.   
HRMS (ESI) m/z calc’d for C10H20NO2 [m + H]+: 186.1494, found: 186.1503. 
 
 
 (-)-tert-butyl (R)-(1-(methoxy(methyl)amino)-1-oxohex-5-en-3-yl)carbamate (2g): 
[α]D 25 = -10.77° (c 1.04, CHCl3).   
1H NMR (500 MHz, CDCl3) δ 5.77 (ddt, J=17.2, 10.2, 7.2Hz, 1H), 5.37 (s, 1H), 5.10-5.05 (m, 
2H), 4.01-3.97 (m, 1H), 3.66 (s, 3H), 3.16 (s, 3H), 2.74-2.71 (m, 1H), 2.59-2.55 (m, 1H), 2.41-
2.30 (m, 2H), 1.41 (s, 9H).   
13C NMR (125 MHz, CDCl3) δ 172.7, 155.6, 135.1, 117.9, 79.2, 61.5, 47.4, 39.1, 35.4, 32.2, 
28.6.   
IR (film, cm-1): 3349, 2977, 1710, 1658, 1498, 1365, 1172.   
HRMS (ESI) m/z calc’d for C13H25N2O4 [m + H]+: 273.1814, found: 273.1815. 
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 (±)-tert-butyl-3-((tert-butoxycarbonyl)amino)hex-5-enoate (2h): 
1H NMR (500 MHz, CDCl3) δ 5.80-5.71 (m, 1H), 5.10-5.07 (m, 2H), 4.98 (br s, 1H), 3.95 (m, 
1H), 2.45-2.37 (m, 2H), 2.32-2.24 (m, 2H), 1.44 (s, 9H), 1.42 (s, 9H).   
13C NMR (125 MHz, CDCl3) δ 171.1, 155.3, 134.3, 118.2, 81.1, 79.3, 47.4, 39.7, 39.1, 28.5, 
28.2.   
IR (film, cm-1): 3356, 2979, 1720, 1502, 1165.   
HRMS (ESI) m/z calc’d for C15H28NO4 [m + H]+: 286.2018, found: 286.2016. 
 
 
 (±)-tert-butyl (1-((tert-butyldiphenylsilyl)oxy)pent-4-en-2-yl)carbamate (2i): 
1H NMR (500 MHz, CDCl3) δ 7.67-7.64 (m, 4H), 7.45-7.37 (m, 6H), 5.74 (ddt, J=17.2, 10.2, 
7.1Hz, 1H), 5.13-5.06 (m, 1H), 5.05 (d, J=10.2Hz, 1H), 4.70 (br s, 1H), 3.75-3.66 (m, 3H), 2.41-
2.29 (m, 2H), 1.45 (s, 9H), 1.08 (s, 9H).   
13C NMR (125 MHz, CDCl3) δ 155.6, 135.7, 134.8, 133.4, 129.9, 127.9, 117.7, 79.2, 65.0, 51.6, 
36.4, 28.6, 27.0, 19.5.   
IR (film, cm-1): 3450, 2931, 2858, 1716, 1496, 1172, 1112.   
HRMS (ESI) m/z calc’d for C26H38NO3Si [m + H]+: 440.2621, found: 440.2625. 
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 (+)-di-tert-butyl oct-7-ene-1,5-diyl(S)-dicarbamate (2j): 
 [α]D25 = +14.6˚ (c 0.97, CHCl3) 
1H NMR (500 MHz, CDCl3) δ 5.75 (ddt, J = 19.5, 9.3, 7.2 Hz, 1H), 5.10 – 5.02 (m, 2H), 4.58 (s, 
1H), 4.36 (d, J = 7.9 Hz, 1H), 3.61 (s, 1H), 3.10 (q, J = 6.1 Hz, 2H), 2.19 (ddq, J = 28.0, 13.5, 
6.6 Hz, 2H), 1.53 – 1.28 (m, 15H). 
13C NMR (125 MHz, CDCl3) δ 156.16 , 155.80 , 134.54 , 117.80 , 79.14 , 49.94 , 40.45 , 39.78 , 
34.48 , 29.90 , 28.55 , 23.20. 
IR (film, cm-1):  3346, 2977,  2931, 2861, 1691, 1523.5, 1365, 1250, 1174. 
HRMS (ESI) m/z calc’d for C18H35N2O4 [m + H]+: 343.2597, found: 343.2595. 
 
 
 (±)-tert-butyl (1-phenylbut-3-en-1-yl)carbamate (2k): 
1H NMR (500 MHz, CDCl3) δ 7.38-7.28 (m, 5H), 5.70 (ddt, J=17.2, 10.2, 7.0Hz, 1H), 5.15-5.09 
(m, 2H), 4.89 (br s, 1H), 4.76 (br s, 1H), 2.54 (m, 2H), 1.44 (s, 9H).   
13C NMR (125 MHz, CDCl3) δ 155.3, 134.1, 128.6, 127.3, 126.4, 118.3, 79.5, 54.1, 41.4, 28.5.   
IR (film, cm-1): 3340, 2979, 1680, 1529, 1369, 1253, 1166.   
HRMS (ESI) m/z calc’d for C15H22NO2 [m + H]+: 248.1651, found: 148.1655. 
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 (±)-tert-butyl (1-(4-methoxyphenyl)pent-4-en-2-yl)carbamate (2l): 
1H NMR (500 MHz, CDCl3) δ 7.10 (d, J=8.5 Hz, 2H), 6.83 (d, J=8.5 Hz, 2H), 5.79 (ddt, J=17.4, 
10.5, 7.1Hz, 1H), 5.10-5.06 (m, 2H), 4.39 (br s, 1H), 3.79 (s, 3H), 2.77-2.66 (m, 2H), 2.24 (dt, 
J=12.7, 6.2Hz, 1H), 2.09 (dt, J=14.3, 7.2Hz, 1H), 1.41 (s, 9H).   
13C NMR (125 MHz, CDCl3) δ 158.3, 155.5, 134.6, 130.5, 118.0, 113.9, 79.2, 55.4, 51.3, 39.6, 
38.1, 28.5.   
IR (film, cm-1): 3361, 2977, 1703, 1512, 1247, 1172.   
HRMS (ESI) m/z calc’d for C17H26NO3 [m + H]+: 292.1913, found: 292.1904.   
 
 
 (+)-tert-butyl (R)-3-(2-((tert-butoxycarbonyl)amino)pent-4-en-1-yl)-1H-indole-1-
carboxylate (2m): 
[α]D 25= + 1.75° (c 1.26, CHCl3).  
1H NMR (500 MHz, CDCl3) δ 8.13 (br s, 1H), 7.60 (d, J=8.5 Hz, 1H), 7.42 (s, 1H), 7.33-7.30 
(m, 1H), 7.26-7.23 (m, 1H), 5.85-5.77 (m, 1H), 5.12-5.09 (m, 2H), 4.47 (br s, 1H), 4.00 (m, 1H), 
2.93-2.83 (m, 2H), 2.32(dt, J=12.6, 6.1Hz,1H), 2.17 (dt, J=14.4, 7.3Hz, 1H), 1.67 (s, 9H), 1.43 
(s, 9H).   
13C NMR (125 MHz, CDCl3) δ 155.6, 149.9, 134.7, 131.1, 124.6, 124.0, 122.7, 119.6, 118.3, 
117.2, 115.4, 83.7, 79.4, 50.0, 38.6, 30.1, 28.6, 28.5.   
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IR (film, cm-1): 3371, 2977, 1732, 1712, 1454, 1371, 1255, 1165.   
HRMS (ESI) m/z calc’d for C23H33N2O4 [m + H]+: 401.2440, found: 401.2431.   
 
 tert-butyl (2-methylpent-4-en-2-yl)carbamate (2n): 
1H NMR (500 MHz, CDCl3) δ 5.74-5.66 (m, 1H), 5.02-4.98 (m, 2H), 4.42 (br s, 1H), 2.31 (d, J= 
7.1 Hz, 2H), 1.35 (s, 9H), 1.18 (s, 6H).   
13C NMR (125 MHz, CDCl3) δ 154.4, 134.2, 118.3, 78.5, 52.1, 44.7, 28.5, 27.1.   
IR (film, cm-1): 3363, 2977, 1722, 1710, 1500, 1365, 1168.   
HRMS (ESI) m/z calc’d for C11H22NO2 [m + H]+: 200.1651, found: 200.1644.   
 
 
 (±)-tert-butyl (2,3-dimethylhex-5-en-3-yl)carbamate (2o): 
1H NMR (500 MHz, CDCl3) δ 5.81-5.73 (m, 1H), 5.07-5.04 (m, 2H), 4.31 (s, 1H), 2.56 (m, 1H), 
2.29 (dd, J=7.3, 13.8Hz, 1H), 2.23 (m, 1H), 1.40 (s, 9H), 1.08 (s, 3H), 0.87 (d, J=7.0Hz, 3H), 
0.85 d, J=7.0Hz, 3H).  
13C NMR (125 MHz, CDCl3) δ 154.5, 134.6, 118.1, 78.6, 57.7, 40.4, 33.9, 28.6, 19.8, 17.3.   
IR (film, cm-1): 3363, 3076, 2976, 1722, 1711, 1498, 1390, 1265, 1274, 1243, 1171, 1080.   
HRMS (ESI) m/z calc’d for C13H26NO2 [m+H]+: 228.1964, found: 228.1964, found: 228.1966. 
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 (±)-tert-butyl (1-(4-methoxyphenyl)-2-methylpent-4-en-2-yl)carbamate (2p): 
1H NMR (500 MHz, CDCl3) δ 7.08 (d, J=8.5 Hz,  2H), 6.82 (d, J=9.0 Hz, 2H), 5.83 (ddt, J=17.6, 
10.3, 7.4Hz, 1H), 5.13-5.09 (m, 2H), 4.25 (br s, 1H), 3.78 (s, 3H), 3.12 (d, J=13.5 Hz, 1H), 2.77 
(d, J=13.5 Hz, 1H), 2.67-2.63 (m, 1H), 2.23 (dd, J=7.5, 13.5 Hz, 1H), 1.46 (s, 9H), 1.12 (s, 3H).   
13C NMR (125 MHz, CDCl3) δ 158.2, 154.5, 134.0, 131.6, 129.8, 118.6, 113.4, 78.7, 55.2, 55.1, 
43.1, 42.9, 28.6, 24.5.   
IR (film, cm-1): 3363, 2977, 1712, 1612, 1512, 1248, 1169.   
HRMS (ESI) m/z calc’d for C18H28NO3 [m + H]+: 306.2069, found: 306.2072. 
 
 (-)-tert-butyl ((R)-3-((tert-butoxycarbonyl)amino)hex-5-enoyl)-L-leucinate (5): 
[α]D 25 = -14.74° (c  1.14 , CHCl3).   
1H NMR (500 MHz, CDCl3) δ 6.02 (br s, 1H), 5.81-5.72 (m, 1H), 5.34 (br s, 1H), 5.14-5.08 (m, 
2H), 4.51-4.46 (m, 1H), 3.95-3.88 (m, 1H), 2.48-2.26 (m, 4H), 1.67-1.57 (m, 2H), 1.46 (s, 9H), 
1.42 (s, 9H), 0.95 (d, J= 5 Hz, 3H), 0.93 (d, J=5 Hz, 3H).   
13C NMR (125 MHz, CDCl3) δ 172.2, 155.6, 134.7, 118.3, 82.1, 79.3, 51.4, 47.8, 42.0, 39.8, 
39.0, 28.5, 28.1, 25.1, 22.9, 22.3.  
IR (film, cm-1): 3389, 3079, 2967, 1745, 1693, 1549, 1365, 1172.   
HRMS (ESI) m/z calc’d for C21H39N2O5 [m +H]+: 399.2859, found: 399.2860. 
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III.  Reaction Development, Scope, Applications, and Mechanistic Investigations. 
Optimization of Reaction Conditions shown in Table 1. 
General Procedure for Reaction Optimization.  A 1-dram vial was charged with substrate 2a 
(78.4 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst 
(15.1 mg, 0.1 equiv., 0.03 mmol), acid additive (if solid) in the amount indicated.  A stir bar was 
added to the vial, then 1,4-dioxane (0.15 mL, 2.0 M with respect to substrate) was added to the 
vial via syringe, followed by acid additive (if liquid) in the amount indicated.  The vial was 
capped with a Teflon-lined cap and stirred at 45°C for 24h. The reaction was diluted with 
CH2Cl2 and transferred to a separatory funnel.  The mixture was washed with H2O, the layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3x 20 mL).  Combined 
organics were dried over anhydrous MgSO4, filtered through a pad of Celite, and concentrated. 
1H NMR spectroscopy was performed on the crude reaction mixture to determine the 
diastereostereomeric ratio.  Flash chromatography was performed (10% to 20% 
Acetone/Hexanes) to isolate product 3a as a solid.  (See below for characterization data for 3a).   
 
Entry 1.  Standard conditions. The General Procedure was followed using substrate 2a (78.4 
mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), and White catalyst 
(15.1 mg, 0.1 equiv., 0.03 mmol). No diastereomeric ratio was determined.  Flash 
chromatography yielded 3a (Run 1:  8.3 mg, 14%; Run 2: 8.6 mg, 14%; Avg. 14%) and 
recovered 2a (Run1: 50.9 mg, 65%; Run 2: 50.8 mg, 65%; avg = 65%). 
 
Entry 2.  AcOH. The General Procedure was followed using substrate 2a (78.4 mg, 1.0 equiv., 
0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst (15.1 mg, 0.1 equiv., 
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0.03 mmol), and acetic acid (25.7 µL, 1.5 equiv., 0.45 mmol), added after 1,4-dioxane.  1H NMR 
spectroscopy of the crude reaction mixture indicated a 19:1 dr (Run 1: >20:1; Run 2: 18:1; Avg. 
19:1). Flash chromatography yielded 3a (Run 1: 24.2 mg, 40%; Run 2: 24.4 mg, 40%; Avg. 
40%).  
 
Entry 3.  BzOH. The General Procedure was followed using substrate 2a (78.4 mg, 1.0 equiv., 
0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst (15.1 mg, 0.1 equiv., 
0.03 mmol), and benzoic acid (55.0 mg, 1.5 equiv., 0.45 mmol).  1H NMR spectroscopy of the 
crude reaction mixture indicated a >20:1 dr (Run 1: >20:1; Run 2: >20:1; Avg. >20:1). Flash 
chromatography yielded 3a (Run 1: 32.3 mg, 52%; Run 2: 33.5 mg, 55%; Avg. 54%). 
 
Entry 4.  Para-nitrobenzoic acid. The General Procedure was followed using substrate 2a (78.4 
mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst (15.1 
mg, 0.1 equiv., 0.03 mmol), and p-nitrobenzoic acid (75.2 mg, 1.5 equiv., 0.45 mmol).  1H NMR 
spectroscopy of the crude reaction mixture indicated a 8:1 dr (Run 1: 8:1; Run 2: 8:1; Avg. 8:1). 
Flash chromatography yielded 3a (Run 1: 24.7 mg, 40%; Run 2: 25.1 mg, 41%; Avg. 41% ). In 
one experiment we isolated from this mixture linear p-nitrobenzoate product 2ab, (26.0 mg, 20% 
yield, >20:1 E/Z).  
 
 (E)-4-((tert-butoxycarbonyl)amino)-5-phenylpent-2-en-1-yl 4-nitrobenzoate (2ab) 
HN Ot-Bu
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O
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1H NMR (500 MHz, CDCl3) δ 8.29 (d, J=8.85 Hz, 2H), 8.19 (d, J=8.85 Hz, 2H), 7.28-7.25 (m, 
2H), 7.22 (m, 1H), 7.16 (d, J=7.1 Hz, 2H), 5.86 (dd, J=3.45, 15.4 Hz, 1H), 5.74 (dt, J=5.95, 
15.2Hz, 1H), 4.82 (d, J=5.9Hz, 2H), 4.50 (s, 2H), 2.86-2.84 (m, 2H), 1.40 (s, 9H).   
13C NMR (125 MHz, CDCl3) δ 164.4, 155.2, 150.7, 137.1, 135.9, 135.7, 130.9, 129.7, 128.5, 
126.8, 123.9, 123.7, 79.8, 65.7, 52.7, 41.6, 28.5. 
IR (film, cm-1):  3394, 2977, 2360, 1722, 1606, 1529, 1271, 1169. 
HRMS (ESI) m/z calc’d for C23H27N2O6 [m + H]+: 427.1869, found: 427.1866.   
 
Entry 5.  Ortho-nitrobenzoic acid. The General Procedure was followed using substrate 2a 
(78.4 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst 
(15.1 mg, 0.1 equiv., 0.03 mmol), and o-nitrobenzoic acid (75.2 mg, 1.5 equiv., 0.45 mmol). 1H 
NMR spectroscopy of the crude reaction mixture indicated a 15:1 dr (Run 1: 18:1; Run 2: 13:1; 
Avg. 15:1). Flash chromatography yielded 3a (Run1: 14.1 mg, 23%; Run 2: 19.6 mg, 32%; Avg. 
27%).  In one experiment we isolated from this mixture linear o-nitrobenzoate product 2ac, 
(65.3mg, 51% yield, >20:1 E/Z, 51%).   
 
 (E)-4-((tert-butoxycarbonyl)amino)-5-phenylpent-2-en-1-yl 2-nitrobenzoate: 
1H NMR (500 MHz, CDCl3) δ 7.92 (dd, J=1.1, 7.9Hz, 1H), 7.73-7.62 (m, 3H), 7.29-7.17 (m 
5H), 5.82 (dd, J=4.6, 15.5Hz, 1H), 5.71 (dt, J=6.2, 15.5Hz, 1H), 4.78 (d, J=6.0Hz, 2H), 4.50 (m, 
2H), 2.86 (m, 2H), 1.39 (s, 9H).   
HN Ot-Bu
O
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13C NMR (125 MHz, CDCl3) δ 165.2, 155.2, 148.3, 137.2, 136.1, 133.0, 131.9, 130.0, 129.7, 
128.5, 127.7, 126.7, 124.1, 123.2, 79.7, 66.3, 52.6, 41.6, 28.5.   
IR (film, cm-1): 3373, 2925, 1711, 1604, 1535, 1454, 1288, 1253, 1168, 1128, 1072.   
HRMS (ESI) m/z calc’d for C23H27N2O6 [m+H]+: 427.1869, found: 427.1865.   
 
Entry 6.  (BuO)2PO2H, 1.5 equiv. The General Procedure was followed using substrate 2a 
(78.4 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst 
(15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate (83.7 µL, 1.5 equiv., 0.45 mmol), added 
to the vial after 1,4-dioxane. 1H NMR spectroscopy of the crude reaction mixture indicated a 
>20:1 dr (Run 1: >20:1; Run 2: >20:1; Avg. >20:1). Flash chromatography yielded 3a (Run 1: 
31.5 mg, 52%; Run 2: 34.1mg, 56%; Avg. 54%). 
 
Entry 7. (PhO)2PO2H, 1.5 equiv. The General Procedure was followed using substrate 2a (78.4 
mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst (15.1 
mg, 0.1 equiv., 0.03 mmol), and diphenyl phosphate (37.5 mg, 0.5 equiv., 0.15 mmol). 1H NMR 
spectroscopy of the crude reaction mixture indicated a 15:1 (Run 1: >20:1; Run 2: 10:1; Avg. 
15:1) dr.  Flash chromatography yielded 3a (Run 1:  25.4 mg, 42%; Run 2: 25.6mg, 42%; Avg. 
42%). 
 
Entry 8. (BuO)2PO2H, 0.5 equiv.  The General Procedure was followed using substrate 2a 
(78.4 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst 
(15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate (28 µL, 0.5 equiv., 0.15 mmol), added 
to the vial after 1,4-dioxane. 1H NMR spectroscopy of the crude reaction mixture indicated a 
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>20:1 dr (Run 1: >20:1; Run 2: >20:1; Avg. >20:1). Flash chromatography yielded 3a (Run 1: 
38.2 mg, 63%; Run 2: 37.8 mg, 62%; Avg. 63%). 
 
Entry 9.  Gram-scale Procedure of optimized conditions in Entry 8.  The General Procedure 
was followed using substrate 2a (1.5 g, 1.0 equiv., 5.74 mmol), benzoquinone (931 mg, 1.5 
equiv., 8.61 mmol), White catalyst (289 mg, 0.1 equiv., 0.574 mmol), and dibutyl phosphate 
(534 µL, 0.5 equiv., 2.87 mmol) added to the vial after 1,4-dioxane (2.9 mL).  The reaction was 
run in a 20-mL scintillation vial.  After 24 h, the reaction was diluted with CH2Cl2, and washed 
with sat. NaHSO3 solution, then 5% K2CO3 solution. Combined organics were dried over 
anhydrous MgSO4, filtered and concentrated.  Flash chromatography yielded 3a (682.9 mg, 
59%), in >20:1 diastereomeric purity. 
 
Entry 10.  (BuO)2PO2H, 0.2 equiv. The General Procedure was followed using substrate 2a 
(78.4 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst 
(15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate (11 µL, 0.2 equiv., 0.06 mmol), added 
to the vial after 1,4-dioxane. 1H NMR spectroscopy of the crude reaction mixture indicated a 
>20:1 dr (Run 1: >20:1; Run 2: >20:1; Avg. >20:1).  Flash chromatography yielded 3a (Run 1: 
26.8 mg, 44%; Run 2: 27.9 mg, 46%; Avg. 45%).   
 
Entry 11. (BuO)2PO2H, 3 x 0.17 equiv. iterative addition. The General Procedure was 
followed using substrate 2a (78.4 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 
0.45 mmol), White catalyst (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate added in 
3x[10 µL, 0.17 equiv., 0.05 mmol] aliquots at t = 0 h, 1.5 h, and 3 h. 1H NMR spectroscopy of 
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the crude reaction mixture indicated a >20:1 dr (Run 1: >20:1; Run 2: >20:1; Avg. >20:1). Flash 
chromatography yielded 3a (Run 1: 39.0 mg, 64%; Run 2: 39.7 mg, 65%; Avg. 64%). 
 
Entry 12. Pd catalyst deletion. The General Procedure was followed using substrate 2a (78.4 
mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), and dibutyl 
phosphate (28 µL, 0.5 equiv., 0.15 mmol) , added to the vial after 1,4-dioxane. No product was 
observed, thus no diastereomeric ratio was determined.  Flash chromatography to recover 
starting material yielded 2a (Run 1: 75.9 mg, 97%; Run 2: 76.2 mg, 97%; Avg. 97%). 
 
Entry 13.  2,6-Dimethylbenzoquinone as oxidant.    The General Procedure was followed 
using substrate 2a (78.4 mg, 1.0 equiv., 0.3 mmol), 2,6-dimethylbenzoquinone (61.3 mg, 1.5 
equiv., 0.45 mmol), White catalyst (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate (28 
µL, 0.5 equiv., 0.15 mmol), added to the vial after 1,4-dioxane. 1H NMR spectroscopy of the 
crude reaction mixture indicated no observable 3a. Flash chromatography to recover starting 
material yielded 2a (Run 1: 72.0 mg, 92%; Run 2: 74.3 mg, 95%; Avg. 94%). 
 
Entry 14.  Cr(salen)Cl. The General Procedure was followed using substrate 2a (78.4 mg, 1.0 
equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst (15.1 mg, 0.1 
equiv., 0.03 mmol), and (R,R)-Cr(Salen)Cl (19.0 mg, 0.1 equiv., 0.03 mmol).  No product was 
observed, thus no diastereomeric ratio was determined. Flash chromatography to recover starting 
material yielded 2a (Run 1: 68.6 mg, 87%; Run 2: 68.2 mg, 87%; Avg. 87%). 
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Entry 15.  AgOTf.  The General Procedure was followed using substrate 2a (78.4 mg, 1.0 
equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst (15.1 mg, 0.1 
equiv., 0.03 mmol), and silver (I) trifluoromethanesulfonate (7.7 mg, 0.1 equiv., 0.03 mmol).  
Contents were dissolved in acetone (0.3 mL, 1.0 M), and the reaction stirred at 45°C for 4 h.  1H 
NMR spectroscopy of the crude reaction mixture indicated a 11:1 dr (Run 1: 11:1; Run 2: 11:1; 
Avg. 11:1), plus approx. 1.4:1.0 ratio of 3a:2a, with starting material olefin isomers present.  
Flash chromatography yielded 3a (Run 1: 27.6 mg, 45%; Run 2:  26.9 mg, 44%;  Avg. 45%). 
 
Entry 16.  B(C6F5)3. The General Procedure was followed using substrate 2a (78.4 mg, 1.0 
equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), White catalyst (15.1 mg, 0.1 
equiv., 0.03 mmol), and B(C6F5)3 (15.3 mg, 0.1 equiv., 0.03 mmol). Contents were dissolved in 
acetone (0.3 mL, 1.0 M), and stirred at 45°C for 4h.  1H NMR of the crude reaction mixture 
indicated a 11:1 dr (Run 1: 11:1; Run 2: 11:1; Avg. 11:1) plus approx. 0.75:1.0 ratio of 3a:2a  
with significant SM olefin isomers present.  Flash chromatography yielded 3a (Run 1: 14.98 mg, 
25%; Run 2: 15.5 mg, 26%; Avg. 25%). 
 
Entry 17.  Cu(OTf)2. Substrate 2a (78.4 mg, 1.0 equiv., 0.3 mmol), catalyst 1 (15.1mg, 0.1 
equiv., 0.03 mmol), Cu(OTf)2 (10.9 mg, 0.1 equiv., 0.03 mmol), and 1,4-benzoquinone (48.6 mg, 
1.5 equiv., 0.45 mmol), were dissolved in acetone (0.3 mL) and the vial capped with a Teflon-
lined cap.  The vial was stirred at 45°C for 8 h, then removed from heat and cooled to RT.  The 
contents were diluted with dichloromethane and transferred to a separatory funnel.  The contents 
were washed with sat. aq. sodium bisulfite (10 mL).  The aqueous layer was extracted with DCM 
(3x 10 mL), and the combined organic layers dried over anhydrous MgSO4, filtered over a Celite 
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plug, and concentrated.  1H NMR spectroscopy of the crude reaction mixture indicated a 6:1 dr 
(Run 1: 6:1; Run 2: 6:1; Avg. 6:1).  Column chromatography yielded 3a (Run 1: 24.9 mg, 41%; 
Run 2: 23.8 mg, 39%; Avg. 40%). 
 
Assignment of anti vs. syn relative stereochemistry for products 3.     
 
Stereochemistry for vinyloxazolidinone products was assigned based on the reported tendency of 
the CHN and CHO proton chemical shift to appear ~0.2-0.4 ppm higher in the syn diastereomer 
vs. the anti.  Table S2 summarizes the literature data for direct comparisons of selected known 
anti- and syn-vinyloxazoldinone products.  NOE studies were performed on sterically congested 
amine products 3o and 3p to determine the identity of the major diastereomer.   
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Substrate Scope for Table 2. 
General procedures for Pd-Phosphoric acid catalyzed Allylic C-H oxidation for the formation of 
vinyl oxazolidinones.   
Procedure A.  Single addition of (BuO)2PO2H.  
A 1-dram vial was sequentially charged with substrate 2 (1.0 equiv., 0.3mmol), benzoquinone 
(48.6mg, 1.5 equiv., 0.45mmol), and catalyst 1 (15.1mg, 0.1 equiv., 0.03mmol). A stir bar was 
added to the vial, then 1,4-dioxane (0.15 mL, 2.0M with respect to substrate) was added to the 
vial via syringe, followed by dibutyl phosphate (28 µL , 0.5 equiv., 0.15 mmol).  The vial was 
capped with a Teflon cap and stirred at 45°C for 24h.  The reaction was diluted with CH2Cl2 and 
R
O
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O
H
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Table 3. 1H NMR Literature Data for Diastereomers of Products 3 
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transferred to a separatory funnel.  The mixture was washed with H2O, the layers were separated 
and the aqueous layer was extracted with CH2Cl2 (3x 20 mL).  Combined organics were dried 
over MgSO4, filtered through a pad of Celite, and concentrated.  1H  NMR spectroscopy was 
performed on the crude mixture to determine the diastereomeric ratio.  Flash chromatography 
was performed to isolate pure product 3.   
Procedure B.  Iterative addition of (BuO)2PO2H. 
A 1-dram vial was sequentially charged with substrate 2 (1.0 equiv., 0.3 mmol), benzoquinone 
(48.6mg, 1.5 equiv., 0.45mmol), catalyst 1 (15.1mg, 0.1 equiv., 0.03mmol). A stir bar was added 
to the vial, then 1,4-dioxane (0.15 mL, 2.0M with respect to substrate) was added to the vial via 
syringe, followed by dibutyl phosphate (10 µL , 0.17 equiv., 0.15 mmol). The vial was capped 
with a septum cap and stirred at 45°C.  After 1.5 h, a second aliquot of dibutylphosphate (10 µL , 
0.17 equiv., 0.15 mmol)  was added via syringe through the septum cap.  After 1.5 more hours 
(3h total elapsed time), a third aliquot of dibutyl phosphate (10 µL , 0.17 equiv., 0.15 mmol ) 
was added via syringe through the septum cap, and the reaction stirred for an additional 21 h 
(24h total elapsed time). The reaction was diluted with CH2Cl2 and transferred to a separatory 
funnel.  The mixture was washed with H2O, the layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3x 20 mL).  Combined organics were dried over MgSO4, filtered through 
a pad of Celite, and concentrated. 1H  NMR spectroscopy was performed on the crude mixture to 
determine the diastereomeric ratio.  Flash chromatography was performed to isolate pure product 
3. 
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(±)-(4R,5R)-4-benzyl-5-vinyloxazolidin-2-one (3a):  Procedure A was followed using substrate 
2a (78.4 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), catalyst 1 
(15.1mg, 0.1 equiv., 0.03 mmol, and dibutyl phosphate (28 µL , 0.5 equiv., 0.15 mmol) in 1,4-
dioxane (0.15 mL). 1H NMR spectroscopy of the crude reaction mixture indicated a >20:1 dr 
(Run 1: >20:1; Run 2: >20:1; Avg >20:1). Flash chromatography (10% to 20% acetone/hexanes) 
yielded 3a (Run 1: 38.2mg, 63%; Run 2: 37.8mg, 62%; Avg = 63%).   
1H NMR (500MHz, CDCl3) δ 7.35 (m, 2H), 7.27 (m, 1H), 7.18 (m, 2H), 5.81 (ddd, J=6.5, 10.5, 
17.0Hz, 1H), 5.60 (s, 1H), 5.34 (d, J=17.0Hz, 1H), 5.27 (d, J=10.5Hz, 1H), 4.69 (t, J=6.5Hz, 
1H), 3.77 (q, J=7.5Hz, 1H), 2.92 (dd, J=6.0, 14.0Hz, 1H), 2.86 (dd, J=8.0, 13.5Hz, 1H).  
13C NMR (125 MHz, CDCl3) δ 158.5, 136.0, 134.0, 129.2, 129.1, 127.4, 119.1, 82.3, 59.7, 40.9.   
IR (film, cm-1): 3280, 2918, 1751,1454, 1387, 1234.   
HRMS (ESI) m/z calc’d for C12H14NO2 [m+H]+: 204.1025, found: 204.1032. Data is consistent 
with the literature report.7 
 
(±)-(4R,5R)-4-(tert-butyl)-5-vinyloxazolidin-2-one (3b):  Procedure A was followed using 
substrate 2b (68.2 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), 
catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutylphosphate (28 µL , 0.5 equiv., 0.15 
mmol) in 1,4 dioxane (0.15 mL). 1H NMR spectroscopy of the crude mixture indicated a >20:1 
HN
O
O
(±)-3b
77%, >20:1
O
HN
Ph
O
3a
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dr (Run 1: >20:1; Run 2: >20:1; Avg. >20:1).  Flash chromatography (10% to 20% 
acetone/hexanes) yielded 3b (Run 1: 39.3 mg, 75%;  Run 2: 40.0 mg; 79%; Avg. 77%).  
1H NMR (500MHz, CDCl3) δ 6.89 (s, 1H), 5.87 (ddd, J=6.5, 10.5, 17.0Hz, 1H), 5.39 (d, 
J=17.0Hz, 1H), 5.27 (d, J=10.5Hz, 1H), 4.74 (t, J=6.0Hz, 1H), 3.25 (d, J=5.0Hz, 1H), 0.92 (s, 
9H).  
13C NMR (125 MHz, CDCl3) δ 159.8, 136.0, 117.9, 78.7, 67.4, 34.0, 25.2.   
IR (film, cm-1):  3257, 2962, 1753, 1232.   
HRMS (ESI) m/z calc’d for C9H16NO2 [m+H]+: 170.1181, found: 170.1186.   
 
 
 
 (+/-)-(4R,5R)-4-isopropyl-5-vinyloxazolidin-2-one (3c): Procedure A was followed using 
substrate 2c (64.0 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), 
catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol) and dibutyl phosphate (28 µL , 0.5 equiv., 0.15 
mmol), in 1,4-dioxane (0.15 mL).  1H NMR of the crude reaction mixture indicated >20:1 dr 
(Run 1:  >20:1; Run 2: >20:1; Avg. >20:1).  Flash chromatography (10% to 20% 
Acetone/Hexanes) afforded 3c (Run 1: 31.4 mg, 67%; Run 2: 32.4 mg, 70%; Avg. 69%). 
1H NMR (500MHz, CDCl3) δ 6.75 (1H, br s), 5.83 (1H, ddd, J = 6.5, 10.5, 17 Hz), 5.34 (1H, d, J 
= 17 Hz), 5.22 (1H, d, J = 10.5 Hz), 4.61 (1H, t, J = 6.5 Hz), 3.24 (1H, t, J = 6.5 Hz), 1.83-1.67 
(1H, m), 0.90 (3H, d, J = 7 Hz), 0.87 (3H, d, J = 7 Hz). 
13C NMR (125MHz, CDCl3) δ 17.9, 18.1, 32.5, 64.0, 80.8, 118.3, 135.4, 159.9.  
HN
O
O
(±)-3c
69%, >20:1
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Data is consistent with the literature report. 54 
 
 
 
(±)- (4R,5R)-4-cyclohexyl-5-vinyloxazolidin-2-one (3d):  Procedure A was followed using 
substrate 2d (76.0 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), 
and catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), dibutylphosphate (28 µL , 0.5 equiv., 0.15 
mmol) were reacted in 1,4-dioxane (0.15 mL). 1H NMR spectroscopy of the crude mixture 
indicated a >20:1 diastereomeric ratio (Run 1: > 20:1; Run 2: > 20:1; Avg. >20:1).  Flash 
chromatography yielded 3d (Run 1: 42.8 mg, 73%, Run 2: 42.7 mg, 73%, Avg. 73%). 
1H NMR (500 MHz, CDCl3) δ 6.53 (s, 1H), 5.88 (ddd, J=6.5, 10.5, 17.1Hz, 1H), 5.41 (d, 
J=17.1Hz, 1H), 5.28 (d, J=10.5Hz, 1H), 4.72 (t, J=5.8Hz, 1H), 3.29 (t, J=6.2Hz, 1H), 1.80-1.67 
(m, 5H), 1.48-1.41 (m, 1H), 1.28-1.10 (m, 3H), 1.02-0.90 (m, 2H).   
13C NMR (125 MHz, CDCl3) δ 159.5, 135.5, 119.5, 80.9, 63.3, 42.3, 28.8, 28.6, 26.3, 25.9, 25.8.   
IR (film, cm-1): 3265, 2925, 2854, 1758, 1450, 1392, 1240.   
HRMS (ESI) m/z calc’d for C11H18NO2 [m + H]+: 196.1338, found: 196.1333. 
 
HN
O
O
(±)-3e
69%c, 7:1
HN
O
O
(±)-3d
73%, >20:1
	   39 
 (+/-)- (4R,5R)-4-isobutyl-5-vinyloxazolidin-2-one (3e):  Procedure B was followed using 
substrate 2e (68.2 mg, 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), catalyst 1 
(15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate (3 additions of (10 µL,0.17 equiv., 0.05 
mmol) at 0h, 1.5h, and 3h totaling 30 µL, 0.5 equiv., 0.15 mmol) in 1,4-dioxane (0.15 mL). 1H 
NMR spectroscopy of the crude mixture indicated a 7:1 diastereomeric ratio (Run 1: 7:1; Run 2: 
7:1; Avg. 7:1). Flash chromatography (10% to 15% acetone/hexanes) yielded pure 3e as a single 
diastereomer (Run 1: 35.4 mg, 69%; Run 2: 34.3 mg, 68%; Avg. 69%).   
1H NMR (500MHz, CDCl3) δ 6.30 (s, 1H), 5.89 (ddd, J=7.0, 10.5, 17.5 Hz, 1H), 5.40 (d, J=17.0 
Hz, 1H), 5.32 (d, J= 10.5 Hz, 1H), 4.52 (t, J=7 Hz, 1H), 3.60 (m, 1H), 1.67 (m, 1H), 1.52 (ddd, 
J=14.5, 8.6, 6.0Hz, 1H), 1.41 (m, 1H), 0.94 (d, J= 6.5 Hz, 3H), 0.92 (d, J=7.0 Hz, 3H).   
13C NMR (125 MHz, CDCl3) δ 159.5, 134.3, 119.4, 83.7, 56.8, 43.9, 25.2, 23.2, 22.2;  
IR (film, cm-1): 3269, 2956, 2871, 1755, 1648, 1467, 1427, 1388, 1369, 1321, 1271, 1225, 1165, 
1028, 989, 951; HRMS (ESI) m/z  calc’d for C9H16NO2 [m+H]+: 170.1181,  found: 170.1183.  
Data is consistent with the literature report.55 
  
 
 
(+/-)- (4S,5S)-4-methyl-5-vinyloxazolidin-2-one (3f):  Procedure B was followed using 
substrate 2f (55.6 mg, 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), catalyst 1 
(15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate (3 additions of (10 µL,0.17 equiv., 0.05 
mmol) at 0h, 1.5h, and 3h totaling 30 µL, 0.5 equiv., 0.15 mmol) in 1,4-dioxane (0.15 mL). 1H 
Me
HN
O
O
(±)-3f
57%c, 4:1
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NMR spectroscopy of the crude mixture indicated a 4:1 diastereomeric ratio (Run 1: 4:1, Run 2: 
4:1). Flash chromatography (10% to 20% acetone/hexanes) yielded 3f as a 9:1 diastereomeric 
ratio (Run 1: 21.9 mg, 57%, Run 2: 21.6 mg, 57%, avg: 57%).   
1H NMR (500 MHz, CDCl3) δ 6.57 (s, 1H), 5.87 (ddd, J=7.0, 10.5, 17.2Hz, 1H), 5.39 (d, 
J=17.2Hz, 1H), 5.30 (d, J=10.5Hz, 1H), 4.45 (t, J=7.0Hz, 1H), 3.64 (app. p, J=6.5Hz, 1H), 1.27 
(d, J=6.2Hz, 3H).   
13C NMR (125 MHz, CDCl3) δ 159.5, 133.8, 119.4, 84.8, 54.1, 19.6.   
IR (film, cm-1): 3293, 2973, 1758, 1412, 1383, 1234, 1016.   
HRMS (ESI) m/z calc’d for C6H10NO2 [m + H]+: 128.0712, found: 128.0713. 
 
 
(+)-N-methoxy-N-methyl-2-((4S,5S)-2-oxo-5-vinyloxazolidin-4-yl)acetamide (3g):  
Run 1: Substrate 2g (81.7 mg, 0.3 mmol) was subjected to Procedure B with benzoquinone (48.6 
mg, 1.5 equiv., 0.45 mmol), catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate 
(3 additions of (10 µL,0.17 equiv., 0.05 mmol) at 0h, 1.5h, and 3h totaling 30 µL, 0.5 equiv., 
0.15 mmol). 1H NMR spectroscopy of the crude mixture indicated an 8:1 diastereomeric ratio. 
Flash chromatography yielded 3g (25.1 mg, 39%) and recovered 2g (40.2 mg with approx. 30% 
unknown impurity, 33%). Recycling of the recovered starting material with appropriately scaled 
amounts of 1, benzoquinone, dibutylphosphate, and 1,4-dioxane yielded 3g (8.9 mg, 13%).  
Combined yield with 1 recycle: 52%.   
HN
O
O
N
O
MeO
(+)-3g
51%, 8:1
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Run 2: Substrate 2g (90 mg, 1.0 equiv., 0.33 mmol) was subjected to Procedure B with 
benzoquinone (53.5 mg, 1.5 equiv., 0.495 mmol), catalyst 1 (16.6 mg, 0.1 equiv., 0.033 mmol), 
and dibutyl phosphate (3 additions of (11 uL, 0.17 equiv., 0.055 mmol) at 0h, 1.5h, and 3h 
totaling 33uL, 0.5 equiv., 0.165 mmol).  1H NMR spectroscopy of the crude mixture indicated an 
8:1 diastereomeric ratio. Flash chromatography yielded 3g (27.4 mg, 39%) and recovered 2g 
(56.4 mg, approx. 2.3:1 with unknown impurity, 33%).  Recycling of the recovered starting 
material with appropriately scaled amounts of 1, benzoquinone, dibutylphosphate, and 1,4-
dioxane yielded 3g (7.0 mg, 9.9%).  Combined yield with 1 recycle: 49%. 
Average values:  51% yield, 8:1 dr. 
Additional purification of the isolated material allowed for isolation of 3g in >20:1 dr, which was 
used to measure the optical rotation.  
[α]D25 = +80.9˚ (c 1.81, CHCl3).   
1H NMR (500 MHz, CDCl3) δ 5.93 (ddd, J=6.8, 10.5, 17.2Hz, 1H), 5.68 (s, 1H), 5.44 (d, 
J=17.1Hz, 1H), 5.35 (d, J=10.5Hz, 1H), 4.61 (t, J=6.7Hz, 1H), 3.91 (m, 1H), 3.70 (s, 3H), 3.19 
(s, 3H), 2.83 (dd, J=2.6, 17.1Hz, 1H), 2.65 (dd, J=10.1, 17.1Hz, 1H).   
13C NMR (125 MHz, CDCl3) δ 171.1, 158.2, 133.8, 119.6, 82.0, 61.5, 54.7, 36.9, 32.2.   
IR (film, cm-1):  3299, 2927, 1759, 1651, 1390, 1228.   
HRMS (ESI) m/z calc’d for C9H15N2O4 [m + H]+: 215.1032, found: 215.1033.   
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(±)-tert-butyl 2-((4R,5R)-2-oxo-5-vinyloxazolidin-4-yl)acetate (3h): Procedure A was 
followed using substrate 2h (85.6 mg, 1.0 equiv., 0.3 mmol,), benzoquinone (48.6 mg, 1.5 
equiv., 0.45 mmol), catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutylphosphate (28 µL , 
0.5 equiv., 0.15 mmol) in 1,4 dioxane (0.15 mL). 1H NMR spectroscopy of the crude mixture 
indicated a >20:1 diastereomeric ratio (Run 1: >20:1 dr; Run 2: >20:1 dr; Avg. >20:1). Flash 
chromatography (10% to 20% acetone/hexanes) yielded 3h (Run 1: 36.6 mg, 54%; Run 2: 38.3 
mg, 56%; Avg.  55%).   
1H NMR (500MHz, CDCl3) δ 5.90 (ddd, J=7.0, 10.5, 17.0Hz, 1H), 5.80 (s, 1H), 5.43 (d, 
J=17.0Hz, 1H), 5.33 (d, J=10.5Hz, 1H), 4.56 (t, J=6.5Hz, 1H), 3.84 (m, 1H), 2.57 (dd, J=4.5, 
16.5Hz, 1H), 2.51 (dd, J=8.5, 16.5Hz, 1H), 1.45 (s, 9H).  
13C NMR (125 MHz, CDCl3) δ 169.8, 158.3, 133.6, 119.7, 82.3, 82.0, 54.7, 40.0, 28.2.   
IR (film, cm-1): 3288, 2979, 2935, 1764, 1726, 1394, 1369, 1157.   
HRMS (ESI) m/z calc’d for C11H18NO4 [m+H]+: 228.1236, found: 228.1235. 
 
 
 
HN
O
O
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(±)-(4R,5R)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-5-vinyloxazolidin-2-one (3i): Procedure 
A was followed using substrate 2i (131.9 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 
equiv., 0.45 mmol), catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutylphosphate (28 µL , 
0.5 equiv., 0.15 mmol) in 1,4 dioxane (0.15 mL). 1H NMR spectroscopy of the crude mixture 
indicated a >20:1 diastereomeric ratio (Run 1: >20:1 dr; Run 2: >20:1 dr; Avg. >20:1). Flash 
chromatography (10% to 20% acetone/hexanes) yielded 3i (Run 1: 78.1mg, 68%; Run 2: on 
0.136mmol = 1 equiv. scale: 35.6mg, 69% yield; Avg. 69%).   
1H NMR (500MHz, CDCl3) δ 7.63 (m, 4H), 7.39-7.47 (m, 6H), 5.95 (br s, 1H), 5.89 (ddd, J=6.5, 
10.5, 17.5Hz, 1H), 5.36 (d, J=17.0Hz, 1H), 5.28 (d, J=10.5Hz, 1H), 4.77 (t, J=6.0Hz, 1H), 3.65 
(m, 3H), 1.06 (s, 9H).  
13C NMR (125 MHz, CDCl3) δ 158.9, 135.7, 134.5, 132.7, 130.2, 128.1, 118.6, 79.4, 64.9, 59.3, 
26.9, 19.3.   
IR (film, cm-1): 3272, 2933, 2858, 1757, 1427, 1113.   
HRMS (ESI) m/z calc’d for C22H27NO3SiNa [m+Na]+: 404.1658, found: 404.1658. 
 
 
tert-butyl (4-((4S,5S)-2-oxo-5-vinyloxazolidin-4-yl)butyl)carbamate (3j):  Procedure A was 
followed using substrate (+)-2j (51.4 mg, 0.15 mmol, 1.0 equiv.), catalyst 1 (7.5 mg, 0.015 
mmol, 0.1 equiv.), benzoquinone (24.3 mg, 0.225 mmol, 1.5 equiv.), and dibutyl phosphate (14 
uL, 0.075 mmol, 0.5 equiv.) in 1,4-dioxane (0.075mL).  1H NMR of the crude reaction mixture 
indicated an approx. dr of 6:1 (Run 1: 6:1; Run 2: 6:1; Avg. 6:1).  Flash chromatography (30% 
3j
60%, 6 :1
BocHN
O
HN
O
n = 3
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acetone / hexanes) provided 3j (Run 1: 26.6 mg, 62%, 16:1 dr mixture; Run 2: 0.17 mmol scale: 
27.0 mg, 58% yield, 15:1 dr mixture);  Avg: 60%, 15:1 dr mixture).   
1H NMR (500 MHz, CDCl3) Major Diastereomer: δ 6.59 (s, 1H), 5.87 (ddd, J = 17.0, 10.0, 7.4 
Hz, 1H), 5.40 (d, J = 17.1 Hz, 1H), 5.30 (d, J = 10.4 Hz, 1H), 4.67 (s, 1H), 4.54 (t, J = 6.5 Hz, 
1H), 3.52 (q, J = 6.4 Hz, 1H), 3.10 (s, 2H), 1.68 – 1.54 (m, 3H), 1.54 – 1.46 (m, 3H), 1.43 (s, 
7H), 1.40 – 1.31 (m, 2H). 
13C NMR (125 MHz, CDCl3) δ 159.39 , 156.25 , 134.35 , 119.18 , 83.09 , 58.33 , 40.22 , 34.20 , 
29.82 , 28.55 , 22.61 .   
IR (film, cm-1): 3316, 2975, 2937, 2867, 1756, 1691, 1523, 1392, 1365, 1276, 1251, 1170, 1022. 
HRMS (ESI) m/z calc’d for C14H25N2O4 [m+H]+: 285.1814, found: 285.1820.   
 
Minor diastereomer:1H NMR (500 MHz, CDCl3) δ 5.05 – 4.99 (m, 1H), 3.87 – 3.81 (m, 1H).  
Only those peaks unobscured by the major diastereomer are listed. 
 
(+/-)-(4R,5R)-4-phenyl-5-vinyloxazolidin-2-one (3k):  Procedure B was followed using 
substrate 2k (74.2 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), 
catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutyl phosphate (3 additions of (10 µL,0.17 
equiv., 0.05 mmol) at 0h, 1.5h, and 3h totaling 30 µL, 0.5 equiv., 0.15 mmol) in 1,4-Dioxane 
(0.15 mL). 1H NMR spectroscopy of the crude mixture indicated a >20:1 diastereomeric ratio 
HN
O
O
(±)-3k
57%c, >20:1
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(Run 1: >20:1; Run 2: > 20:1; Avg. >20:1).  Flash chromatography (10% to 15% 
acetone/hexanes) yielded pure 3k (Run 1: 32.6 mg, 57%; Run 2: 32.5 mg; Avg. 57%).   
1H NMR (500 MHz, CDCl3) δ 7.42-7.33 (m, 5H), 6.02-5.95 (m, 2H), 5.36-5.33 (m, 2H), 4.72 (t, 
J=7.1Hz, 1H), 4.61 (d, J=7.4Hz, 1H).   
13C NMR (125 MHz, CDCl3) δ 158.9, 138.4, 133.3, 129.3, 129.0, 126.4, 120.0, 85.6, 62.6.   
IR (film, cm-1):   3276, 1757, 1456, 1383, 1224, 1030.   
HRMS (ESI) m/z calc’d for C11H12NO2 [m + H]+: 190.0868, found: 190.0871. 
 
 
(±)-(4R,5R)-4-(4-methoxybenzyl)-5-vinyloxazolidin-2-one (3l): Procedure A was followed 
using substrate 2l (87.4 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 
mmol), catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutylphosphate (28 µL , 0.5 equiv., 
0.15 mmol) in 1,4 dioxane (0.15 mL). 1H NMR spectroscopy of the crude mixture indicated a 
>20:1 diastereomeric ratio (Run 1: >20:1 dr; Run 2: >20:1 dr; Avg. >20:1).  Flash 
chromatography (10% to 20% acetone/hexanes) yielded 3l (Run 1: 42.2 mg, 60%;  Run 2: 40.8 
mg, 58% yield; Avg. 59%).   
1H NMR (500MHz, CDCl3) δ 7.09 (d, J=8.5Hz, 2H), 6.85 (d, J=8.5Hz, 2H), 5.79 (ddd, J=6.5, 
10.5, 17.0Hz, 1H), 5.77 (s, 1H), 5.32 (d, J=17.0Hz, 1H), 5.25 (d, J=10.5 Hz, 1H), 4.66 (t, J=6.5 
Hz), 3.79 (s, 3H), 3.72 (q, J=6.0Hz, 1H), 2.84 (dd, J=5.5, 13.5Hz, 1H), 2.79 (dd, J=7.5, 13.5Hz, 
1H).  
HN
O
O
MeO
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13C NMR (125 MHz, CDCl3) δ 158.9, 158.7, 134.1, 130.2, 127.9, 118.9, 114.4, 82.2, 59.8, 55.4, 
40.0.   
IR (film, cm-1):  3298, 2933, 1755, 1514, 1249.   
HRMS (ESI) m/z calc’d for C13H16NO3 [m+H]+: 234.1130, found: 234.1129. 
 
 (-)-tert-butyl 3-(((4S,5S)-2-oxo-5-vinyloxazolidin-4-yl)methyl)-1H-indole-1-carboxylate 
(3m):  Procedure B was followed using substrate 2m (60.0 mg, 1.0 equiv., 0.15 mmol), 
benzoquinone (24.3 mg, 1.5 equiv., 0.225 mmol), catalyst 1 (7.5 mg, 0.1 equiv., 0.015 mmol), 
and dibutyl phosphate (3 additions of (5 µL, 0.17 equiv., 0.025 mmol) at 0h, 1.5h, and 3h 
totaling 15 µL, 0.5 equiv., 0.075 mmol). 1H NMR spectroscopy of the crude mixture indicated a 
>20:1 diastereomeric ratio (Run 1: >20:1; Run 2: >20:1; Avg. >20:1).  Flash chromatography 
(20% acetone/hexanes) yielded (-)-3m (Run 1: 31.3 mg, 60%; Run 2: 28.1 mg, 55%; Avg. 58%).   
[α]D25 = -13.7°, (c 1.78, CHCl3).  
1H NMR (500MHz, CDCl3) δ 8.16 (d, J=6.5Hz, 1H), 7.48 (s, 1H), 7.47 (s, 1H), 7.35 (t, J-
=7.5Hz, 1H), 7.26 (t, J=7.5Hz, 1H), 5.88 (ddd, J=6.5, 10.5, 17.0Hz, 1H), 5.41 (d, J=18Hz, 2H 
overlaps with NH), 5.32 (d, J=10.5Hz, 1H), 4.73 (t, J=6.0Hz, 1H), 3.87 (dt, J=8.4, 5.6Hz, 1H), 
3.02 (dd, J=5.0, 14.5Hz, 1H), 2.93 (dd, J=8.0, 14.0Hz, 1H), 1.68 (s, 9H).  
13C NMR (125 MHz, CDCl3) δ 158.3, 149.6, 134.0, 129.9, 125.1, 124.1, 122.9, 119.3, 118.6, 
115.7, 115.0, 84.2, 82.5, 58.1, 30.5, 28.3.   
IR (film, cm-1): 3280, 2979, 2931, 2360, 1757, 1737, 1454, 1371, 1159.   
HRMS (ESI) m/z calc’d for C19H23N2O4 [m+H]+: 343.1658, found: 343.1667. 
HN
O
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4,4-dimethyl-5-vinyloxazolidin-2-one (3n): Procedure A was followed using substrate 2n (59.8 
mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 mmol), catalyst 1 (15.1 mg, 
0.1 equiv., 0.03 mmol), and dibutylphosphate (28 µL , 0.5 equiv., 0.15 mmol) in 1,4 dioxane 
(0.15 mL). Flash chromatography (10% to 20% acetone/hexanes) yielded 3n (Run 1: 25.1 mg, 
59%; Run 2:  25.9 mg, 61%; Avg. 60 %).  
1H NMR (500 MHz, CDCl3) δ 6.30 (s, 1H), 5.83 (ddd, J=7.1, 10.6, 17.5Hz, 1H), 5.44 (d, 
J=7.2Hz, 1H), 5.36 (d, J=10.6Hz, 1H), 4.56 (d, J=7.1Hz, 1H), 1.32 (s, 3H), 1.15 (s, 3H).   
13C NMR (125 MHz, CDCl3) δ 158.9, 130.9, 120.2, 86.9, 58.4, 27.1, 23.8.   
IR (film, cm-1): 3290, 2975, 1753, 1388, 1371, 1031.   
HRMS (ESI) m/z calc’d for C7H12NO2 [m + H]+: 142.0868, found: 142.0867. 
 
 (±)- (4R,5R)-4-isopropyl-4-methyl-5-vinyloxazolidin-2-one (3o): Procedure A was followed 
using substrate 2o (68.2 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 
mmol), catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutylphosphate (28 µL , 0.5 equiv., 
0.15 mmol) in 1,4 dioxane (0.15 mL). 1H NMR spectroscopy of the crude mixture indicated a 5:1 
Me
HN
O
O
Me
3n
60%
HN
O
O
Me
(±)-3o
71%, 5:1
	   48 
diastereomeric ratio (Run 1: 5:1; Run 2: 5:1; Avg. 5:1). Flash chromatography (10% to 20% 
acetone/hexanes) yielded 3o (Run 1: 35.8 mg, 70%; Run 2: 36.6 mg, 72%; Avg. 71%). 
1H NMR (500 MHz, CDCl3) δ 5.84 (ddd, J=17.1, 10.55, 6.7 Hz, 1H), 5.47 (d, J= 17.1 Hz, 1H), 
5.37 (d, J=10.55 Hz, 1H), 5.25 (s, 1H), 4.75 (d, J=6.65 Hz, 1H), 1.86 (heptet, J=6.85 Hz, 1H), 
1.11 (s, 3H), 0.97 (d, J=6.8 Hz, 3H), 0.94 (d, J = 6.9Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 158.0, 132.2, 119.8, 84.1, 63.2, 37.4, 18.7, 17.4, 17.2. 
IR (film, cm-1): 3251, 2966, 2360, 1751, 1467, 1367, 1284. 
HRMS (ESI) m/z calc’d for C9H16NO2 [m +H]+: 170.1181, found: 170.1183. 
 
  
Minor diastereomer syn-3o: 1H NMR (500 MHz, CDCl3) δ 5.97 (ddd, J=7.35, 10.5, 17.4 Hz, 
1H), 5.46 (d, J=17.1 Hz, 1H), 4.61 (d, J=7.35 Hz, 1H), 1.25 (s, 3H), 0.86 (d, J=6.85, 3H).  Only 
unobscured peaks are listed; data obtained from a ~9:1 anti/syn dr mixture.   
 
 
(±)-(4R,5R)-4-(4-methoxybenzyl)-4-methyl-5-vinyloxazolidin-2-one (3p): Procedure A was 
followed using substrate 2p (91.6 mg, 1.0 equiv., 0.3 mmol), benzoquinone (48.6 mg, 1.5 equiv., 
0.45 mmol), catalyst 1 (15.1 mg, 0.1 equiv., 0.03 mmol), and dibutylphosphate (28 µL , 0.5 
equiv., 0.15 mmol) in 1,4 dioxane (0.15mL). 1H NMR spectroscopy of the crude mixture 
HN
O
O
Me
MeO
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61%, 4:1
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indicated a 4:1 diastereomeric ratio (Run 1: 4:1 dr; Run 2: 4:1 dr; Avg. 4:1). Flash 
chromatography (10% to 20% acetone/hexanes) yielded 3p (Run 1: 45.5 mg, 61%;  Run 2: 44.1 
mg, 60%; Avg. 61%). 
1H NMR (500 MHz, CDCl3) δ 7.09 (d, J = 8.6 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 5.81 (ddd, J = 
17.3, 10.6, 6.9 Hz, 0H), 5.45 (dt, J = 17.1, 1.1 Hz, 1H), 5.37 (dt, J = 10.6, 1.1 Hz, 1H), 5.32 (s, 
0H), 3.80 (s, 2H), 2.83 (d, J = 13.7 Hz, 1H), 2.76 (d, J = 13.6 Hz, 1H), 1.11 (s, 1H). 
13C NMR (125 MHz, CDCl3) δ 159.04 , 158.03 , 131.39 , 131.13 , 127.21 , 120.15 , 114.23 , 
85.28 , 61.31 , 55.42 , 45.41 , 21.94 . 
IR (film, cm-1): 3272, 2969, 2915, 2836, 1751, 1612, 1513, 1463, 1382, 1301, 1251, 1180, 1116, 
1030. 
HRMS (ESI) m/z calc’d for C14H18NO3 [m + H]+: 248.1287, found: 248.1292.   
 
Applications to synthesis of hydroxyamino acid motifs from Figure 3. 
 
(±)- (4R,5S)-4-benzyl-2-oxooxazolidine-5-carboxylic acid (4a):  (±)-3a (100 mg, 1.0 equiv., 
0.49 mmol) was dissolved in MeCN (1 mL), CCl4 (2 mL), and H2O (3 mL) in a 40mL 
scintillation vial, and the mixture cooled to 0°C.  RuCl3 xH2O (6.5 mg, 0.05 equiv., 0.025 mmol) 
in MeCN (0.5 mL + 0.5 mL wash) was added to the vial, followed by H5IO6 (670 mg, 6.0 equiv., 
2.94 mmol).  The mixture was stirred for 5-10 min at 0°C and then warmed to RT and stirred 
until complete conversion of 3a was observed by TLC (4-5 h).  The reaction mixture was diluted 
with 1M KHSO4 solution and extracted with EtOAc (4 x 30 mL), dried over anhydrous MgSO4, 
HN O
CO2H
O
Ph
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filtered through a pad of Celite, and concentrated to yield 4a (Run 1: 94.9 mg, 88%; Run 2: 98.3 
mg, 91%; Avg. 89% yield) as an off-white solid in sufficient purity for further transformations. 
1H NMR (500 MHz, CDCl3) δ 7.36 (m, 2H), 7.30 (t, J=7.3Hz, 1H), 7.05 (d, J=7.0Hz, 2H), 5.61 
(s, 1H), 4.76 (d, J=4.6Hz, 1H), 4.19 (dt, J=4.7, 9.2 Hz, 1H), 3.11 (dd, J=4.9, 13.7 Hz, 1H), 2.91 
(dd, J=8.6, 13.7 Hz, 1H).   
HRMS (ESI) calc’d for C11H12NO4 [m + H]+: 222.0766, found: 222.0758.   
Data are in agreement with the literature report.56, 57 
 
(±)-(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid, hydrochloride salt (4):  
Oxazolidinone-carboxylic acid (±)-4a (98.4 mg, 1.0 equiv., 0.446 mmol) was dissolved in 6M 
HCl solution (2.5 mL, 0.18M) in a 20 mL scintillation vial.  The vial was capped with a Teflon-
lined cap, and stirred at 100°C for 16 h.  The vial was cooled to RT, and the contents were 
transferred to a separatory funnel with the aid of H2O and Et2O.  The aqueous phase was washed 
with Et2O (2 x 20 mL), and the combined aqueous layers were concentrated via rotary 
evaporation at 60°C.  The crude residue was dissolved in H2O (3 mL) and passed through a 
column of DOWEX-50w x8 200 resin (H+ type), eluting first with H2O (25 mL), followed by 
1M NH4OH solution (50 mL).  The combined NH4OH portions were concentrated by rotary 
evaporation at 60°C (note: the solution is highly prone to bumping during rotary evaporation). 
To form the hydrochloride salt, 10% HCl solution (3 mL) was added to the flask containing the 
concentrated residue, and the mixture again concentrated, with a few cycles of addition of H2O 
and concentration to remove excess H2O and HCl.  The residue was then dissolved in 3-4 mL of 
CO2HPh
NH2•HCl
OH(±)-4
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H2O, the solution frozen by placing in a -78°C bath for 5 min., and lyophilized for 36 h, yielding 
4 (101.2mg, 97% yield).   
1H NMR (500 MHz, D2O) δ 7.44-7.41 (m, 2H), 7.38-7.35 (m, 3H), 4.33 (m, 1H), 3.95-3.93 (m, 
1H), 3.14 (dd, J=7.3, 14.05 Hz, 1H), 3.01 (dd, J=8.05, 13.9 Hz), 1H.   
HRMS (ESI) calc’d for C10H14NO3 [m + H]+: 196.0974, found: 196.0974. 
These data are in agreement with the literature report.55 
 
tert-butyl (2-((4S,5S)-2-oxo-5-vinyloxazolidin-4-yl)acetyl)-L-leucinate (6):   
Run 1: Due to the poor solubility of 5, 5 (79.7 mg, 0.2 mmol) was dissolved in CH2Cl2 and 
blown down to near dryness with a stream of dry nitrogen, then subjected to Procedure B with 
benzoquinone (32.4 mg, 1.5 equiv., 0.3 mmol), catalyst 1 (10.1 mg, 0.1 equiv., 0.02 mmol), and 
dibutyl phosphate (3 additions of (6 µL, 0.17 equiv., 0.033 mmol) at 0h, 1.5h, and 3h totaling 18 
µL, 0.5 equiv., 0.1 mmol). 1H NMR spectroscopy of the crude mixture indicated a 6:1 
diastereomeric ratio.  Flash chromatography (20% to 40% acetone/hexanes) yielded pure 6 
(38.9mg, 57%, 6:1 mixture of diastereomers). 
Run 2:  Substrate 5 (66.4 mg, 1.0 equiv., 0.17 mmol) was subjected as above with benzoquinone 
(28.1 mg, 1.5 equiv., 0.26 mmol), catalyst 1 (8.5 mg, 0.1 equiv., 0.017 mmol), dibutylphosphate 
(3 additions of (6 uL, 0.17 equiv., 0.028 mmol) at 0h, 1.5h, and 3h, totaling 18 uL, 0.5 equiv., 
0.085 mmol).  1H NMR spectroscopy of the crude mixture indicated a 6:1 diastereomeric ratio.  
Flash chromatography (20% to 40% acetone / hexanes) yielded 6 (32.9 mg, 57%, 6:1 mixture of 
diastereomers).   
6, 57%, 6:1
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Averge values:  57% yield, 6:1 dr. 
1H NMR (500 MHz, CDCl3) δ 6.50 (s, 1H), 5.92 (ddd, J = 17.2, 10.4, 6.8 Hz, 1H), 5.43 (d, J = 
17.1 Hz, 1H), 5.34 (d, J = 10.4 Hz, 1H), 4.57 (t, J = 6.4 Hz, 1H), 4.43 (td, J = 8.9, 8.4, 5.2 Hz, 
1H), 2.52 – 2.48 (m, 2H), 1.72 – 1.63 (m, 1H), 1.55 (ddd, J = 21.3, 8.9, 5.4 Hz, 2H), 1.46 (s, 9H), 
0.94 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.5 Hz, 4H). 
13C NMR (125 MHz, CDCl3) δ 173.12 , 169.72 , 158.53 , 133.68 , 119.57 , 82.68 , 82.25 , 55.84 , 
51.87 , 41.20 , 41.09 , 28.13 , 25.14 , 23.02 , 21.84 . 
HRMS (ESI) m/z calc’d for C17H29N2O5 [m + H]+: 341.2076, found: 341.2071. 
IR (film, cm-1): 3305, 2960, 1755, 1658, 1546, 1369, 1151. 
 
 
Minor diastereomer (syn-6): 
1H NMR (500 MHz, CDCl3) δ 6.58 (s, 1H), 5.82 (ddd, J = 17.2, 10.6, 6.7 Hz, 1H), 5.49 (d, J = 
17.2 Hz, 1H), 5.12 (t, J = 7.4 Hz, 1H), 4.28 (ddd, J = 11.3, 8.3, 3.4 Hz, 1H), 2.41 (dd, J = 14.1, 
11.0 Hz, 1H), 2.29 (dd, J = 14.0, 3.4 Hz, 1H).  (only the peaks with no overlap with the major 
diastereomer are listed).   
13C NMR (125 MHz, CDCl3) δ 207.71 , 170.45 , 130.66 , 79.46 , 53.70 , 38.16 , 29.85. (minor 
peaks observed in the mixture).    
Regiodivergent synthesis of 1,2-amino alcohols from Figure 4. 
N
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 (+)-(S)-N-((S,E)-2-((tert-butyldimethylsilyl)oxy)propylidene)-2-methylpropane-2-
sulfinamide (7a): Prepared according to a modified literature procedure.  To a solution of 
freshly prepared aldehyde (-)-758 (1.7 g, 9.1 mmol, 1.5 equiv.) in THF (20 mL) at rt under a 
nitrogen atmosphere was added Ti(OEt)4 (0.259 mL, 12.38 mmol, 2.0 equiv.). The mixture was 
stirred for 5 min, then (Ss)-tert-butane sulfinamide (749.9 mg, 6.19 mmol, 1.0 equiv.) was added, 
and the reaction stirred at rt for 24h.  The mixture was diluted with EtOAc and poured into a 
rapidly stirring solution of brine (15 mL), and the resulting slurry stirred for 30 min.  The slurry 
was then filtered through a pad of Celite, and the filter cake was washed several times with 
EtOAc.  The filtered solution was extracted with EtOAc (3 x 30 mL), dried over MgSO4, and 
concentrated.  Flash chromatography (10-15% EtOAc / Hexanes) afforded 1.31 g of 7a, 73% 
yield as a single diastereomer.  
[α]D25 = +168.9º (c 1.05, CHCl3). Data is in agreement with the literature report for this 
compound.22 
    
 (S)-N-((2S,3R)-2-((tert-butyldimethylsilyl)oxy)hex-5-en-3-yl)-2-methylpropane-2-
sulfinamide (7b):  Aldimine 7a (676.3 mg, 2.31 mmol, 1.0 equiv.) in CH2Cl2 (15 mL) was 
cooled to -78ºC.  Then, freshly prepared allylmagnesium bromide (5mL of 1.0M solution in 
Et2O, 2.0 equiv.) was added slowly dropwise to the reaction mixture.  The reaction was stirred at 
-78ºC, monitoring by TLC for conversion.  Upon completion (approx. 3h), the reaction was 
OTBS
H
N S O
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quenched at -78ºC by addition of 10% aq. HCl solution and then warmed to RT.  The aqueous 
layer was extracted with EtOAc (3x 20 mL), and combined organics were dried over anhydrous 
MgSO4 and concentrated.  Flash chromatography (20% to 33% EtOAc / Hexanes) yielded the 
title compound as a single diastereomer (598.2 mg, 78% yield).  
[α]D26 = +56.14º (c 1.14, CHCl3).  
1H NMR (500MHz, CDCl3) δ 5.86 (m, 1H), 5.16 (m, 2H), 3.80 (m, 1H), 3.37 (d, J=7.0Hz, 1H), 
3.21 (m, 1H), 2.42 (m, 2H), 1.21 (s, 9H), 1.14 (d, J=6.5 Hz, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.05 
(s, 3H).  
13C NMR (125 MHz, CDCl3) δ 134.8, 118.8, 70.8, 61.3, 56.2, 36.1, 25.9, 22.9, 20.0, 18.1, -3.95, 
-4.66.  
IR (film, cm-1): 3242, 3078, 2594, 2858, 2362, 1641, 1471, 1363, 1255.   
HRMS (ESI) calc’d for C16H36NO2SiS [m + H]+: 334.2236, found: 334.2237.   
These data are in agreement with the literature report of this compound.22 
 
 
 (+)- tert-butyl ((2S,3R)-2-((tert-butyldimethylsilyl)oxy)hex-5-en-3-yl)carbamate (8):  
Preparation of HCl-Dioxane solution:  At rt under nitrogen atmosphere, a solution of MeOH 
(0.13 mL, 3.3 mmol) in 1,4-dioxane (3.0 mL) was treated with acetyl chloride slowly dropwise 
(0.21 mL, 3.0 mmol).  The reaction was stirred for 20 min after the addition to ensure complete 
conversion, before use in the deprotection step.  Sulfinamide Deprotection / N-Boc protection: 
To a solution of 7b (100 mg, 0.3 mmol, 1.0 equiv.) in Et2O (3 mL) at 0ºC was added freshly 
prepared HCl (0.9 mL of 1.0M solution in dioxane, 0.9 mmol, 3.0 equiv.).  The mixture was 
OTBS
NHBoc
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allowed to warm to rt while stirring overnight. The reaction mixture was concentrated by 
blowing a stream of dry nitrogen over the mixture for approximately 20 min.  The crude material 
was dissolved in THF (0.75 mL) and H2O (0.75 mL) at rt, followed by the addition of NaHCO3 
(75.6 mg, 0.9 mmol, 3.0 equiv.) and Boc2O (0.14 mL, 0.6 mmol, 2.0 equiv.).  The mixture was 
stirred for 24 h, then diluted with EtOAc and H2O.  The aqueous layer was extracted with EtOAc 
(3x 20 mL), and combined organics were dried over MgSO4 and concentrated.  Flash 
chromatography (5% EtOAc / Hexanes) provided the title compound (74.7 mg, 76% yield).  
[α]D25 = +22.7º (c 1.17, CHCl3).  
1H NMR (500MHz, CDCl3) δ 5.86-5.77 (m, 1H), 5.09-5.03 (m, 2H), 4.53 (d, J=9.5Hz, 1H), 3.93 
(m, 1H), 3.51 (m, 1H), 2.35-2.30 (m, 1H), 2.18-2.12 (m, 1H), 1.43 (s, 9H), 1.13 (d, J=6.5 Hz, 
3H), 0.89 (s, 9H), 0.05 (s, 6H).  
13C NMR (125 MHz, CDCl3) δ 155.7, 135.7, 117.1, 79.1, 70.3, 55.4, 33.0, 28.6, 25.7, 20.5, 18.1, 
-4.3, -4.8.   
IR (film, cm-1): 3338, 2954, 2858, 1718, 1704, 1500, 1365, 1253, 1174.   
HRMS (ESI) calc’d for C17H35NO3SiNa [M + Na]+: 352.2284, found: 352.2284.   
 
 (-)-(4R,5S)-4-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-vinyloxazolidin-2-one (9):  
Procedure A was followed using (+)-8 (300 mg, 0.91 mmol, 1.0 equiv.), catalyst 1 (45.3 mg, 
0.09 mmol, 0.1 equiv.), benzoquinone (148.1 mg, 1.37 mmol, 1.5 equiv.), and dibutylphosphate 
(84.7 uL, 0.455 mmol, 0.5 equiv.) in 1,4-dioxane (0.46 mL).  1H NMR of the crude reaction 
OTBS
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mixture indicated >20:1 dr.  Flash chromatography (10 to 20% acetone / hexanes) afforded 9 
(161.0 mg, 63% yield).   
[α]D24 = -16.1˚ (c 0.87, CHCl3).   
1H NMR (500 MHz, CDCl3) δ 6.71 (s, 1H), 5.89 (ddd, J=6.0, 10.5, 17.0 Hz, 1H), 5.40 (d, J=17.5 
Hz, 1H), 5.26 (d, J=10.5Hz, 1H), 4.90 (t, J=6.0 Hz, 1H), 3.79 (m, 1H), 3.37 (t, J=4.2Hz, 1H), 
1.14 (d, J=6.5Hz, 3H), 0.88 (s, 9H), 0.07 (s, 6H).   
13C NMR (125 MHz, CDCl3) δ 159.6, 135.6, 117.5, 78.5, 69.5, 63.8, 25.8, 19.8, 18.0, -4.2, -4.7.   
IR (film, cm-1): 3271, 2929, 2856, 1739, 1471, 1389, 1255, 1224, 1146, 1088.   
HRMS (ESI) m/z calc’d for C13H26NO3Si [m + H]+: 272.1682, found: 272.1683. 
 
 (-)-(4R,5S)-4-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-3-methyl-5-vinyloxazolidin-2-one 
(9b):  NaH (6.8 mg, 60% in mineral oil, 0.17 mmol, 1.5 equiv.) was dissolved in DMF under 
nitrogen atmosphere in a flame-dried round bottom flask, and cooled to 0°C. Oxazolidinone (-)-9  
(30 mg, 0.11 mmol, 1.0 equiv.) in DMF was then added dropwise and the mixture stirred at 0C 
for 90 min.  Methyl iodide (17 uL, 0.28 mmol, 2.5 equiv.) was added dropwise, and the mixture 
stirred at 0C until full conversion was observed by TLC (approx. 2h).  The solution was diluted 
with Et2O, and quenched with sat. NH4Cl solution.  The aqueous layer was extraced with Et2O 
(4x 20 mL).  Combined organics were washed with brine, dried over anhydrous MgSO4, filtered 
and concentrated.  Flash chromatography (25% EtOAc / Hexanes) afforded 9b (28.8 mg, 92% 
yield).   
[α]D26 = -23.2˚ (c 1.44, CHCl3).   
OTBS
O
N
O
(-)-9b
Me
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1H NMR (500 MHz, CDCl3) δ 5.85 (ddd, J=6.5, 10.5, 17.0Hz, 1H), 5.40 (d, J=17.0Hz, 1H), 5.26 
(d, J=10.5Hz, 1H), 4.78 (t, J=6.0Hz, 1H), 4.02 (dq, J=2.0, 6.5Hz, 1H), 3.24 (dd, J=2.0, 5.0Hz, 
1H), 2.88 (s, 3H), 1.13 (d, J=6.5Hz, 3H), 0.87 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H).   
13C NMR (125 MHz, CDCl3) δ 158.1, 135.9, 117.8, 74.3, 68.4, 65.9, 29.9, 25.7, 18.9, 17.9, -4.1, 
-4.9.   
IR (film, cm-1): 2954, 2929, 2858, 1757, 1432, 1405, 1255, 1147, 1078.   
HRMS (ESI) m/z calc’d for C14H28NO3Si [m + H]+: 286.1838, found: 286.1829. 
 
 (-)-(4R,5S)-4-((S)-1-((tert-butyldimethylsilyl)oxy)ethyl)-5-(2-hydroxyethyl)-3-
methyloxazolidin-2-one (10):  Oxazolidinone (-)-9b (28.8 mg, 0.1 mmol, 1.0 equiv.) was 
dissolved in THF in a flame-dried 2-dram vial under nitrogen atmosphere.  9-BBN solution (0.6 
mL of 0.5 M solution, 0.3 mmol, 3.0 equiv.) was added, and the vial heated in a 50˚C for 18h.  
The vial was removed from heat and cooled to 0˚C. THF (1 mL) was added, followed by 6N 
NaOH (67 µL), 30% H2O2 solution (0.12 mL), and EtOH (0.2 mL).  Some white foamy 
precipitate was observed immediately following the addition of these reagents.  The vial was 
placed in a 50˚C bath and stirred, at which point the precipitate dissolved.  After approx. 4h full 
conversion was observed by TLC.  The crude reaction mixture was concentrated and loaded 
directly onto a silica gel column for flash chromatography purification.  Flash chromatography 
(30% Acetone / Hexanes) afforded the title compound (20.7 mg, 68% yield).   
[α]D26 = -37.6 ˚ (c 1.035, CHCl3).   
OTBS
O
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O
OH
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1H NMR (500 MHz, CDCl3) δ 4.51 (dt, J=8.9, 4.4Hz, 1H), 3.98 (dq, J=1.9, 6.4Hz, 1H), 3.87-
3.79 (m, 2H), 3.25 (dd, J=1.95, 4.5Hz, 1H), 2.89 (s, 3H), 1.95-1.89 (m, 1H), 1.85-1.79 (m, 1H), 
1.24 (s, 1H), 1.12 (d, J=6.4Hz, 3H), 0.87 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H).   
13C NMR (125 MHz, CDCl3) δ 158.2, 72.0, 68.4, 66.5, 58.8, 38.7, 30.1, 25.7, 18.6, 17.9, -4.2, -
4.9.   
IR (film, cm-1): 3421, 2929, 2858, 1739, 1440, 1255, 1151, 1091, 1056.   
HRMS (ESI) m/z calc’d for C14H30NO4Si [m + H]+: 304.1944, found: 304.1939. 
 
 Synthesis of 11 was conducted according to a modified literature procedure.59 Allylic 
alcohol 11a60 (100 mg, 1.0 equiv., 0.44 mmol) was dissolved in pyridine (250 µL, 2.5 mL/g 
substrate) and cooled to 0°C.  Diethyl chlorophosphate (70 µL, 1.1 equiv., 0.48 mmol) was 
added dropwise to the stirring solution and the resulting solution stirred at 0°C for 1h.  H2O (0.5 
mL, 2 mL / mL pyridine) was added to quench the reaction.  The aqueous layer was extracted 
with Et2O (2 x 25 mL).  Combined organics were washed with 10% aq. HCl, sat. NaHCO3, and 
H2O, then dried over anhydrous MgSO4 and concentrated, yielding 11 (144.9mg, 90% yield).  
Due to the presumed instability of 11 to silica gel, flash chromatography was not performed. In 
cases where residual pyridine impurities were observed by 1H NMR of the crude product, 
redissolving the crude product in Et2O and performing additional washes with 10% HCl 
followed by drying the organics over anhydrous MgSO4 served to remove the remaining 
pyridine.   
Equation 1. Synthesis of Allylic Phosphate 11 
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1H NMR (500 MHz, CDCl3) δ 5.72-5.65 (m, 2H), 4.51 (m, 3H), 4.08 (pentet, J=6.9 Hz, 4H), 
3.99 (m, 1H), 1.77-1.73 (m, 1H), 1.41 (s, 9H), 1.30 (t, J=7.1 Hz, 6H), 0.88 (d, J=6.9Hz, 3H), 
0.86 (d, J=6.9 Hz, 3H).   
13C NMR (125 MHz, CDCl3) δ 155.54 , 134.00 , 125.42 (d, J = 6.9 Hz), 79.42 , 67.35 (d, J = 5.5 
Hz), 63.84 (d, J = 5.9 Hz), 56.92 , 32.48 , 28.47 , 18.82 , 18.13 , 16.25 , 16.20. 
IR (film, cm-1):  3345, 2991, 2360, 2331, 1709, 1523, 1390, 1365, 1265, 1172. 
HRMS calc’d for C16H33NO6P [m +H]+: 366.2046, found: 366.2046. 
Equation 2. Reactivity of 11 Under Standard Conditions 
 
 A 1-dram vial was charged with 11 (36.5 mg, 1.0 equiv., 0.1 mmol), catalyst 1 (5.0 mg, 
0.1 equiv., 0.01 mmol), benzoquinone (16.2 mg, 1.5 equiv., 0.15 mmol), 1,4-dioxane-d8 (50 µL), 
and nitrobenzene internal standard (3 uL), and stirred at 45°C for 24 h.  1H NMR spectroscopy of 
the mixture indicated a 38% yield of 3a, >20:1 dr.   
Equation 3. Competition Experiment 
 
Procedure A was followed using substrate 2a (52.3 mg, 0.2 mmol, 1.0 equiv.), allylic 
phosphate 11 (73.1 mg, 0.2 mmol, 1.0 equiv.), catalyst 1 (10.1 mg, 0.02 mmol, 0.1 equiv.), 
benzoquinone (32.4 mg, 0.3 mmol, 1.5 equiv.), dibutyl phosphate (18.6 µL, 0.1 mmol, 0.5 
equiv.) in 1,4-dioxane (0.1 mL).  Run 1: 1H NMR analysis of the crude reaction mixture 
indicated a 2:1 mixture of 3a to 3c, each in >20:1 dr.  Flash chromatography (10% acetone / 
NHBoc
OPO3Et2
11
1  (10 mol%)
(BuO)2PO2H (50 mol%)
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hexanes to 20%) yielded 31.3 mg of a 2:1 mixture of 3a and 3c, corresponding to 56% yield 3a 
and 28% yield 3c.  Run 2:  1H NMR analysis of the crude reaction mixture indicated a 2:1 
mixture of 3a to 3c, each in >20:1 dr.  Flash chromatography yielded 31.8 mg of a 2:1 mixture of 
3a and 3c, corresponding to 56% yield 3a  and 28% yield 3c.  Avg. values:  56% 3a, 28% 3c, 
>20:1 dr for both products. 
Kinetic comparison of allylic phosphate 11 vs. terminal olefin substrate 2c from Figure 5.   
General procedure for the kinetic study: A ½ dram vial was charged with 2c (21.3 mg, 1.0 
equiv., 0.1 mmol) or 11 (36.5 mg, 1.0 equiv., 0.1 mmol), catalyst 1 (5.0 mg, 0.1 equiv., 0.01 
mmol), benzoquinone (16.2 mg, 1.5 equiv., 0.15 mmol).  The contents were then dissolved in 
1,4-dioxane-d8 (0.2 mL, 0.5 M), and dibutylphosphate (10 uL, 0.5 equiv., 0.05 mmol) was added, 
followed by internal standard nitrobenzene (3 µL).  Note:  The reaction concentration was 
lowered to ensure full solubility of all components and to facilitate analysis of the reaction by 
NMR. The vial was capped with a septum cap and stirred at RT. Time points were recorded by 
removal of 10 µL aliquots of the reaction mixture via microliter syringe through the septum cap, 
to minimize exposure to additional atmospheric water.  Each aliquot was transferred into an 
NMR tube and further diluted to the appropriate volume by addition of CDCl3.  The tube was 
then agitated to ensure full mixing of the sample and CDCl3.  Yields and conversion were 
calculated from ratios relative to nitrobenzene as internal standard in the 1H NMR spectrum (500 
MHz).  Typical acquisition parameters for a sample were relaxation delay = 15.0 seconds, 
number of scans = 16, gain = 54.  Each timepoint is the average value of at least three runs. 
Studies from Figure 6. 
Catalytic activity from Figure 6A. 
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Preparation of (BnO)2PO2Ag:  In a round bottom flask, dibenzyl phosphate (500 mg, 1.0 equiv., 
1.8 mmol) was suspended in H2O (9 mL, 0.2 M) at rt and stirred vigorously.  Sodium carbonate 
(95.4 mg, 0.5 equiv., 0.9 mmol) was added to the stirring suspension (the solution became clear 
and heterogeneous at this point) and stirred for 30 min.  Note:  if all solid does not dissolve upon 
addition of sodium carbonate, addition of a slight excess should allow for complete dissolution.  
The round bottom flask was wrapped in aluminum foil to protect from light sources, and silver 
nitrate (305.8 mg, 1.0 equiv., 1.8 mmol) was added in one portion, and the resulting mixture 
stirred for 30 min.  A white solid precipitate formed, and the mixture was filtered via suction 
filtration with a Buchner funnel using minimal H2O to transfer and wash.  The white solid was 
dried for 30 min in the dark under suction, then the solid was transferred to a foil-wrapped flask 
and dried under high vaccum for 24 h, affording (BnO)2PO2Ag (569 mg, 82%).  
Use of (BnO)2PO2Ag in catalytic reaction:  A 1- dram vial was charged with substrate 2a 
(78.4mg, 0.3 mmol, 1.0 equiv.), [Bis-sulfoxide-PdCl2] 1261 (13.7 mg, 0.03 mmol, 0.1 equiv.), 
Silver dibenzyl phosphate (freshly prepared, see above)62 (23.1 mg, 0.06 mmol, 0.02 equiv.), 
dibenzyl phosphate (41.7 mg, 0.15 mmol, 0.5 equiv.), and benzoquinone (48.6 mg, 0.45 mmol, 
1.5 equiv.).  1,4-Dioxane was added (0.15 mL), and the resulting heterogeneous mixture stirred 
at 45°C.  The reaction was quenched and worked up according to Procedure A.  1H NMR of the 
crude reaction mixture indicated a >20:1 dr (run 1: >20:1, run 2: >20:1, avg = >20:1).  Flash 
chromatography (10% acetone/hexanes to 20%) afforded 3a (Run1: 32.7 mg, 54% yield; Run 2: 
32.7 mg, 54% yield, Avg = 54% yield).   
Control experiment from Figure 6B. 
A 1- dram vial was charged with substrate 2a (78.4mg, 0.3 mmol, 1.0 equiv.), [Bis-
sulfoxide-PdCl2] 12 (13.7 mg, 0.03 mmol, 0.1 equiv.), Silver dibenzyl phosphate (freshly 
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prepared, see above) (23.1 mg, 0.06 mmol, 0.02 equiv.), and benzoquinone (48.6 mg, 0.45 mmol, 
1.5 equiv.).  1,4-Dioxane was added (0.15 mL), and the resulting heterogeneous mixture stirred 
at 45°C.  The reaction was quenched and worked up according to Procedure A.  1H NMR of the 
crude reaction mixture indicated a starting material to product ratio of 2.6:1.0 (Run 1: 2.5:1.0; 
Run 2: 2.7:1.0, Avg. 2.6:1.0) >20:1 dr of 3a (run 1: >20:1, run 2: >20:1, avg = >20:1).  Flash 
chromatography (10% acetone/hexanes to 20%) afforded 3a (Run1: 11.0 mg, 18% yield; Run 2: 
12.2 mg, 20% yield, Avg = 19% yield). 
Control experiment from Figure 6C. 
 Procedure A was followed by charging an aluminum foil-wrapped 1-dram vial with 2a 
(78.4 mg, 1.0 equiv., 0.3 mmol), [Bis-sulfoxide-PdCl2] 11 (13.7 mg, 0.1 equiv., 0.3 mmol), 
dibenzyl phosphate (41.7 mg, 0.5 equiv., 0.15 mmol), benzoquinone (48.6 mg, 1.5 equiv., 0.45 
mmol) and 1,4-dioxane (0.15 mL).  1H NMR analysis of the crude mixture indicated no 3a; the 
major components present were 2a and its olefin isomerization products, with minor peaks 
indicative of Lewis acid decomposition products of 2a.  Flash chromatography to recover 
starting material yielded an inseparable mixture of 2a and olefin isomers (43.0 mg, 55%).   
Stoichiometric Allylic C-H Cleavage study from Figure 6D. 
A 1-dram vial was charged with [Bis-sulfoxide-PdCl2] 12 (45.6 mg, 1.0 equiv, 0.1 mmol) 
and silver dibenzyl phosphate (38.5mg, 2.0 equiv., 0.2 mmol).  Then, 1,4-dioxane (0.5 mL, 2M) 
was added to the vial, followed by 1-undecene (0.2 mL, 10.0 equiv., 1.0 mmol).  The vial was 
wrapped in Aluminum foil to minimize light exposure, capped and stirred at 45°C for 16 h.  The 
reaction was quenched by addition of tetrabutylammonium chloride (111.2 mg, 4.0 equiv., 0.4 
mmol) in acetone (1 mL) to trap any π-allyl Pd species in solution.  The crude reaction mixture 
was filtered through a small plug of silica gel to remove metallic Pd, rinsing with CHCl3.  Flash 
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chromatography of the mixture (1 to 5% EtOAc / Hexanes) yielded π–allyl PdCl dimer as a 
bright yellow solid (Run 1: 28.9 mg, 98%, Run 2: 26.9 mg, 91% yield, Avg = 95% yield). 
 
1H NMR (500 MHz, CDCl3) δ 5.26 (td, J = 11.5, 6.8 Hz, 1H), 3.88 (d, J = 6.6 Hz, 1H), 3.85 (m, 
2H), 2.82 (d, J = 11.9 Hz, 1H), 1.81 – 1.19 (m, 28H), 0.88 (t, J = 6.6 Hz, 3H). Data is consistent 
with the literature reports.4, 15  
1.5 REFERENCES 
1. White, M. C. Adding Aliphatic C-H Bond Oxidations to Synthesis. Science 2012, 335, 807-809. 
2. Godula, K.; Sames, D. C-H bond functionalization in complex organic synthesis. Science 2006, 312, 67-72. 
3. Fraunhoffer, K. J.; Bachovchin, D. A.; White, M. C. Hydrocarbon oxidation vs C-C bond-forming 
approaches for efficient syntheses of oxygenated molecules. Org. Lett. 2005, 7, 223-226. 
4. Chen, M. S.; Prabagaran, N.; Labenz, N. A.; White, M. C. Serial ligand catalysis: A highly selective allylic 
C-H oxidation. J. Am. Chem. Soc. 2005, 127, 6970-6971. 
5. Covell, D. J.; White, M. C. A chiral Lewis acid strategy for enantioselective allylic C-H oxidation. Angew. 
Chem. Int. Ed. 2008, 47, 6448-6451. 
6. Covell, D. J.; White, M. C. A C-H oxidation approach for streamlining synthesis of chiral polyoxygenated 
motifs. Tetrahedron 2013, 69, 7771-7778. 
7. Ammann, S. E.; Rice, G. T.; White, M. C. Terminal Olefins to Chromans, Isochromans, and Pyrans via 
Allylic C-H Oxidation. J. Am. Chem. Soc. 2014, 136, 10834-10837. 
8. Fraunhoffer, K. J.; White, M. C. syn-1,2-amino alcohols via diastereoselective allylic C-H amination. J. 
Am. Chem. Soc. 2007, 129, 7274-7275. 
9. Reed, S. A.; White, M. C. Catalytic intermolecular linear allylic C-H amination via heterobimetallic 
catalysis. J. Am. Chem. Soc. 2008, 130, 3316-3317. 
10. Reed, S. A.; Mazzotti, A. R.; White, M. C. A Catalytic, Brønsted Base Strategy for Intermolecular Allylic 
C-H Amination. J. Am. Chem. Soc. 2009, 131, 11701-11706. 
Me
PdCl/2
n = 7
	   64 
11. Rice, G. T.; White, M. C. Allylic C-H Amination for the Preparation of syn-1,3-Amino Alcohol Motifs. J. 
Am. Chem. Soc. 2009, 131, 11707-11711. 
12. Qi, X. B.; Rice, G. T.; Lall, M. S.; Plummer, M. S.; White, M. C. Diversification of a beta-lactam 
pharmacophore via allylic C-H amination: accelerating effect of Lewis acid co-catalyst. Tetrahedron 2010, 66, 
4816-4826. 
13. Jiang, C.; Covell, D. J.; Stepan, A. F.; Plummer, M. S.; White, M. C. Sequential Allylic C-H 
Amination/Vinylic C-H Arylation: A Strategy for Unnatural Amino Acid Synthesis from alpha-Olefins. Org. Lett. 
2012, 14, 1386-1389. 
14. Young, A. J.; White, M. C. Catalytic Intermolecular Allylic C-H Alkylation. J. Am. Chem. Soc. 2008, 130, 
14090-14091. 
15. Young, A. J.; White, M. C. Allylic C-H Alkylation of Unactivated alpha-Olefins: Serial Ligand Catalysis 
Resumed. Angew. Chem. Int. Ed. 2011, 50, 6824-6827. 
16. Howell, J. M.; Liu, W.; Young, A. J.; White, M. C. General Allylic C-H Alkylation with Tertiary 
Nucleophiles. J. Am. Chem. Soc. 2014, 136, 5750-5754. 
17. Braun, M. G.; Doyle, A. G. Palladium-Catalyzed Allylic C-H Fluorination. J. Am. Chem. Soc. 2013, 135, 
12990-12993. 
18. Stang, E. M.; White, M. C. Molecular Complexity via C-H Activation: A Dehydrogenative Diels-Alder 
Reaction. J. Am. Chem. Soc. 2011, 133, 14892-14895. 
19. Grennberg, H.; Gogoll, A.; Backvall, J. E. Acid-Induced Transformation of Palladium(0) Benzoquinone 
Complexes to Palladium(II) and Hydroquinone. Organometallics 1993, 12, 1790-1793. 
20. Decharin, N.; Stahl, S. S. Benzoquinone-Promoted Reaction of O2 with a Pd(II)-Hydride. J. Am. Chem. 
Soc. 2011, 133, 5732-5735. 
21. Popp, B. V.; Stahl, S. S. Palladium-Catalyzed Oxidation Reactions: Comparison of Benzoquinone and 
Molecular Oxygen as Stoichiometric Oxidants. Top. Organometal. Chem. 2007, 22, 149-189. 
22. Strambeanu, I. I.; White, M. C. Catalyst-Controlled C-O versus C-N Allylic Functionalization of Terminal 
Olefins. J. Am. Chem. Soc. 2013, 135, 12032-12037. 
23. Lin, G. J.; Huang, P. Q. A concise and fully selective synthesis of the ant venom alkaloid (3S,5R,8S,9S)-3-
butyl-5-propyl-8-hydroxyindolizidine. Org. Biomol. Chem. 2009, 7, 4491-4495. 
	   65 
24. Akiyama, T. Stronger Brønsted acids. Chem. Rev. 2007, 107, 5744-5758. 
25. Terada, M. Binaphthol-derived phosphoric acid as a versatile catalyst for enantioselective carbon-carbon 
bond forming reactions. Chem. Commun. 2008, 4097-4112. 
26. Kampen, D.; Reisinger, C. M.; List, B. Chiral Brønsted Acids for Asymmetric Organocatalysis. Top. Curr. 
Chem. 2009, 291, 395-456. 
27. Xu, H.; Zuend, S. J.; Woll, M. G.; Tao, Y.; Jacobsen, E. N. Asymmetric Cooperative Catalysis of Strong 
Brønsted Acid-Promoted Reactions Using Chiral Ureas. Science 2010, 327, 986-990. 
28. Rueping, M.; Uria, U.; Lin, M. Y.; Atodiresei, I. Chiral Organic Contact Ion Pairs in Metal-Free Catalytic 
Asymmetric Allylic Substitutions. J. Am. Chem. Soc. 2011, 133, 3732-3735. 
29. Cheon, C. H.; Yamamoto, H. Super Brønsted acid catalysis. Chem. Commun. 2011, 47, 3043-3056. 
30. Mukherjee, S.; List, B. Chiral counteranions in asymmetric transition-metal catalysis: Highly 
enantioselective Pd/Brønsted acid-catalyzed direct alpha-allylation of aldehydes. J. Am. Chem. Soc. 2007, 129, 
11336-113367. 
31. Chai, Z.; Rainey, T. J. Pd(II)/Brønsted Acid Catalyzed Enantioselective Allylic C-H Activation for the 
Synthesis of Spirocyclic Rings. J. Am. Chem. Soc. 2012, 134, 3615-3618. 
32. Roggen, M.; Carreira, E. M. Enantioselective Allylic Thioetherification: The Effect of Phosphoric Acid 
Diester on Iridium-Catalyzed Enantioconvergent Transformations. Angew. Chem. Int. Ed. 2012, 51, 8652-8655. 
33. Pfeffer, P. E.; Silbert, L. S.; Chirinko, J. M. Alpha Anions of Carboxylic-Acids. 2. Formation and 
Alkylation of Alpha-Metalated Aliphatic Acids. J. Org. Chem. 1972, 37, 451-452. 
34. Lebel, H.; Leogane, O. Boc-protected amines via a mild and efficient one-pot Curtius rearrangement. Org. 
Lett. 2005, 7, 4107-10. 
35. Ellman, J. A.; Owens, T. D.; Tang, T. P. N-tert-butanesulfinyl imines: versatile intermediates for the 
asymmetric synthesis of amines. Acc. Chem. Res. 2002, 35, 984-95. 
36. Ferreira, E. M.; Stoltz, B. M. Catalytic C - H bond functionalization with palladium(II): Aerobic oxidative 
annulations of indoles. J. Am. Chem. Soc. 2003, 125, 9578-9579. 
37. Li, F.; Li, Z. M.; Yang, H.; Jager, V. New approaches to branched beta-amino alpha-hydroxy acids, taxol 
side-chain analogs. Z. Naturforsch. B 2008, 63, 431-446. 
	   66 
38. Shaw, K. J.; Barbachyn, M. R. The oxazolidinones: past, present, and future. Ann. NY Acad. Sci. 2011, 
1241, 48-70. 
39. Juaristi, E. Structural Types of Relevant beta-Amino Acid Targets. Enantioselective Synthesis of Beta-
Amino Acids, 2nd Edition 2005, 1-17. 
40. Feske, B. D. Bestatin: Three decades of synthetic strategies. Curr. Org. Chem. 2007, 11, 483-496. 
41. Matsushima, Y.; Kino, J. A new simple route to deoxyamino sugars from non-sugar material: synthesis of 
D-tolyposamine and 4-epi-D-tolyposamine and formal synthesis of D-vicenisamine. Tetrahedron Lett. 2005, 46, 
8609-8612. 
42. Matsushima, Y.; Nakayama, T.; Tohyama, S.; Eguchi, T.; Kakinuma, K. Versatile route to 2,6-
dideoxyamino sugars from non-sugar materials: Syntheses of vicenisamine and kedarosamine. J. Chem. Soc. Perk. 
Trans. 1 2001, 569-577. 
43. Schroeder, D. R.; Colson, K. L.; Klohr, S. E.; Lee, M. S.; Matson, J. A.; Brinen, L. S.; Clardy, J. 
Pyrrolosporin A, a new antitumor antibiotic from Micromonospora sp C39217-R109-7. 2. Isolation, physico-
chemical properties, spectroscopic study and X-ray analysis. J. Antibiot. 1996, 49, 865-872. 
44. Trost, B. M.; Sudhakar, A. R., A Cis Hydroxyamination Equivalent - Application to the Synthesis of (-)-
Acosamine. J. Am. Chem. Soc. 1987, 109, 3792-3794. 
45. Mahatthananchai, J.; Bode, J. W.,On the Mechanism of N-Heterocyclic Carbene-Catalyzed Reactions 
Involving Acyl Azoliums. Acc. Chem. Res. 2014, 47, 696-707. 
46. Phillips, E. M.; Chan, A.; Scheidt, K. A. Discovering New Reactions with N-Heterocyclic Carbene 
Catalysis. Aldrichim. Acta 2009, 42, 55-66. 
47. Vora, H. U.; Wheeler, P.; Rovis, T. Exploiting Acyl and Enol Azolium Intermediates via N-Heterocyclic 
Carbene-Catalyzed Reactions of alpha-Reducible Aldehydes. Adv. Synth. Catal. 2012, 354, 1617-1639. 
48. Shapiro, N. D.; Rauniyar, V.; Hamilton, G. L.; Wu, J.; Toste, F. D., Asymmetric additions to dienes 
catalysed by a dithiophosphoric acid. Nature 2011, 470, 245-249. 
49. Yeung, Y. Y.; Gao, X. R.; Corey, E. J., A general process for the haloamidation of olefins. Scope and 
mechanism. J. Am. Chem. Soc. 2006, 128, 9644-9645. 
50. Agami, A.; Couty, F.; Venier, O. A Highly Diastereoselective Epoxidation of N-Boc 2-
Alkenyloxazolidines - Application in Asymmetric-Synthesis. Synlett 1995, 1027-1028. 
	   67 
51. Still, W. C.; Kahn, M.; Mitra, A., Rapid Chromatographic Technique for Preparative Separations with 
Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925. 
52. Evans, D. A.; Wu, L. D.; Wiener, J. J. M.; Johnson, J. S.; Ripin, D. H. B.; Tedrow, J. S. A general method 
for the synthesis of enantiomerically pure beta-substituted, beta-amino acids through alpha-substituted succinic acid 
derivatives. J. Org. Chem. 1999, 64, 6411-6417. 
53. Abell, A. D.; Gardiner, J. Synthesis of substituted cyclohexenyl-based beta-amino acids by ring-closing 
metathesis. Org. Lett. 2002, 4, 3663-6. 
54. Knight, J. G.; Ainge, S. W.; Harm, A. M.; Harwood, S. J.; Maughan, H. I.; Armour, D. R.; Hollinshead, D. 
M.; Jaxa-Chamiec, A. A. Enantioselective synthesis of 3,6-Dihydro-1H-pyridin-2-ones: Unexpected regioselectivity 
in the palladium-catalyzed decarboxylative carbonylation of 5-vinyloxazolidin-2-ones. J. Am. Chem. Soc. 2000, 122, 
2944-2945. 
55. Sakaitani, M.; Ohfune, Y. Syntheses and Reactions of Silyl Carbamates. 2. A New Mode of Cyclic 
Carbamate Formation from Tert-Butyldimethylsilyl Carbamate. J. Am. Chem. Soc. 1990, 112, 1150-1158. 
56. Herranz, R.; Castropichel, J.; Vinuesa, S.; Garcialopez, M. T. An Improved One-Pot Method for the 
Stereoselective Synthesis of the (2S,3R)-3-Amino-2-Hydroxy Acids - Key Intermediates for Bestatin and Amastatin. 
J. Org. Chem. 1990, 55, 2232-2234. 
57. Lee, J. H.; Kim, J. H.; Lee, B. W.; Seo, W. D.; Yang, M. S.; Park, K. H. Stereospecific synthesis of the 
(2R,3S)- and (2R,3R)-3-amino-2-hydroxy-4-phenylbutanoic acids from D-glucono-delta-lactone. Bull. Kor. Chem. 
Soc. 2006, 27, 1211-1218. 
58. Kimura, M.; Ezoe, A.; Mori, M.; Iwata, K.; Tamaru, Y. Regio- and stereoselective nickel-catalyzed 
homoallylation of aldehydes with 1,3-dienes. J. Am. Chem. Soc. 2006, 128, 8559-8568. 
59. Belelie, J. L.; Chong, J. M., Stereoselective reactions of acyclic allylic phosphates with organocopper 
reagents. J. Org. Chem. 2001, 66, 5552-5555. 
60. Reetz, M. T.; Griebenow, N.; Goddard, R. Stereoselective Syntheses of Alpha-Hydroxy-Gamma-Amino 
Acids - Possible Gamma-Turn Mimetics. J. Chem. Soc. Chem. Comm. 1995, 1605-1606. 
61. Evans, D. R.; Huang, M. S.; Seganish, W. M.; Fettinger, J. C.; Williams, T. L. Facile access to 
enantiomerically pure bis(sulfoxide) chelates of late transition metals. Inorg. Chem. Commun. 2003, 6, 462-465. 
	   68 
62. Hardre, R.; Khaled, A.; Willemetz, A.; Dupre, T.; Moore, S.; Gravier-Pelletier, C.; Le Merrer, Y. Mono, di 
and tri-mannopyranosyl phosphates as mannose-1-phosphate prodrugs for potential CDG-Ia therapy. Bioorg. Med. 
Chem. Lett. 2007, 17, 152-155. 
 	  
	   69 
CHAPTER 2: 
 
A STRATEGY INSPIRED BY NONRIBOSOMAL PEPTIDE SYNTHETASE FOR THE 
OXIDATIVE DIVERSIFICATION OF AMINO ACIDS AND PEPTIDES VIA SMALL 
MOLECULE IRON CATALYSISa 
 
2.1 INTRODUCTION 
 Natural products of nonribosomal peptide synthetase (NRPS) origin display diverse and 
complex topologies and functional group arrays that effect an impressive range of therapeutic 
activities, including anticancer (bleomycin), immunosupression (cyclosporine), and antibiotic 
activity (β-lactams, vancomycin).1, 2 Much of this diversity derives from a synthetic strategy that 
entails pre-2, 3 and post-assembly oxidative tailoring enzyme modifications of both the chiral 
amino acid building blocks and the assembled peptide scaffolds. In the pre-assembly stage single 
proteinogenic amino acids serve as precursors for enzymatic diversification into non-
proteinogenic amino acids. The expanded pool of structurally and functionally diverse amino 
acids are incorporated into peptide chains that may undergo post-assembly oxidative 
modifications that add functionality and effect changes in topology. For example, tyrosine is 
enzymatically diversified to β-hydroxytyrosine and 4-hydroxyphenylglycine in the pre-assembly 
stage of vancomycin biosynthesis, accounting for four residues in the heptapeptide natural 
product.4, 5 After assembly by NRPS into a linear heptapeptide chain, further modifications occur 
to afford the fully mature vancoymcin skeleton (Figure 9). The high degree of C—H oxidative 
modifications in both the pre-assembly stage (e.g. C—H hydroxylation, decarboxylation) and 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
a The material in this chapter is adapted from Osberger, T. J.; Rogness, D. C.; Kohrt, J. T.; Stepan, A. F.; and White, 
M. C. Nature, 2016, in press. Author contributions: T.J.O. and D.C.R. are equal contributors, and conducted the 
experiments and analyzed the data. M.C.W. and T.J.O. wrote the manuscript. 
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post-assembly stage (i.e. oxidative etherification and arylation) of vancomycin biosynthesis is 
illustrative of the diversity of oxidative transformations that can be performed by the iron 
enzymes involved in its synthesis. 
Figure 9. Pre- and Post-Assembly Modifications in Vancomycin Biosynthesis 
 
 Inspired by NRPS tailoring enzymes, we envisioned a chemical synthetic strategy 
wherein a small molecule catalyzed C-H oxidation of a monomeric amino acid or a specific 
residue in a peptide generates a highly versatile synthetic intermediate primed for transformation 
into numerous structural and functional group types. Similar strategies have been reported using 
early stage diversification of prefunctionalized pluripotent building blocks for diversity-oriented 
synthesis of peptidomimetic scaffolds.6, 7 However, limited examples of C-H oxidation reactions 
of amino acid derivatives are known, and few have been demonstrated in peptides.8-12 Chelate-
controlled C-H arylations are limited to reaction with N-terminal residues, and stoichiometric C-
H hydroxylation methods suffer from operational difficulty, modest efficiency, and have no 
demonstrated chemoselectivity in peptides. An overview of the possible products of C-H 
oxidation of proteinogenic amino acid side chains led us to focus on developing a selective 
hydroxylation for C5 of proline to provide an excellent first example of our envisioned strategy. 
Selective hydroxylation at C5 of proline would afford a 5-hydroxyproline (5-HP) intermediate 
possessing a highly versatile hemiaminal functional group (Figure 10B). Subsequent 
transformations on the hemiaminal would yield valuable unnatural amino acids (UAAs) and 
UAA-containing peptides. 
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Figure 10. Iron C-H Hydroxylation Catalysts for Oxidation of Amino Acids and Peptides 
 
 Current synthetic routes to 5-HP and 5-functionalized proline derivatives typically rely 
on multistep synthetic routes from pre-functionalized glutamic acid or pyroglutamic acid 
derivatives.13, 14 Recently, methods have been developed to form α-aryl pyrrolidines using iron 
salts15 or photoredox catalysts,16 and chiral α-nitrile pyrrolidines using oxidase enzymes.17, 18 
These methods proceed via generation of positively charged nitrogen via amino radical cation 
formation or quaternization of the amine followed by deprotonation or hydrogen atom 
abstraction of the α-hydrogen of the homo- and heterolytically weakest C-H bond. On a proline-
core, C-H abstraction may occur at the weakest α-(C2)-H bond (BDE ~ 87 kcal/mol19) versus the 
α-(C5)-H (BDE ~ 90 kcal/mol20), leading to racemization or decarboxylation. For example, free 
hydroxyl radical oxidations proceed via hydrogen abstraction at C2 followed by decarboxylation 
to form 2-pyrrolidone derivatives21; similarly, photoredox reactions proceed via decarboxylation 
to afford racemic 2-arylated derivatives.16   
 We sought a method for the direct (C5)-H hydroxylation of proline that would preserve 
the stereocenter at C2 and the α-carbon of all other residues present in a peptide. We additionally 
required an oxidant capable of high selectivity for oxidation of the target proline residue over 
Fe
N
N
N
N
F3C
CF3
F3C
F3C
NCMe
NCMe
Fe
N
N
N
N
NCMe
NCMe
(R,R)-Fe(PDP) 13
(SbF6)2
(SbF6)2
(R,R)-Fe(CF3PDP) 14
b
Fe Cat X or X,
H2O2, AcOH
RHN COY
N
R
COY
NR2
Functionalized Unnatural 
AAs
R[Ox] =
Functionalized UAA-containing
Di-, Tri- & Tetrapeptides
OHO
OH
Pre-Assembly Modifications
N
H
N
O
N
H
O
CO2Me
Me
OH
N
H
O
H
N
O
O
HN
OHN
CO2MeOn =3
NsHN
H
N
O Me
N
H
O
CO2Me
CO2H
Ns
H
H
N
Ns
COY
EDG R[Ox]
NsHN
H
N
O
N
H
O
CO2Me
MeHO
N
R
COYHO
5-Hydroxyproline
(5-HP )
Highly Versatile 
Intermediate
N
Ns
COY
RHN COY
O
25
R = Ns, Peptide
Y = OMe, Peptide
Post-Assembly Modifications
NsHN
Me
N
H
O H
N
O
CO2Me
Me
NHBn
Proline and Proline-
containing peptides
a
	   72 
other amino acid side-chain C-H bonds. Thus, we evaluated the non-heme iron catalysts 
Fe(PDP)22, 23 13 and Fe(CF3PDP) 1424 (Figure 10A). These bulky, electrophilic C-H oxidation 
catalysts do not discriminate solely based on C-H bond dissociation energies, but rather select 
between C-H based on their electronic, steric, and stereoelectronic properties. Furthermore, 
catalysts 13 and 14 had been shown to tolerate peptide bond functionality in the stereoretentive 
oxidation of an isoleucine derivative and dipeptide,24 suggesting that site selectivity for C5 
proline oxidation would be likely, given that C2 is both sterically and electronically deactivated. 
Additionally, Fe(PDP) 13 was shown to oxidize hyperconjugatively activated C-H bonds (e.g., 
ethereal C-H bonds) at faster rates than other aliphatic C-H bonds,23 suggesting chemoselectivity 
for α-(C5)-H of proline, hyperconjugatively activated by the adjacent nitrogen lone pair, would 
effectively compete with C-H oxidation of aliphatic amino acid residues. 
2.2 RESULTS AND DISCUSSION 
 We initially investigated our NRPS-inspired strategy on the oxidation of a protected 
proline derivative, N-(4-nitrophenylsulfonyl) proline methyl ester (-)-15, with Fe(PDP) (Figure 
11A). Oxidation of (-)-15 under slow addition conditions23, 25 with Fe(PDP) (25 mol%), AcOH, 
and H2O2 at room temperature furnished glutamic acid derivative (-)-16 (77%), the product of 
full oxidation at C5 of proline, which likely proceeds through 5-HP or its open-chain amino 
aldehyde tautomer. We hypothesized that milder conditions for oxidation may enable direct 
formation of 5-HP while limiting further over-oxidation. Lowering the temperature of the 
reaction to 0 °C and lowering the catalyst loading (Fe(PDP), 15 mol%, iterative addition), we  
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Figure 11. Oxidative Diversification of Proline to Unnatural Amino Acid Derivatives 
 
were able to isolate 5-HP in good yield (62%) with minimal amounts of over-oxidation products 
(see experimental section). Subjection of proline homologue pipecolic acid to the same 
conditions afforded 6-hydroxypipecolic acid derivative 17 with similar efficiency (53%). 
Reaction of N-Boc proline methyl ester under these conditions afforded primarily N-Boc 
pyroglutamic acid methyl ester (see experimental section). These experiments demonstrated that 
control could be exerted over the C5 oxidation state in the product by choice of appropriate 
reaction conditions. Notably, neither C2 oxidation nor racemization were observed, even under 
the relatively forcing reaction conditions used to produce (-)-16.   
 We questioned whether we could achieve our “pre-assembly” oxidative tailoring strategy 
by derivatization of the hemiaminal functional group installed by oxidation of (-)-15 to 5-HP, 
diversifying proline into unnatural amino acids. Due to the prevalence of arylated proline 
derivatives26, 27 and other substituted variants in pharmaceutical research28, 29 and catalysis,30, 31 
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we desired to accomplish a synthesis of 5-aryl proline motifs using our newly developed 
oxidation chemistry. A sequential oxidation / arylation procedure was developed wherein crude 
5-HP generated from oxidation of (-)-15 with Fe(PDP) is treated with BF3OEt2 to form a 
sulfonyl iminium species, which undergoes diastereoselective nucleophilic attack by an electron-
rich arene (Figure 11B). Using the electron-rich arenes phenol and 2-naphthol as nucleophiles in 
this process afforded 5-substituted proline derivatives (+)-18 and (-)-19 in high yields with 
generally high regioselectivity (3.1:1 o/p for 18 and >20:1 for adduct 19). A novel side-chain 
linkage between tyrosine and proline was forged using this oxidative arylation methodology to 
form (-)-20, similar to the side-chain cross-links seen in the oxidative tailoring enzyme 
transformations of vancomycin biosynthesis. This chemistry was applied to form a natural 
product-amino acid conjugate (+)-21 between proline and the polyphenol natural product 
resveratrol; similar molecules display intriguing biological activity.32 Additionally, the aromatic 
scope extended beyond phenol nucleophiles, as high yields and good selectivities were observed 
with heteroarenes such as anthrone, benzothiophene, and indole in this transformation, affording 
adducts 22-24. The proline-aryl adducts formed through this oxidative arylation procedure were 
obtained with generally high selectivity for the syn diastereomer (except for anthrone adduct (-)-
22, which was isolated as the anti product), possibly due to steric interactions with the 
nitrophenylsulfonyl group appended to the proline nitrogen. Diastereoselectivity for this 
transformation was confirmed by X-ray crystallography of adducts (-)-19, (+)-23, and (+)-24. 
Collectively, the two-step oxidation/arylation sequence developed herein gives access to 5-
arylproline derivatives with high functional and stereochemical enrichment. 
 We anticipated that further transformations of 5-HP via its open-chain aldehyde tautomer 
would be a second path to access linear unnatural amino acid structures that remain challenging 
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synthetic targets,33, 34 complementing the rigid aryl-proline derivatives obtained above. An 
approach beginning with Fe(PDP) oxidation of (-)-15 to 5-HP followed by transformation of the 
aldehyde tautomer via either reduction, olefination, or reductive amination was developed 
(Figure 11C). Reduction of crude 5-HP with sodium borohydride afforded bis-homoserine 
analogue (+)-25. Similarly, oxidation of (L-proline) with Fe(PDP) and treatment of the crude 5-
HP with a simple Wittig reagent afforded homoallylglycine derivative (+)-26, and its 
enantiomeric product was easily generated by beginning with (D)-proline (see experimental 
section). Likewise, homologous alkenyl amino acid (L)-2-amino-6-heptenoic acid (-)-27 was 
generated by applying the sequence to an (L)-pipecolic acid derivative. The retention of 
stereochemistry at C2 of the proline starting material over the oxidation/derivatization sequences 
was established by synthetic derivatization of the products and comparison of the optical activity 
of products (-)-16, (+)-25, and (+)-26 to known compounds (Figure 12).   
 Performing the hydroxylation of (-)-15 with Fe(PDP) followed by reductive amination 
provided a general procedure for the installation of amines to furnish valuable unnatural amino 
acids, including dibenzylornithine derivative (+)-28 and the fluorescent (2-pyridyl)-piperazine-
containing derivative (-)-29, directly and in optically active form. Furthermore, we explored the 
formation of amino acid backbone-to-side-chain linkages by employing tryptophan methyl ester 
in the reductive amination, affording conjugate (+)-30; in principle any suitably protected amino 
acid can be utilized in this manner. The use of sterically unencumbered primary amines in this 
two-step procedure resulted in reductive amination followed by intramolecular cyclization of the 
amine onto the methyl ester to create 3-aminopiperidinone structures like (+)-31 with retention 
of optical purity. Because additional functionality can be united with the proline component upon 
the introduction of functionalized amines, further derivatization is possible from the cyclized 
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products. For example, (-)-15 oxidation / reductive amination with propargylamine furnished 
alkyne-containing aminopiperidinone scaffold (+)-32, which was converted to triazole (+)-33 via 
a copper-catalyzed azide-alkyne cycloaddition.  
Figure 12. Optical Activity of Oxidation / Functionalization Products 
 
 The nosyl protecting group of the newly synthesized unnatural amino acids via proline 
oxidation/derivatization can be removed under mild conditions (thiophenol or p-
methoxythiophenol and base) to afford the derivatives as their free amines (Figure 13). 
Figure 13. Removal of Nosyl Protecting Group 
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 Alternatively, exchange of the nosyl group for an N-Boc protecting group (before or after nosyl 
cleavage) was possible, which proved convenient for purposes of purification and isolation. 
These procedures afford unnatural amino acid derivatives 35-38 with protecting group schemes 
common to conventional peptide synthesis.   
 The power of iron-catalyzed aliphatic C-H hydroxylation to form unnatural amino acid 
materials was evaluated for other common amino acids possessing oxidizable side chain residues 
with stronger tertiary and secondary C-H bonds (Figure 14). We found that application of 
Fe(PDP) for oxidation of the tertiary C-H bonds in leucine and valine derivatives (+)-39 and (+)- 
42 afforded hydroxylated products (+)-40 and (+)-43, respectively, which are important in 
synthesis35  and appear in natural products and their metabolites.36, 37 Similar efficiency for 
secondary C-H oxidation was observed when norvaline derivative (+)-45 was subjected to 
oxidation with Fe(CF3PDP), affording ketone derivative (+)-46, also of high utility in amino acid 
and peptide studies. Significantly, good hydroxylation activity of Fe(PDP) was retained in the 
oxidation of dipeptide substrates containing leucine and valine residues, affording tertiary 
hydroxylated dipeptides (-)-48 and (+)-51, respectively.  
Figure 14. Oxidative Diversification of Aliphatic Side Chain Amino Acids 
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Collectively, the transformations demonstrated herein constitute a small-molecule catalysis 
approach to a NRPS-like “pre-assembly” oxidative modification strategy. A small collection of 
four amino acids (proline, leucine, valine, and norvaline) are converted to twenty-one optically 
active unnatural amino acids representing seven distinct functional group arrays: alcohols, 
fluorines, aryls, carboxylates, olefins, ketones, and amines.  
 The “post-assembly” oxidative modifications achieved by tailoring enzymes associated 
with NRPS are particularly remarkable for their ability to transform complex peptides with high 
chemoselectivity with little interference from the numerous other functional groups present in 
these settings. Our strategy of employing Fe(PDP) 13 and Fe(CF3PDP) 14 for oxidations in 
peptides was made possible by the catalysts’ high functional group tolerance for the amide 
peptide bond and preference for oxidation at C5 of proline over oxidation of other aliphatic C-H 
bonds (Figure 15). For example, tripeptide (-)-52 containing a proline, leucine, and alanine 
residue was selectively converted to the 5-hydroxyproline derivative 53 by oxidation with 
Fe(PDP) at 0 °C, with no observed oxidation at leucine. Significantly, the more challenging 
over-oxidation of proline to glutamic acid in tripeptide (-)-54 proceeded efficiently at room 
temperature with Fe(CF3PDP) to afford (-)-55, underscoring the chemoselectivity possible with 
these oxidations. We observed Fe(CF3PDP) to be superior to Fe(PDP) for proline over-oxidation 
to glutamic acid in peptide settings, possibly due to its increased selectivity for secondary 
oxidation over tertiary, and the increased steric bulk around the catalyst center minimizing 
deleterious coordination with the many Lewis basic sites on the peptide substrate. The oxidative 
diversification sequences developed for proline were explored in the challenging setting of 
tetrapeptide (-)-56, which possesses potentially oxidizable residues leucine and tyrosine. Proline 
oxidation occurred with high site-selectivity, and functionalization via reductive amination or 
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arylation afforded naphthol amine (+)-57 and naphthol adduct (-)-58, respectively. Additionally, 
we examined the positional flexibility for proline oxidation, and found that oxidation of 
tripeptides (-)-59 and (-)-63 containing internal proline residues proceeded in excellent yields for 
Fe(CF3PDP) catalyzed over-oxidation to glutamic acid derivatives (-)-60 and (-)-64, as well as 
efficient conversion to amine and bis-homoserine-containing derivatives (-)-61 and (-)-62 by 
Fe(PDP) oxidation and reduction or reductive amination.  
Figure 15. Direct Oxidative Modification of N-terminal, C-Terminal, and Internal Proline Residues by Fe(PDP) 
Catalyzed C-H Hydroxylation 
 
 We sought to further validate our hypothesis that selective oxidation of proline residues 
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assembly” oxidative strategy for the late stage diversification of peptides into new sequences 
containing unnatural amino acids (Figure 16A). Tripeptide (-)-52 was subjected to the entire 
range of proline oxidative diversification sequences to install a phenol (oxidative arylation), 
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(reduction), and four different amines (reductive amination) in good yields (average 40% yield 
over two steps, 63% step average) with no epimerization of any residues detected, as judged by 
analysis of tripeptide (-)-66. Thus, eight novel peptide sequences 65-72 were rapidly furnished 
from a single tripeptide starting material, highlighting the power of such reactions for effective 
diversification of a native proline residue in a peptide setting. Alternative routes to synthesize the 
eight peptide sequences created here would require individual syntheses from their respective 
amino acid building blocks, including access to the unnatural residues.  
Figure 16. Fe(PDP) Catalyzed Oxidative Diversification of Tripeptides and Macrocycles 
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 Macrocyclic peptides are highly prevalent in NRPS natural products, and are valued as 
therapeutics relative to linear sequences due to their increased stability and pharmacokinetic 
properties.38-41 Therefore, we investigated how the installation of new functional groups from 
proline residues enabled by the methodology we developed could lead to the rapid construction 
of peptide macrocycles. Using the phenol-, carboxylate-, and olefin-derived tripeptides 65-67 
obtained from our oxidative diversification sequences, macrocycles 73-75 were prepared using 
five-step transformations involving alkene appendage to the UAA residue, coupling of a fourth 
alkene-containing amino acid to the C-terminus, conversion of Nosyl to a Boc group, ring-
closing metathesis, and hydrogenation (Figure 16A, bottom). These routes rapidly furnished 
distinct macrocycles with ethereal, amide, and all-hydrocarbon linkers on their backbones. The 
presence of different linkers on macrocyclic peptides has been shown to modulate the biological 
properties of the overall molecule.42 Collectively, the small library synthesized from tripeptide (-
)-52 demonstrates the breadth of functionally and structurally enriched molecules that can be 
accessed using our “post-assembly” oxidative strategy.  
 Proline has long been recognized by chemists as a tool to enforce turn-like reactive 
conformations to promote macrocyclizations,43 and pseudoproline derivatives have also been 
explored for this effect.44-46 We became interested in exploring the use of our chemistry on a 
proline-containing peptide macrocycle, where the proline residue may be diversified at very late 
stage to reveal an unnatural amino acid residue (Figure 16B). Encouraged by the high positional 
flexibility of the proline oxidation observed in linear tripeptides (see above), we assembled 
proline-containing linear pentapeptide (-)-76 using homoallylglycine derivative (+)-26 [derived 
from pre-assembly oxidation/olefination of (-)-15]. Subjection of this linear diene to ring-closing 
metathesis with Hoveyda-Grubbs 2nd generation catalyst followed by reduction of the resulting 
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olefin afforded the desired 18-membered pentapeptide macrocycle (-)-77. Performing Fe(PDP) 
catalyzed C-H oxidation and reductive amination on (-)-77 with dibenzylamine yielded 
dibenzylornithine-containing macrocycle (-)-78, underscoring the potential for proline residues 
to serve as diversifiable structural elements that may be transformed into functionally and 
structurally altered unnatural amino acid residues at late stages in complex peptide settings.  
2.3 CONCLUSIONS 
 In conclusion, we have developed a strategy for the small-molecule iron catalyzed 
oxidative diversification of amino acids and peptides via C-H oxidation, inspired by the strategic 
usage of oxidative tailoring enzymes in NRPS. We envision this strategy will prove beneficial in 
exploring small-peptide therapeutics by enabling the rapid exploration of the structure space and 
key physical properties such as polarity, charge, steric, and stereochemical effects. These results 
will inspire further innovation in the field of non-directed, chemoselective C-H oxidation 
reactions that reveal the enormous potential of C-H bonds in complex settings.  
2.4 EXPERIMENTAL SECTION  
General Methods. 
Catalysts Fe(PDP) 13 and Fe(CF3PDP) 14 were prepared according to literature 
procedures.22, 24 The catalysts were stored at 0°C.  Prior to use catalysts 13 and 14 were warmed 
to room temperature and weighed out in air. Acetic acid (glacial) was obtained from JT Baker 
and used as received.  H2O2 (50% wt aqueous solution) was purchased from Sigma Aldrich, and 
used as received.  Amino acid materials including L-Proline, D-Proline, L-Valine, L-Leucine, D-
Allylglycine, L-Tyrosine, L-Norvaline, L-Glutamic acid dimethyl ester hydrochloride, L-
Tryptophan methyl ester hydrochloride, N-Boc amino acids, amino acid methyl ester 
hydrochloride salts, 3-(3-Dimethylaminopropyl)-1-ethyl-carbodiimide hydrochloride (EDC), 1-
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hydroxybenzotriazole (HOBt, wetted with 20% water), O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium hexafluorophosphate (HATU) were purchased from Chem-Impex 
International, Inc. and used as received.  4-nitrophenylsulfonyl chloride (NsCl) was purchased 
from Sigma Aldrich and used without further purification.  Diisopropylethylamine (DIPEA) and 
triethylamine (NEt3) were purchased from Sigma Aldrich and distilled over calcium hydride 
prior to use.  Metathesis catalysts Benzylidene-bis(tricyclohexylphosphine)dichlororuthenium 
(Grubbs I) and (1,3-Bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene)dichloro(o-
isopropoxyphenylmethylene)ruthenium (Hoveyda-Grubbs II) were purchased from Sigma 
Aldrich, and stored and weighed out in an inert atmosphere glove box.  
All oxidation reactions were carried out under air with magnetic stirring, with no 
precautions taken to exclude moisture.  All other reactions were conducted in dry glassware with 
magnetic stirring under an inert atmosphere of dry nitrogen or argon, unless otherwise noted.  
Thin-layer chromatography was conducted with E. Merck silica gel 60 F254 precoated plates 
(0.25 mm) and visualized with KMnO4 and UV.  Flash column chromatography was performed 
as described by Still et al. using EM reagent silica gel 60 (230-400 mesh).47   
1H NMR spectra were recorded on a Varian Unity-500 (500 MHz) or Varian Unity 
Inova-500 (500 MHz) spectrometer, using solvent as an internal standard (CDCl3 at 7.26 ppm).  
Data are reported as: s=singlet, d=doublet, t=triplet, q=quartet, p=pentet, oct=octet, m=multiplet, 
br=broad, app=apparent; coupling constants in Hz; integration.  Proton-decoupled 13C NMR 
spectra were recorded on a Varian Unity 500 (125 MHz) spectrometer and are reported in ppm 
using solvent as internal standard (CDCl3 at 77.16 ppm, MeOH-d4 at 49.00 ppm, Acetone-d6 at 
206.26 ppm).  High resolution mass spectrometry (HRMS) was performed at the Unversity of 
Illinois Mass Spectrometry Laboratory (Dr. Furong Sun, Director) using a Waters Q-TOF Ultima 
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ESI spectrometer.  Infrared (IR) spectra were recorded as thin films on NaCl plates on a Perkin-
Elmer Spectrum BX FT-IR and are reported in wavenumbers (cm-1).  Optical rotations were 
obtained using a JASCO DIP-360 digital polarimeter (cell dimensions: 3.5 x 50 mm) and are 
reported as follows [α]DT/°C concentration (c = g / 100 mL, solvent).   
Synthesis of Nosyl amino acid methyl ester substrates.   
General procedure for the N-(p-Nitrosulfonyl) protection of Amino-acid methyl ester 
hydrochloride salts.   
To a glass round-bottom flask containing a Teflon stir bar was added amino-acid methyl 
ester hydrochloride (1 equiv) and CH2Cl2 (0.2 M), and the reaction was cooled to 0 ◦C in an ice 
bath.  To this was added Triethylamine (NEt3, 2.2 equiv) dropwise over 2 minutes, followed by 
Dimethylaminopyridine (DMAP, 0.1 equiv) and 4-Nitrosulfonyl Chroride (1.1 equiv).  The 
reaction was stirred at 0 ◦C for 30 minutes, and then warmed to room temperature and monitored 
by TLC for conversion of the hydrochloride salt (typically 2-4 hours).   
 Upon completion, the reaction was transferred to a separatory funnel and washed with H2O 
(1x), 1M NaHCO3 (1x), and Brine (3x).  (The H2O and NaHCO3 washed were each extracted 
with CH2Cl2 (1x), and the organic layers were combined before proceeding to the subsequent 
wash).  The combined organic layers were then dried over Na2SO4, filtered, and concentrated in 
vacuo to afford a crude residue, which was purified via flash chromatography (Ethyl 
Acetate/Hexanes mixtures). 
 
Methyl ((4-nitrophenyl)sulfonyl)-L-prolinate (-)-15. 
N
Ns
CO2Me
N
H
CO2H
1) SOCl2, MeOH,
0°C to rt
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(L)-Proline (2 g, 1.0 equiv., 17.3 mmol) was dissolved in MeOH (150 mL) and cooled to 0°C.  
Thionyl chloride (8.8 mL, 7.0 equiv., 121.6 mmol) was added slowly dropwise to the reaction, 
and the resulting solution was stirred overnight, allowed to gradually warm to rt.  The crude 
solution was concentrated, with several additions of MeOH (25 mL) and concentrations to 
remove thionyl chloride byproducts, to afford crude (L)-Proline methyl ester hydrochloride.  The 
crude material was dissolved in CH2Cl2 (100 mL) and cooled to 0°C.  To this stirring solution 
was added NEt3 (5.5 mL, 2.2 equiv., 38.1 mmol), DMAP (211 mg, 0.1 equiv., 1.73 mmol), and 
4-nitrophenylsulfonyl chloride (NsCl, 4.21 g, 1.1 equiv., 19 mmol).  The resulting solution was 
stirred overnight and allowed to warm gradually to rt.  The mixture was concentrated to afford a 
crude solid.  To this solid was added 130 mL of 2:1 MeOH / H2O, and the resulting slurry was 
heated to boiling until all solids dissolved.  The solution was then allowed to cool to rt, resulting 
in the crystallization of off-white solid (crystals or needles) from a yellow solution.  The product 
was isolated by vacuum filtration, washing with rt H2O, and air dried for 30 min followed by 
further drying under high vacuum overnight, to afford (-)-15 (3.967 g, 73% yield).  
1H NMR (500 MHz, Chloroform-d) δ 8.37 (d, J = 8.8 Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 4.46 
(dd, J = 8.7, 3.7 Hz, 1H), 3.71 (s, 3H), 3.46 (dd, J = 7.3, 5.9 Hz, 2H), 2.25 – 2.12 (m, 1H), 2.09 – 
1.82 (m, 3H);  
13C NMR (125 MHz, Chloroform-d) δ 172.2, 150.2, 144.8, 128.8, 124.3, 60.7, 52.6, 48.4, 31.1, 
24.9;  
IR (film, cm-1) 3106, 2958, 2885, 1747, 1606, 1531, 1438, 1351, 1311, 1207, 1162, 1101, 1024, 
1012, 856;  
HRMS (ESI) m/z calc’d for C12H15N2O6S [M+H]+: 315.0651, found 315.0652;  
[α]D27 = -79.8˚ (c=1.06, CH2Cl2). 
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General Procedure for Reaction Optimization. 
The following were prepared prior to the start of the reaction: 1) 1-dram borosilicate vial(s) 
containing 5 mol % (S,S)-Fe(PDP)(MeCN)2(SbF6)2 catalyst (23.3 mg, 0.025 mmol, 0.05 equiv) 
one vial per iteration; 2) 2-dram borosilicate vial(s) containing a solution of H2O2 (50 wt% in 
H2O, indicated equiv.) in 4.5 mL MeCN, one vial per iteration; 3) a single 40 mL borosilicate 
vial containing proline substrate (-)-15 (157 mg, 1.0 equiv., 0.5 mmol), MeCN (1 mL), and a 
magnetic stir bar.  The vials containing peroxide and substrate were then kept at rt or cooled to 0 
°C for 5 min prior to beginning the reaction.  Glacial acetic acid (14.3 µL, 0.5 equiv., 0.25 mmol) 
and the contents of one catalyst vial were then added to the substrate-containing vial (0.5 mL 
MeCN was used to rinse any remaining solid catalyst into the reaction vial). To this solution 
were then added the contents of a single vial containing H2O2 solution dropwise over the course 
or 2-3 min.  The resulting solution was allowed to stir at the indicated temperature for 10 min.  
The process of addition of catalyst, acetic acid, and H2O2 solution were iterated the indicated 
number of times at ten minute intervals.  The crude reaction mixture was concentrated onto silica 
gel and purified via flash chromatography, eluting with 9:1 CHCl3/EtOAc. 
Equiv. H2O2 / AcOH 
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Table 4. Oxidation of (-)-15 to 5-HP 
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Table S1, entry 1.  The General Procedure was followed using a single iteration of catalyst (1 x 5 
mol%), AcOH, and H2O2 solution (36.7 µL, 1.2 equiv., 0.6 mmol), at rt.  Flash chromatography 
afforded rsm (69.1 mg, 44%), 5-HP (65.1 mg, 40%), and PGA (5 mg, 3%).   
Table S1, entry 2.  The General Procedure was followed using two iterations of catalyst (2 x 5 
mol%), AcOH, and H2O2 solution (36.7 µL, 1.2 equiv., 0.6 mmol), at rt.  Flash chromatography 
afforded rsm (40.8 mg, 26%), 5-HP (76.3 mg, 46%), and PGA (14.8 mg, 9%).  
Table S1, entry 3.  The General Procedure was followed using three iterations of catalyst (3 x 5 
mol%), AcOH, and H2O2 solution (36.7 µL, 1.2 equiv., 0.6 mmol), at rt.  Flash chromatography 
afforded rsm (14.1 mg, 9%), 5-HP (77.6 mg, 47%), and PGA (16.4 mg, 10%).  
Table S1, entry 4.  The General Procedure was followed using three iterations of catalyst (3 x 5 
mol%), AcOH, and H2O2 solution (36.7 µL, 1.2 equiv., 0.6 mmol), at 0 °C.  Flash 
chromatography afforded rsm (22.0 mg, 14%), 5-HP (99 mg, 60%), PGA (21.6 mg, 13%).  
Table S1, entry 5.  The General Procedure was followed using three iterations of catalyst (3 x 5 
mol%), AcOH, and H2O2 solution (56.0 µL, 0.95 mmol, 1.9 equiv.), at 0 °C.  Flash 
chromatography afforded rsm (15.7 mg, 10%), 5-HP (107 mg, 65%), and PGA (27.3 mg, 17%).  
Table S1, entry 6.  The General Procedure was followed using Boc-Proline methyl ester as 
substrate (114.6 mg, 1.0 equiv., 0.5 mmol) and employing three iterations of catalyst (3 x 5 
mol%), AcOH, and H2O2 solution (56.0 µL, 0.95 mmol, 1.9 equiv.), at 0 °C.  Flash 
chromatography, eluting with 20 to 40 to 50% EtOAc / Hexanes afforded rsm (5.6 mg, 5%) and 
N-Boc-PGA48 (45.1 mg, 39%) with no 5-HP product observed.   
General C-H Oxidation Procedure A.   
Iterative addition of 3 x 5 mol % catalyst at 0 °C. Used for Oxidations of Ns-Pro-OMe and 
Proline-containing substrates:  The following were prepared prior to the start of the reaction:  
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1) Three 1-dram borosilicate vials each containing 5 mol % (S,S)-Fe(PDP)(MeCN)2(SbF6)2 
catalyst (23.3 mg, 0.025 mmol, 0.05 equiv.);  2) Three 2-dram borosilicate vials each containing 
a solution of H2O2 (50 wt% in H2O, 56.0 µL, 0.95 mmol, 1.9 equiv.) in 4.5 mL CH3CN 
(solutions were then placed in an ice-bath to cool for at least 5 mins);  3) A single 40 mL 
borosilicate vial containing the proline substrate (0.5 mmol, 1.0 equiv.), CH3CN (1 mL) and a 
magnetic stir bar.  The 40 mL reaction vial was then placed in an ice-bath and allowed to stir for 
30 seconds before adding glacial AcOH (14.3 µL, 0.5 equiv) and the contents of a single 
catalyst-containing vial in one addition (0.5 mL CH3CN was used to rinse any remaining solid 
catalyst into the reaction vial.).  To this solution was added the contents of a single peroxide 
solution vial dropwise over the course of 2-3 mins (small aliquots were pipetted over in order to 
prevent significant warming).  The resulting solution was allowed to stir for 10 mins in the ice-
bath before the second round of AcOH/catalyst/oxidant was added and also allowed to stir for 10 
mintues again.  This process was repeated for a third and final time before the reaction was 
analyzed by TLC.  Note: For 1.0 mmol and 0.30 sized reactions, the quantities of reagents were 
scaled accordingly. 
Purification 1: Flash chromatography. To purify the reaction by flash chromatography, the 
reaction was concentrated onto silica gel in vacuo for dry loading onto the column, and then 
eluted using the solvent system or gradient noted for individual products.  Note: Dry loading 
directly from crude mixtures for flash chromatography was used primarily to avoid potential 
issues of insolubility when attempting to re-dissolve concentrated crude materials; additionally, 
many of the peptide products could only be efficiently dissolved in very polar, strongly eluting 
solvents (e.g., methanol, acetone), making wet loading unsuitable for the gradients employed in 
the flash purification.  With any especially acid-sensitive compounds, dry loading may lead to 
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decomposition, so care must be taken with these compounds (see compound 17 below for an 
example).  
Purification 2: Plug purification of crude reaction mixture. When taking the product mixture on 
crude (as in the two-step oxidation / functionalization procedures provided below), the crude 
reaction mixture was poured onto a pad of packed, dry silica gel (approx. 50 mL dry volume for 
0.5 mmol scale reaction) and allowed to sit for 5 min to ensure full adsorption of the crude 
materials onto the silica gel. Ethyl acetate (500 mL) was then passed through the plug to produce 
eluent that appeared clear to light yellow while the brown color (Fe catalyst byproducts) 
remained within the silica-gel plug.  Concentration of the eluent affords crude 5-HP (5-
hydroxyproline) products for further functionalization. 
General C-H Oxidation Procedure B.  
25 mol % slow addition at rt:  A 40 mL screwtop vial was charged with the following: 
substrate (0.5 mmol, 1.0 equiv), CH3CN (1.0 mL, 0.5 M), AcOH (14.3 µL, 0.25 mmol, 0.5 
equiv) and a magnetic stir bar. The vial was placed on a stir plate and stirred vigorously at room 
temperature while open to atmosphere. A 1.0 mL syringe was loaded with a solution of 
Fe(PDP)(MeCN)2(SbF6)2 catalyst (116.5 mg, 0.125 mmol, 25 mol %) in CH3CN (0.625 mL, 0.2 
M) and placed on a syringe pump set with an addition rate of 0.5 mL/1 h (0.0083 mL/min).  
Secondly, a 10 mL syringe was loaded with a solution of H2O2 (50 wt % in H2O, 170 µL, 2.5 
mmol, 5.0 equiv) in CH3CN (6.25 mL, 0.4 M) and also placed onto a syringe pump set to the 
same addition rate of 5 mL/1 h (0.083 mL/min). Both syringes were equipped with 26G needles 
and directed into the center of the uncapped vial (note:  precautions should be taken not to touch 
the sides of the vial with the needle tips). The two additions were initiated simultaneously so that 
both solutions of Fe(PDP) catalyst and H2O2 were added to the reaction vial over the course of 
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75 min. The crude mixture was concentrated onto a small amount of silica gel via rotary 
evaporation and purified by flash chromatography. Procedure B was used to form products (+)-
40, (+)-46, (-)-55, (-)-60, (-)-64, and (-)-66. 
General C-H Oxidation Procedure C. 
25 mol% Fe catalyst with elevated H2O2 and AcOH at rt:  The General procedure B was 
followed, instead using H2O2 (9.0 equiv.) in CH3CN (6.25 mL, 0.72 M) and AcOH (5.0 equiv.).  
Procedure C was used to form products (-)-16, (-)-48, and (+)-51.  Additionally, a modified 
Procedure C was used to form product (+)-43.   
Selection of slow addition method. When examining a new substrate for oxidation with 
Fe(PDP) or Fe(CF3PDP), it is recommended to begin with Procedure B.  In cases where low 
conversion is observed, we then recommend Procedure C in order to increase conversion.  If 
further experimentation is required, it is possible to vary the ratios of H2O2 and AcOH.  The 
importance of acetic acid in Fe / H2O2 oxidations is discussed elsewhere.22, 49-52  
Selection of enantiomer for Fe(PDP) oxidations.  In general, either (S,S)-Fe(PDP) or (R,R)-
Fe(PDP) can be selected to perform the reactions contained herein without a significant change 
in product distribution or yield.  For most oxidations of proline containing substrates, (S,S)-
Fe(PDP) was employed.  In the case of oxidations of monomeric amino acid substrates, the 
enantiomer was selected on the basis of availability at the time the reactions were performed.  
The enantiomer used is noted for each individual substrate. 
Selection of nitrogen protecting group. Ortho-Nosyl, N-Boc, N-phenylsulfonyl, N-(4-
bromo)phenylsulfonyl, and N-Acetyl variants of amino acid esters were also examined for the 
oxidation reactions.  These protecting groups suffered from poor conversion (presumably via 
nitrogen binding and inactivation at the Fe center) and/or poor stability of the group to the 
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oxidative conditions of the reaction.  Thus, the para-Nosyl group appears to be uniquely 
effective nitrogen protecting group for this reaction under the conditions evaluated. 
Data for Figure 11. 
 
 
(S)-5-methoxy-4-((4-nitrophenyl)sulfonamido)-5-oxopentanoic acid  (-)-16. 
Nosyl Proline methyl ester (-)-15 was reacted with (R,R)-Fe(PDP)(MeCN)2(SbF6)2 (116.5 mg, 
0.25 eq, 0.125 mmol), AcOH (143 uL, 5.0 eq, 2.5 mmol), and H2O2 (276 uL, 9.0 eq, 4.5 mmol) 
according to Procedure C.  The crude mixture was purified by flash chromatography on silica 
using 5% MeOH/CHCl3 + 0.5% AcOH to yield (-)-16.  Run 1: 129.8 mg, 0.375 mmol, 75%. Run 
2: 134.1 mg, 78%.  Average: 77%. 
1H NMR (500 MHz, Methanol-d4) δ 8.38 (d, J = 8.8 Hz, 2H), 8.06 (d, J = 8.8 Hz, 2H), 4.08 (dd, 
J = 5.1, 9.25 Hz, 1H), 3.47 (s, 3H), 2.38 (t, J = 7.3 Hz, 2H), 2.10-2.03 (m, 1H), 1.85-1.77 (m, 
1H); 
13C NMR (125 MHz, Methanol-d4) δ 175.9, 172.8, 151.4, 147.9, 129.5, 125.2, 56.4, 54.8, 52.7, 
30.4, 28.8; 
HRMS (ESI) calc’d for: C12H15N2O8S [M+H]+: 347.0549, found: 347.0552;  
[α]D26 = -9.7° (c = 0.98, MeOH).  
 	  
NsHN CO2Me
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Methyl (2S)-5-hydroxy-1-((4-nitrophenyl)sulfonyl)pyrrolidine-2-carboxylate  (5-HP). 
Nosyl-Proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted with (S,S)-
Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH according to Procedure A.  The crude reaction 
mixture was purified by flash chromatography using 9:1 CHCl3:EtOAc.  Run 1: 5-HP (102.7 
mg, 0.31 mmol, 62%); Run 2: 5-HP (102.0 mg, 0.31 mmol, 62%). Average 62%.  Isolated as an 
inseparable mixture of C5-epimers. 
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.35 Hz, 4H), 8.10 (d, J = 8.8 Hz, 4H), 5.68 (br s, 
1H), 5.61 (d, J = 3.85, 1H), 4.52 (d, J = 9.15 Hz, 1H), 4.43 (m, 1H), 3.65 (s, 3H), 3.63 (s, 3H), 
2.85-2.76 (m, 1H), 2.62-2.52 (m, 1H), 2.32-2.25 (m, 1H), 2.20-2.05 (m, 3H), 2.00-1.92 (m, 2H);  
13C NMR (125 MHz, CDCl3) δ 172.8, 171.7, 150.22, 145.6, 128.9, 124.2, 85.6, 84.6, 60.7, 60.2, 
53.0, 52.6, 34.3, 32.9, 29.1, 28.3; 
HRMS (ESI) calc’d for: C12H13N2O6 [M-OH]+: 313.0494, found: 313.0479.  	  
	  
Methyl (R)-1-((4-nitrophenyl)sulfonyl)piperidine-2-carboxylate S-1. 
1H NMR (500 MHz, Chloroform-d) δ 8.3 (d, J = 8.9 Hz, 2H), 7.9 (d, J = 8.9 Hz, 2H), 4.8 (d, J = 
4.6 Hz, 1H), 3.9 – 3.8 (m, 1H), 3.6 (s, 3H), 3.2 (td, J = 12.7, 2.8 Hz, 1H), 2.2 – 2.1 (m, 1H), 1.8 
(tdd, J = 13.6, 5.9, 3.5 Hz, 1H), 1.7 – 1.6 (m, 2H), 1.6 – 1.5 (m, 1H), 1.2 (qt, J = 14.0, 3.6 Hz, 
1H);  
N
Ns
CO2Me
HO
N
Ns
CO2Me
	   93 
13C NMR (125 MHz, Chloroform-d) δ 170.8, 149.9, 145.8, 128.5, 124.1, 55.5, 52.3, 43.1, 28.0, 
24.9, 20.2;  
IR (film, cm-1) 2951, 1739, 1531, 1350, 1244, 1188, 1161, 1111, 1059, 947, 856, 743;  
HRMS (ESI) m/z calc’d for C27H40N45O9S [M+H]+: 329.0807, found 329.0804; 
[α]D27 = +21.6° (c = 1.1, CHCl3).  
 
 
Methyl (2R)-6-hydroxy-1-((4-nitrophenyl)sulfonyl)piperidine-2-carboxylate (17).  
(+)-Nosyl-Pipecolic acid methyl ester S-1 (Parallel reactions, 2 x 656.6 mg, 1.0 eq, 2.0 mmol 
total starting material) was reacted with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH in 
MeCN according to Procedure A.  The crude reaction mixture was purified by flash 
chromatography on silica using 3:1à3:2 Hexanes:EtOAc. (Note: the hemiaminal product of this 
reaction is less stable than 5HP, and care must be taken when concentrating the crude reaction 
mixture onto silica gel for chromatography.  Excessively long times on the rotary evaporator 
(>30 min) or excessively high temperatures (>30°C) resulted in greatly reduced yields.) Run 1: 
343.8 mg, 50%. Run 2:  381.4 mg, 55%. Average: 53%.  Isolated 17 as an inseparable mixture of 
C6-epimers. 
1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 9.0 Hz, 2H), 8.08 (d, J = 9.0 Hz, 2H), 5.69 (dt, J = 
2.55, 8.55 Hz, 1H), 4.85 (dd, J = 1.65, 6.6 Hz, 1H), 4.62 (d, J = 8.4 Hz, 1H), 3.60 (s, 3H), 2.15-
2.12 (m, 1H), 2.12-2.08 (m, 1H), 1.99-1.94 (m, 1H), 1.90-1.80 (m, 1H), 1.68-1.63 (m, 2H), 1.58-
1.54 (m, 1H); 
N
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13C NMR (125 MHz, CDCl3) δ 174.1, 150.3, 145.7, 129.2, 124.1, 76.6, 54.9, 53.3, 32.5, 27.4, 
13.4; 
HRMS (ESI) calc’d for: C13H15N2O6S [M-OH]+: 327.0651, found: 327.0645. 
 
Standard procedure for 2-step oxidation / arylation sequence. Nosyl proline methyl ester (-)-
15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to Procedure A with (S,S)-
Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture was plugged through 
silica gel and concentrated.  The crude residue was dissolved in CH2Cl2 (1.5 mL) and transferred 
to a flame-dried 40mL scintillation vial under inert atmosphere.  Nucleophile (1.0 eq, 0.5 mmol) 
was added as a solution in CH2Cl2 (1 mL) and the stirring mixture cooled to -78°C.  BF3OEt2 
(123 μL, 2.0 eq, 1.0 mmol) was added dropwise to the reaction, and the mixture was stirred at -
78°C for 1h, then warmed to 0 °C for 2h.  The crude reaction was then concentrated onto silica 
gel and purified by flash chromatography. 
 
Note on the diastereoselectivity of the arylation. A plausible explanation for syn-
diastereoselectivity is as follows: In the N-Nosyl iminium intermediate, the C2 methyl ester is 
pointing “up”, so it is reasonable that the large nitrophenylsulfonyl group may orient itself away 
(“down”) to avoid steric interactions, thus sterically blocks the bottom face. The result ofthis 
conformation is a top-face nucleophilic attack, resulting in syn-configuration relative to the C2 
methyl ester.   
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Methyl-(2S,5R)-5-(2-hydroxyphenyl)-1-((4-nitrophenyl)sulfonyl)pyrrolidine-2-carboxylate 
(+)-18. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated. Arylation with phenol (47.1 mg, 1.0 eq, 0.5 
mmol) according to the Standard Procedure was then performed.  The crude reaction was 
concentrated onto silica gel and purified by flash chromatography on silica eluting with 20% 
EtOAc/Hexanes to afford (+)-18 as a 3.1:1 mixture of ortho/para isomers.  Run 1: 79.7 mg, 
39%. Run 2:  78.4 mg, 39%. Average: 39% (62% per step). Further purification of the 
regioisomers by flash chromatography (18% EtOAc/Hexanes à 30%) yielded the major ortho 
isomer (+)-18 as a single regio- and diastereomer. 
Ortho-substitution for the major isomer was established on the basis of the 1H NMR data, which 
showed 4 distinct signals attributed to the phenol group, consistent with ortho substitution. 2,5-
Syn-stereochemistry was assigned by 1D NOE experiments, which are consistent with a syn 
relationship between the 2- and 5- protons of the proline ring.  This is analogous to 1D NOE 
signals for (-)-19 (naphthol adduct), (+)-23 (indole adduct), and (+)-24 (benzothiophene adduct) 
which have also been confirmed by X-Ray crystal structure. 
1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 8.38 (d, J = 8.9 Hz, 2H), 8.03 (d, J = 8.9 Hz, 2H), 
7.69 (dd, J = 1.3, 7.6 Hz, 1H), 7.04 (dt, J = 1.6, 7.9 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.73 (dt, J 
= 0.9, 7.6 Hz, 1H), 5.17 (t, J = 6.75 Hz, 1H), 4.61 (t, 6.3 Hz, 1H), 3.82 (s, 3H), 2.21-2.12 (m, 
2H), 2.06-1.99 (m, 1H), 1.96-1.88 (m, 1H); 
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13C NMR (125 MHz, CDCl3) δ 175.5, 154.7, 150.0, 143.9, 130.6, 130.3, 129.2, 123.3, 121.2, 
120.3, 118.2, 65.8, 60.9, 53.7, 31.6, 29.3; 
HRMS (ESI) calc’d for: C18H17N2O7S [M-H]-: 405.0756, found: 405.0749;  
[α]D26 = +56.2° (c = 1.07, CH2Cl2).  
 
 
 
Methyl-(2S,5R)-5-(2-hydroxynaphthalen-1-yl)-1-((4-nitrophenyl)sulfonyl)pyrrolidine-2-
carboxylate (-)-19. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated. Arylation with 2-naphthol (144.2 mg, 2.0 eq, 
1.0 mmol) according to the Standard Procedure was then performed.  The crude reaction was 
concentrated onto silica gel and purified by flash chromatography on silica eluting with 4:1à2:1 
Hexanes/EtOAc afforded (-)-19 as a single regio- and diastereomer.  Run 1: 139.7 mg, 61%.  
Run 2: 138.0 mg, 60%. Average: 61% (78% per step). 
2,5-Syn-stereochemistry was assigned by obtaining an X-Ray crystal structure of (-)-19, and 1D 
NOE experiments are also consistent with a syn relationship between the 2- and 5- protons of the 
proline ring. 
N
CO2Me
Ns
OH
	   97 
1H NMR (500 MHz, Chloroform-d) δ 8.38 (s, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.83 (d, J = 8.8 Hz, 
2H), 7.74 (d, J = 8.0 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.50 (d, J = 8.9 Hz, 1H), 7.43 (d, J = 8.9 
Hz, 2H), 7.38 (t, J = 7.4 Hz, 1H), 6.54 (d, J = 8.8 Hz, 1H), 5.76 (dd, J = 11.2, 6.1 Hz, 1H), 5.15 
(d, J = 9.1 Hz, 1H), 3.97 (s, 3H), 2.54 (tdd, J = 12.5, 10.5, 6.5 Hz, 1H), 2.44 (qd, J = 12.7, 6.4 
Hz, 1H), 2.32 (dq, J = 14.0, 6.5 Hz, 2H);  
13C NMR (126 MHz, Chloroform-d) δ 175.6, 153.7, 150.2, 143.1, 132.6, 130.6, 129.3, 129.1, 
129.0, 127.5, 123.5, 123.1, 121.0, 120.1, 112.0, 60.5, 59.9, 53.9, 30.7, 29.3;  
IR (film, cm-1) 3384, 3104, 2958, 1737, 1621, 1602, 1531, 1471, 1440, 1349, 1313, 1220, 1160, 
1089;  
HRMS (ESI) m/z calc’d for C22H21N2O7S [M+H]+: 457.1069, found 457.1069;  
[α]D28 = -37.8˚ (c = 1.12, CH2Cl2). 
 
 
 
Methyl-(2S,5R)-5-(2-hydroxy-5-((S)-3-methoxy-2-(5-nitro-1,3-dioxoisoindolin-2-yl)-3-
oxopropyl)phenyl)-1-((4-nitrophenyl)sulfonyl)pyrrolidine-2-carboxylate (-)-20. 
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Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated. Arylation with N-(4-nitrophthaloyl)-Tyrosine 
methyl ester (185.2 mg, 1.0 eq, 0.5 mmol) according to the Standard Procedure was then 
performed.  The crude reaction was concentrated onto silica gel and purified by flash 
chromatography on silica eluting with 25%à40% EtOAc/Hexanes afforded (-)-20 as a single 
regio- and diastereomer.  Run 1: 123 mg, 36% yield.  Run 2: 129.8 mg, 38% yield. Average: 
37% (61% per step).  
Ortho-substitution was assigned based on the 1H NMR data, which display 3 distinct peaks and 
chemical shift values consistent with substitution ortho to the phenol moiety.  2,5-Syn-
stereochemistry was assigned by 1D NOE experiments, which are consistent with a syn 
relationship between the 2- and 5- protons of the proline ring.  This is analogous to 1D NOE 
signals for (-)-19 (naphthol adduct), (+)-23 (indole adduct), and (+)-24 (benzothiophene adduct) 
which have also been confirmed by X-Ray crystal structure. 
1H NMR (500 MHz, CDCl3) δ 8.55-8.51 (m, 2H), 8.07 (d, J = 8.95 Hz, 2H), 7.92 (d, J = 8.15 
Hz, 1H), 7.39 (s, 1H), 7.29 (d, J = 8.85 Hz, 2H), 6.96 (dd, J = 2.15, 8.25 Hz, 1H), 6.80 (d, J = 2.2 
Hz, 1H), 6.31 (d, J = 8.3 Hz, 1H), 5.12 (dd, J = 5.05, 11.45 Hz, 1H), 4.91 (d, J = 9.05 Hz, 1H), 
4.57 (dd, J = 6.15, 10.9 Hz, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.55-3.45 (m, 2H), 2.34-2.25 (m, 
1H), 2.24-2.09 (m, 3H); 
13C NMR (125 MHz, CDCl3) δ175.3, 168.7, 165.8, 165.6, 153.9, 151.8, 150.1, 143.9, 135.9, 
132.9, 131.2, 130.6, 129.5, 128.8, 128.1, 124.9, 123.6, 121.8, 119.1, 118.7, 66.0, 61.1, 54.4, 53.7, 
53.3, 33.4, 31.5, 29.2; 
HRMS (ESI) calc’d for: C30H25N4O13S [M-H]-: 681.1139, found: 681.1133;  
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[α]D26 = -99.0° (c = 1.15, CH2Cl2).  
 
 
 
 
Methyl-(2S,5R)-5-(2,6-dihydroxy-4-((E)-4-hydroxystyryl)phenyl)-1-((4-
nitrophenyl)sulfonyl)pyrrolidine-2-carboxylate (+)-21.   
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated. Arylation with resveratrol (114.1 mg, 2.0 eq, 
1.0 mmol) according to the Standard Procedure was then performed.  The crude reaction was 
concentrated onto silica gel and purified by flash chromatography on silica eluting with 5:1 
CHCl3/EtOAc to afford (+)-21 as a 2.4:1.0 mixture of C2/C4 isomers.  Run 1: 116.2 mg, 43%; 
Run 2: 116.4 mg, 43%.  Average: 43% (66% per step).   
The mixture was dissolved in 10:1 CH2Cl2/Acetone in a 1-dram vial and that vial was placed 
uncapped into a 20 mL scintillation vial containing pentane, which was then capped and allowed 
to sit for 24h.  Upon sitting, small amounts of the pure 2-isomer (+)-21 crystallized and were 
sufficient for characterization.  The structure was assigned as the 2-isomer on the basis of the 1H 
and 13C NMR data, which display the expected number of peaks and splitting patterns consistent 
with symmetrical substitution (at C2) on the resveratrol fragment.  
N
Ns
CO2Me
OH
OH
HO
	   100 
1H NMR (500 MHz, Acetone-d6) δ 8.43 (s, 3H), 8.32 (d, J = 8.9 Hz, 2H), 8.05 (d, J = 8.9 Hz, 
2H), 7.41 (d, J = 8.5 Hz, 2H), 6.96 (d, J = 16.3 Hz, 1H), 6.84 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 
16.3 Hz, 1H), 6.45 (s, 2H), 5.25 (dd, J = 6.2, 10.1 Hz, 1H), 4.79-4.75 (m, 1H), 3.87 (s, 3H), 2.27-
2.10 (m, 4H);  
13C NMR (125 MHz, Acetone-d6) δ 175.5, 158.2, 157.1, 151.3, 143.2, 139.9, 130.5, 129.9, 
129.4, 128.8, 126.2, 124.7, 116.4, 110.6, 106.7, 62.2, 58.9, 53.6, 31.1, 30.6; 
HRMS (ESI) calc’d for: C26H24N2O9NaS [M+Na]+: 563.1100, found: 563.1099;  
[α]D26 = +51.4° (c = 0.81, MeOH).  
 
Methyl-(2S,5S)-1-((4-nitrophenyl)sulfonyl)-5-(10-oxo-9,10-dihydroanthracen-9-
yl)pyrrolidine-2-carboxylate (-)-22. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated. Arylation with anthrone (97.1 mg, 1.0 eq, 0.5 
mmol) according to the Standard Procedure was then performed.  The crude reaction was loaded 
directly onto a silica gel column and purified by flash chromatography eluting with CH2Cl2 to 
afford (-)-22 as a single regio- and diastereomer.  Run 1: 153 mg, 60%.  Run 2: 142 mg, 56%.  
Average: 58% (76% per step).  
1H NMR (500 MHz, Acetone-d6) δ 8.56 (d, J = 8.8 Hz, 2H), 8.39 (d, J = 8.8 Hz, 2H), 8.27 (d, J = 
6.9 Hz, 1H), 8.21 (d, J = 7.8 Hz, 1H), 7,82-7.70 (m, 4H), 7.62 (t, J = 7.1 Hz, 1H), 7.55 (t, 7.4 Hz, 
1H), 5.28 (d, J = 3.3 Hz, 1H), 4.42 (dd, J = 3.4, 8.8 Hz, 1H), 4.30 (d, J = 8.8 Hz, 1H), 3.47 (s, 
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3H), 1.75-1.61 (m, 1H), 1.33 (dd, J = 7.4, 13.0 Hz, 1H), 1.16 (dd, J = 7.1, 13.5 Hz, 1H), 0.36-
0,18 (m, 1H);  
13C NMR (126 MHz, Chloroform-d) δ 184.7, 171.9, 150.4, 144.6, 141.6, 139.6, 133.7, 133.3, 
132.9, 132.8, 129.8, 129.5, 128.5, 128.3, 128.0, 127.9, 124.2, 68.3, 63.3, 52.5, 45.9, 28.5, 25.5;  
HRMS (ESI) m/z calc’d for C26H23N2O7S [M+H]+: 507.1226, found 507.1234;  
[a]D27 = -35.9◦ (c=0.57, CH2Cl2). 
Figure 17. Calculated Structure and NMR data for compound 22 
 
The energy minimized structures for the cis- and trans-diastereomers of anthrone-proline 
adduct 22 were calculated using 6-31 G(d,p) level of theory in Gaussian, and the NMR chemical 
shift and coupling constants were calculated using mPW1PW91/6-311G(d,p) in Gaussian.  The 
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results of these calculations support our assignment of (-)-22 as the trans-isomer.  The energy 
minimized structure of trans-22 positions one of the anthrone aryl rings directly under Hb (Figure 
17A), whereas the anthrone is positioned away from the ring in cis-22 (Figure 17B). The 
proximity of Hb to the π-system in trans-22 suggests a significant shielding effect on Hb due to 
the aromatic ring current, which is observed for (-)-22 and calculated for trans-22 (δ Hb observed 
= 0.28 ppm, calc’d for trans-22 = 0.48 ppm vs. 0.84 for cis-22, Figure 17C). Further 
experimental evidence of the proximity of Hb to the aromatic ring is provided by the observation 
of NOE correlations between Hb and aryl resonances at 8.27, 7.82, 7.75, and 7.62 ppm (Figure 
18). Coupling constant calculations for the key resonances Hc and Hd, near the proline-anthrone 
junction, also support assignment of (-)-22 as trans, with calculated results for trans-22 matching 
the multiplicity and coupling constant nicely with those observed for (-)-22, while those 
calculated for cis-22 predict additional coupling inconsistent with the observed data (Figure 
17C).  
Figure 18. 2D NOESY for compound (-)-22. 
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Methyl (2S,5R)-1-((4-nitrophenyl)sulfonyl)-5-(1-(phenylsulfonyl)-1H-indol-3-yl)pyrrolidine-
2-carboxylate  (+)-23. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated. Arylation with N-phenylsulfonyl indole (128.7 
mg, 1.0 eq, 0.5 mmol) according to the Standard Procedure was then performed.  The crude 
reaction was concentrated onto silica gel and purified by flash chromatography on silica eluting 
with 20%à40% EtOAc/Hexanes to afford (+)-23 as a single regio- and diastereomer. Run 1: 168 
mg, 59%.  Run 2: 142.8 mg, 50%.  Average: 55% (74% per step).  
2,5-Syn-stereochemistry was assigned by obtaining an X-Ray crystal structure, and 1D NOE 
experiments are also consistent with a syn relationship between the 2- and 5- protons of the 
proline ring. 
1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 8.2 Hz, 2H), 7.74 (d, J = 8.4 Hz, 1H), 7.65 – 
7.59 (m, 2H), 7.58 – 7.49 (m, 7H), 7.16 (t, J = 7.8 Hz, 1H), 7.04 (t, J = 7.6 Hz, 1H), 5.05 (t, J = 
7.1 Hz, 1H), 4.88 (dd, J = 9.3, 4.0 Hz, 1H), 3.89 (s, 3H), 2.46 – 2.35 (m, 1H), 2.33 – 2.24 (m, 
1H), 2.22 – 2.12 (m, 2H);  
N
CO2Me
Ns
N
PhO2S
	   104 
13C NMR (126 MHz, Chloroform-d) δ 173.0, 149.3, 144.4, 138.5, 135.1, 134.4, 129.7, 129.1, 
127.8, 127.2, 126.1, 125.0, 123.2, 123.1, 120.8, 119.5, 113.4, 61.0, 58.8, 53.0, 32.7, 29.3;  
IR (film, cm-1) 3106, 3070, 2954, 1749, 1606, 1531, 1448, 1351, 1313, 1174, 1124, 1095;  
HRMS (ESI) m/z calc’d for C26H24N3O8S2 [M+H]+: 570.1005, found 570.1005;  
[α]D28 = +11.8˚ (c = 1.60, CH2Cl2). 
 
 
Methyl (2S,5R)-5-(2-methylbenzo[b]thiophen-3-yl)-1-((4-nitrophenyl)sulfonyl)pyrrolidine-
2-carboxylate  (+)-24. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated. Arylation with 2-methylbenzothiophene (74.1 
mg, 1.0 eq, 0.5 mmol) according to the Standard Procedure was then performed.  The crude 
reaction was concentrated onto silica gel and purified by flash chromatography on silica eluting 
with 10%à20%à25%à30%à40% EtOAc/Hexanes to afford (+)-24 as a single regio- and 
diastereomer.  Run 1: 108.2 mg, 47%. Run 2: 103.8 mg, 45%.  Average: 46% (68% per step).  
Crystals suitable for X-ray diffraction were obtained by dissolving (+)-24 in minimal CH2Cl2 in a 
1-dram vial, and placing that vial uncapped in a 20 mL scintillation vial containing pentane, 
which was capped and allowed to sit for 12h.   
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2,5-Syn-stereochemistry was assigned by obtaining an X-Ray crystal structure of (+)-24, and 1D 
NOE experiments are also consistent with a syn relationship between the 2- and 5- protons of the 
proline ring. 
1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 8.1 Hz, 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.8 
Hz, 2H), 7.33 (d, J = 7.9 Hz, 1H), 7.07 (t, J = 7.3 Hz, 1H), 7.01 (t, J = 7.4 Hz, 1H), 5.11 (dd, J = 
5.6, 10.9 Hz, 1H), 5.03 (dd, J = 2.3, 10.4 Hz, 1H), 2.63-2.46 (m, 5H, overlap includes a singlet 
~2.60, ~3H), 2.40-2.34 (m, 1H), 2.16-2.11 (m, 1H);  
13C NMR (125 MHz, CDCl3) δ 173.27, 148.6, 143.7, 140.4, 137.5, 128.4, 125.7, 123.9, 123.7, 
123.1, 122.1, 121.4, 59.9, 59.3, 52.8, 30.7, 28.8, 14.1; 
HRMS (ESI) calc’d for: C21H21N2O6S2 [M+H]+: 461.0841, found: 461.0834;  
[α]D28 = +34.1° (c = 1.03, CH2Cl2). 
 
Methyl (S)-5-hydroxy-2-((4-nitrophenyl)sulfonamido)pentanoate (+)-25.  
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated.  The crude residue was dissolved in 1:1 CH2Cl2 
/ EtOH (8 mL) and cooled to 0°C.  NaBH4 (23 mg, 0.6 mmol, 1.2 eq) was added in a few 
portions and the reaction allowed to warm to RT.  After 2h complete conversion of hemiaminal 
was observed by TLC.  The crude reaction mixture was concentrated onto silica gel and purified 
by flash chromatography eluting with 2.5%à 4% MeOH/CH2Cl2 to afford (+)-25.  Run 1: 53.6 
mg, 32%.  Run 2: 49.8 mg, 30%.  Average: 31% (57% per step).  
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1H NMR (500 MHz, CDCl3) δ 8.34 (d, J = 8.6 Hz, 2H), 8.04 (d, J = 8.6 Hz, 2H), 4.06 (dd, J = 
4.8, 7.8 Hz, 1H), 3.71-3.63 (m, 2H), 3.54 (s, 3H), 1.95-1.88 (m, 1H), 1.85-1.78 (m, 1H), 1.68-
1.61 (m, 2H), 1.12 (t, J = 7.1 Hz, 1H, R-OH); 
13C NMR (125 MHz, CDCl3) δ 171.9, 150.2, 145.9, 128.6, 124.4, 62.0, 55.8, 52.9, 30.2, 27.9; 
HRMS (ESI) calc’d for: C12H15N2O7S [M-H]-: 331.0600, found: 331.0603; 
[α]D26 = +27.2° (c = 1.5, CHCl3). 
 
 
Methyl (S)-2-((4-nitrophenyl)sulfonamido)hex-5-enoate (+)-26. 
 Wittig Reagent Preparation:  A flame-dried flask under inert atmosphere was charged with 
methyltriphenylphosphonium bromide (535 mg, 3.0 eq, 1.5 mmol) in THF (6 mL) and cooled to 
0°C.  Sodium tert-butoxide (151 mg, 2.7 eq, 1.35 mmol) was added in one portion and the 
reaction allowed to warm to rt, stirring for 12h. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated.  The crude residue was dissolved in THF (5 
mL) and added dropwise to the previously prepared solution of Wittig reagent in THF at 0°C, 
stirred overnight and allowed to warm to RT. The crude reaction mixture was concentrated onto 
silica gel and purified by flash chromatography eluting with 8:1 CHCl3/EtOAc to afford (+)-26.  
Run 1: 72.7 mg, 44%.  Run 2: Reaction run starting with 3 mmol of Nosyl-proline methyl ester 
and all other reagents scaled accordingly; 416.5 mg, 42%. Average: 43% (66% per step). 
Reaction run starting from (D)-(+)-Nosyl-Proline methyl ester; 66.4 mg, 40% (63% per step). 
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1H NMR (500 MHz, Chloroform-d) δ 8.34 (d, J = 8.9 Hz, 2H), 8.05 (d, J = 8.8 Hz, 2H), 5.81 – 
5.65 (m, 1H), 5.61 (d, J = 9.3 Hz, 1H), 5.00 (dd, J = 13.7, 2.1 Hz, 2H), 4.09 – 3.91 (m, 1H), 3.54 
(s, 3H), 2.12 (app. q, J = 7.0 Hz, 2H), 1.93 – 1.82 (m, 1H), 1.75 (dt, J = 13.8, 7.2 Hz, 1H);  
13C NMR (126 MHz, Chloroform-d) δ 171.9, 150.2, 145.8, 136.3, 128.6, 124.4, 116.6, 55.5, 
52.9, 32.5, 29.1;  
IR (film, cm-1) 3264, 3108, 3087, 2946, 2902, 1743, 1643, 1606, 1527, 1434, 1348, 1319, 1305, 
1228, 1164, 1089, 983;  
HRMS (ESI) m/z calc’d for C13H16N2O6NaS [M+Na]+: 351.0627, found 351.0634;  
[α]D28 = +51.3˚ (c = 1.16, CH2Cl2). 
 
 
Methyl (R)-2-((4-nitrophenyl)sulfonamido)hept-6-enoate (-)-27.  
Wittig reagent was prepared as above for (+)-26.  (+)-Ns-Pipecolic acid methyl ester (S-1) (656.7 
mg, 1.0 equiv., 2.0 mmol) was reacted according to Procedure A with (S,S)-
Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The	  crude	  reaction	  mixture	  was	  plugged	  through	  silica	   gel	   and	   concentrated. The crude reaction mixture was plugged through silica gel with 
EtOAc and concentrated.  The crude residue was dissolved THF (5 mL) and added dropwise to 
the previously prepared solution of Wittig reagent in THF at 0 °C, stirred overnight and allowed 
to warm to rt. The crude reaction mixture was concentrated onto silica gel and purified by flash 
chromatography eluting with 3:1 Hexanes/EtOAc to afford (-)-27.  Run 1: 246.7 mg, 36%. Run 
2: 266.9 mg, 39%.  Average: 37% (61% per step). 
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1H NMR (500 MHz, Chloroform-d) δ 8.35 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 5.70 
(ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.52 (d, J = 9.2 Hz, 1H), 5.07 – 4.86 (m, 2H), 4.00 (ddd, J = 
9.3, 7.7, 5.1 Hz, 1H), 3.55 (s, 3H), 2.03 (q, J = 6.6 Hz, 2H), 1.78 (ddd, J = 21.7, 7.5, 5.2 Hz, 1H), 
1.65 (dq, J = 15.5, 7.8 Hz, 1H), 1.43 (p, J = 7.5 Hz, 2H);  
13C NMR (126 MHz, Chloroform-d) δ 171.9, 150.2, 145.8, 137.6, 128.6, 124.4, 115.5, 55.9, 
52.8, 32.9, 32.7, 24.2;  
IR (film, cm-1) 3238, 2948, 2917, 2867, 1739, 1639, 1608, 1529, 1456, 1429, 1348, 1307, 1268, 
1164, 1143, 1087;  
HRMS (ESI) m/z calc’d for C14H18N2O6SNa [M+Na]+: 365.0783, found 365.0782;  
[α]D26 = -43.5˚ (c = 0.62, CH2Cl2). 
 
General Procedure for Reductive Amination.  
A crude reaction mixture containing 5-HP (0.5 mmol scale proline substrate, generated using 
Procedure A) was dissolved in CH2Cl2 (8 mL), and amine (1.0 eq, 0.5 mmol) was added in 
CH2Cl2 (1 mL), followed by sodium triacetoxyborohydride (317.9 mg, 3.0 eq, 1.5 mmol).  The 
reaction was stirred overnight at RT, and concentrated onto silica gel for column 
chromatography. 
 
 
Methyl (S)-5-(dibenzylamino)-2-((4-nitrophenyl)sulfonamido)pentanoate  (+)-28. 
NsHN CO2Me
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Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated.  The crude reaction mixture was then subjected 
to the General Procedure for Reductive Amination, using dibenzyl amine (98.6 mg, 1.0 equiv., 
0.5 mmol).  Flash chromatography eluting with 2%à3%à4% MeOH/CH2Cl2 afforded (+)-28.  
Run 1: 158.8 mg, 62%.  Run 2: 139.8 mg, 55%.  Average: 59% (77% per step).  
1H NMR (500 MHz, CDCl3) δ  8.29 (d, J = 8.5 Hz, 2H), 7.93 (d, J = 9.0 Hz, 2H), 7.35-7.30 (m, 
8H), 7.28-7.24 (m, 2H), 6.00 (s, 1H), 3.92 (dd, J = 4.8, 7.6 Hz, 1H), 3.56 (d, J = 13.7 Hz, 2H), 
3.52 (s, 3H), 3.51 (d, J = 13.5 Hz, 2H), 2.45-2.35 (m, 2H), 1.82-1.75 (m, 1H), 1.72-1.65 (m, 1H), 
1.56-1.51 (m, 2H);   
13C NMR (125 MHz, CDCl3) δ 172.0, 150.1, 146.0, 139.1, 129.1, 128.5, 128.4, 127.2, 124.3, 
58.3, 55.6, 52.7, 52.2, 30.9, 22.5; 
HRMS (ESI) calc’d for: C26H30N3O6S [M+H]+: 512.1855, found: 512.1851; 
[α]D23 +17.1° (c = 1.08, CHCl3). 
  
Methyl (S)-2-((4-nitrophenyl)sulfonamido)-5-(4-(pyridin-2-yl)piperazin-1-yl)pentanoate (-)-
29.   
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated.  The crude reaction mixture was then subjected 
NsHN CO2Me
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to the General Procedure for Reductive Amination, using 1-(2-pyridyl)-piperazine (81.6 mg, 1.0 
equiv., 0.5 mmol).  Flash chromatography eluting with 2%à4% MeOH/CH2Cl2 afforded (-)-29.  
Run 1: 156.8 mg, 60%.  Run 2: 138.7 mg, 58%.  Average: 59% (77% per step).   
1H NMR (500 MHz, CDCl3) δ 8.23-8.20 (m, 3H), 7.94 (d, J = 8.9 Hz, 2H), 7.50 (ddd, J = 2.0, 
7.25, 8.6 Hz, 1H), 6.67-6.65 (m, 2H), 4.19 (t, J = 4.55 Hz, 1H), 3.72 (ddd, J = 3.1, 7.0, 12.4 Hz, 
2H), 3.59 (dq, J = 3.1, 10.3 Hz, 2H), 3.53 (s, 3H), 2.72 (ddd, J = 3.0, 7.0, 10.5 Hz, 2H), 2.52 
(ddd, J = 2.7, 6.8, 10.3 Hz, 2H), 2.42 (dddt, J = 4.3, 9.1, 14.2, 18.2 Hz, 2H), 2.21 (dddd, J = 3.4, 
5.1, 6.6, 14.8 Hz, 1H), 1.79 (ddt, 3.8, 10.7, 14.7 Hz, 1H), 1.68-1.61 (m, 1H), 1.58-1.49 (m, 1H);  
13C NMR (125 MHz, CDCl3) δ 172.0, 150.1, 146.0, 139.1, 129.1, 128.5, 128.4, 127.2, 124.3, 
58.3, 55.6, 52.7, 52.2, 30.9, 22.5; 
HRMS (ESI) calc’d for: C21H28N5O6S [M+H]+: 478.1760, found: 478.1763;  
[α]D22 = -25.1° (c = 1.24, CHCl3).  
 
Methyl (S)-5-(((S)-3-(1H-indol-3-yl)-1-methoxy-1-oxopropan-2-yl)amino)-2-((4-
nitrophenyl)sulfonamido)pentanoate (+)-30. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated.  The crude reaction mixture was then subjected 
to the General Procedure for Reductive Amination, using a solution of L-tryptophan methyl 
CO2MeNsHN
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ester, HCl salt (128.9 mg, 1.0 equiv., 0.5 mmol) and triethylamine (70 µL, 1.0 equiv., 0.5 mmol) 
in CH2Cl2.  Flash chromatography eluting with 2%à3% MeOH/CH2Cl2 afforded (+)-30.  Run 1: 
134.5 mg, 50%. Run 2: 119.0 mg, 45%.  Average: 48% (69% per step). 
1H NMR (500 MHz, CDCl3) δ 8.25 (d, J = 8.9 Hz, 2H), 8.18 (s, 1H), 7.97 (d, J = 8.9 Hz, 2H), 
7.59 (d, J = 8.5 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 7.9 Hz, 1H), 7.17 (d, J = 2.2 Hz, 
1H), 7.12 (t, J = 7.05 Hz, 1H), 4.13 (dd, J = 4.1, 6.35 Hz, 1H), 3.64 (d, J = 7.05 Hz, 1H), 3.61 (s, 
3H), 3.52 (s, 3H), 3.31 (d, J = 6.1 Hz, 2H), 2.74 (ddd, J = 3. 85, 6.3, 11.4 Hz, 1H), 2.35 (ddd, J = 
3.65, 8.95, 12.25 Hz, 1H), 2.01-1.94 (m, 1H), 1.77 (ddt, J = 4.7, 9.3, 14.7 Hz, 1H), 1.64-1.57 (m, 
1H), 1.35-1.26 (m, 1H); 
13C NMR (125 MHz, CDCl3) δ 174.6, 171.8, 149.9, 147.1, 136.3, 128.3,127.6, 124.2, 123.5, 
122.3, 119.7, 118.8, 111.4, 110.5, 61.4, 55.3, 52.5, 52.0, 47.5, 32.3, 29.1, 25.6; 
HRMS (ESI) calc’d for: C24H29N4O8S [M+H]+: 533.1706, found: 533.1710;  
[α]D25 = +26.2° (c = 0.96, CHCl3). 
 
(S)-N-(1-benzyl-2-oxopiperidin-3-yl)-4-nitrobenzenesulfonamide (+)-31. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated.  The crude reaction mixture was then subjected 
to the General Procedure for Reductive Amination, using benzylamine (53.6 mg, 1.0 equiv., 0.5 
NBn
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mmol).  Flash chromatography eluting with 5% EtOAc/CHCl3 afforded (+)-31.  Run 1: 82.8 mg, 
43%.  Run 2: 80.7 mg, 42%.  Average: 43% (66% per step). 
1H NMR (500 MHz, CDCl3) δ  8.33 (d, J = 9.0 Hz, 2H), 8.10 (d, J = 9.0 Hz, 2H), 7.29-7.23 (m, 
3H), 7.13-7.11 (m, 2H), 6.25 (d, J = 1.0 Hz, 1H), 4.49 (d, J = 14.7 Hz, 1H), 4.45 (d, J = 14.7 Hz, 
1H), 3.63-3.59 (m, 1H), 3.18 (dd, J = 4.3, 7.5 Hz, 2H), 2.45-2.40 (m, 1H), 1.89-1.85 (m, 1H), 
1.82-1.68 (m, 2H); 
13C NMR (125 MHz, CDCl3) δ 167.6, 150.2, 145.4, 136.0, 128.9, 128.7, 128.1, 127.9, 124.5, 
54.1, 51.1, 46.8, 28.8, 20.5; 
HRMS (ESI) calc’d for: C18H20N3O5S [M+H]+: 390.1124; found: 390.1124; 
[α]D27 +62.9° (c = 1.06, CHCl3). 
 
 
(S)-4-nitro-N-(2-oxo-1-(prop-2-yn-1-yl)piperidin-3-yl)benzenesulfonamide (+)-32. 
Nosyl proline methyl ester (-)-15 (157 mg, 1.0 eq, 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture 
was plugged through silica gel and concentrated.  The crude reaction mixture was then subjected 
to the General Procedure for Reductive Amination, using propargylamine (27.5 mg, 1.0 equiv., 
0.5 mmol).  Flash chromatography eluting with 4% EtOAc/CHCl3 afforded (+)-32.  Run 1: 67.9 
mg, 40%.  Run 2: 69.4 mg, 41%.  Average: 41% (64% per step).  
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1H NMR (500 MHz, CDCl3) δ 8.34 (d, J = 8.8 Hz, 2H), 8.10 (d, J = 8.8 Hz, 2H), 6.01 (d, J = 
3.15 Hz, 1H), 4.12 (dq, J = 2.45, 17.3 Hz, 2H), 3.58 (ddd, J = 11.5, 5.4, 3.5 Hz, 1H), 3.40 (dd, J 
= 4.05, 8.25 Hz, 2H), 2.48-2.43 (m, 1H), 2.22 (t, J = 2.5 Hz, 1H), 2.00 (ddd, J = 17.3, 7.1, 3.0 
Hz, 1H), 1.92-1.85 (m, 1H), 1.84-1.74 (m, 1H);  
13C NMR (125 MHz, CDCl3) δ 167.4, 150.2, 145.3, 128.7, 124.5, 77.6 72.9, 54.1, 46.9,36.6, 
29.1, 20.6; 
HRMS (ESI) calc’d for: C14H16N3O5S [M+H]+: 338.0811, found: 338.0807;  
[α]D26 = +56.9° (c = 1.11, CH2Cl2). 
 
Methyl (S)-2-(4-((3-((4-nitrophenyl)sulfonamido)-2-oxopiperidin-1-yl)methyl)-1H-1,2,3-
triazol-1-yl)acetate (+)-33. 
Nosyl-aminopiperidinone (+)-32 (35.2 mg, 1.0 eq, 0.1 mmol) was dissolved in 5:1 THF:H2O (2 
mL).  Methyl azidoacetate (17.3 mg, 1.5 eq, 0.15 mmol) in 1 mL THF:H2O was added, followed 
by sodium ascorbate (3.6 mg, 0.2 eq, 0.02 mmol) and CuSO4-5H2O (2.5 mg, 0.1 eq, 0.01 mmol).  
The blue copper species turned dark brown over  30 seconds, and the mixture was stirred at rt for 
2h. The reaction was recharged with additional methyl azidoacetate, sodium ascorbate, and 
copper sulfate, and stirred for 2h, when full conversion of starting material was observed.  The 
reaction was diluted with H2O and CH2Cl2.  The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (5 x 20 mL).  Combined organic layers were dried over Na2SO4, and 
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concentrated onto silica gel for purification.  Flash chromatography eluting with 1%à2%à3% 
MeOH/CH2Cl2 afforded (+)-33 (27.4 mg, 61%).  
1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 8.8 Hz, 2H), 8.10 (d, J = 8.8 Hz, 2H), 7.62 (s, 1H), 
6.09 (m, 1H), 5.16 (d, J = 17.6 Hz, 1H), 5.10 (d, J = 17.6 Hz, 1H), 4.57 (d, J = 14.7 Hz, 1H), 
4.51 (d, J = 14.7 Hz, 1H), 3.82 (s, 1H), 3.56 (ddd, J = 2.3, 5.4, 11.3, Hz, 2H), 3.48-3.43 (m, 2H), 
2.41 (dq, J = 3.9, 13.3 Hz, 1H), 1.96-1.91 (m, 1H), 1.88-1.77 (m, 1H), 1.72 (qd, J = 3.8, 12.4 Hz, 
1H); 
13C NMR (125 MHz, CDCl3) δ 167.6, 166.7, 150.3, 145.3, 143.4, 128.8, 124.5, 54.1, 53.3, 50.8, 
48.0, 42.9, 28.8, 20.6; 
HRMS (ESI) calc’d for: C17H21N6O7S [M+H]+: 453.1192, found: 453.1183;  
[α]D27 = +42.9° (c = 1.0, CH2Cl2). 
Experimental data from Figure 12. 
dimethyl ((4-nitrophenyl)sulfonyl)-L-glutamate (+)-34. 
 Prepared from commercially available materials: (L)-Glutamic acid dimethyl ester 
hydrochloride (211.6 mg, 1.0 equiv., 1.0 mmol) was reacted with NsCl (243.5 mg, 1.1 equiv., 1.1 
mmol), NEt3 (0.31 mL, 2.2 equiv., 2.2 mmol), and DMAP (12.2 mg, 0.1 equiv., 0.1 mmol) in 
CH2Cl2 (10 mL) according to the General Nosylation Procedure.  Flash chromatography, eluting 
with 3:2 Hexanes/EtOAc, afforded (+)-34.  
1H NMR (500 MHz, Chloroform-d) δ 8.34 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 5.72 (d, 
J = 9.1 Hz, 1H), 4.09 (td, J = 9.0, 4.8 Hz, 1H), 3.68 (s, 3H), 3.56 (s, 3H), 2.60 – 2.32 (m, 2H), 
2.26 – 2.08 (m, 1H), 2.01 – 1.84 (m, 1H);  
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13C NMR (125 MHz, Chloroform-d) δ 173.1, 171.4, 150.2, 145.6, 128.6, 124.4, 55.2, 53.0, 52.1, 
29.5, 28.1;  
IR (film, cm-1) 3274, 3253, 3108, 2956, 1737, 1531, 1438, 1351, 1311, 1211, 1166, 1111, 1091, 
983, 854, 738;  
HRMS (ESI) m/z calc’d for C13H16N2O8S [M+H]+: 361.0706, found 361.0705;  
[α]D26 = +31.3˚ (c=1.07, CH2Cl2). 
Derived from Ns-Pro-OMe: Ns-Glu(OH)-OMe (-)-16 (50 mg, 1.0 equiv., 0.14 mmol, obtained 
from oxidation of (-)-15, was dissolved in 1:1 MeOH/CH2Cl2 at rt.  Then, a solution of 
trimethylsilyldiazomethane (2M in Et2O, 0.14 mL, 2.0 equiv., 0.28 mmol), was added dropwise 
to the solution, which bubbled immediately and remained yellow after the bubbling had ceased.  
The reaction was quenched by addition of drops of AcOH until the color of the solution changed 
from yellow to clear.  The solution was concentrated onto silica gel and purified via flash 
chromatography, eluting with 3:2 Hexanes / EtOAc to afford the title compound (48.2 mg, 96%).  
The sample was spectroscopically identical to that prepared using the above procedure. 
[α]D26 = +34.1˚ (c=1.07, CH2Cl2). 
 
methyl (S)-2-((tert-butoxycarbonyl)amino)hex-5-enoate (+)-35. 
Derived from commercially available sources: (S)-2-((tert-butoxycarbonyl)-amino)-hex-5-enoic 
acid (50 mg, 1.0 equiv., 0.22 mmol) was dissolved in 1:1 MeOH/CH2Cl2 at rt.  Then, a solution 
of trimethylsilyldiazomethane (2M in Et2O, 0.22 mL, 2.0 equiv., 0.44 mmol), was added 
dropwise to the solution, which bubbled immediately and remained yellow after the bubbling had 
ceased.  The reaction was quenched by addition of drops of AcOH until the color of the solution 
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changed from yellow to clear.  The solution was concentrated onto silica gel and purified via 
flash chromatography, affording (+)-35.  The sample obtained with this route was 
spectroscopically identical to the same molecule prepared from (-)-15.   
[α]D26 = +14.2˚ (c=1.10, CH2Cl2). 
 
 
 
Mitsunobu reaction of Proline-derived bishomoserine compound to re-form Ns-Pro-OMe. 
Triphenylphosphine (31.5 mg, 1.3 equiv., 0.12 mmol) was dissolved in CH2Cl2 (5 mL) at rt, and 
diethylazodicarboxylate (DEAD, 40% wt in PhMe, 41 mg, 1.5 equiv., 1.4 mmol) was added 
dropwise to the stirring solution.  Finally, Ns-Bishomoserine-OMe (+)-25 (30 mg, 1.0 equiv., 
0.09 mmol) was added as a solution in CH2Cl2 (1 mL).  The solution was stirred at RT overnight, 
concentrated, and purified via flash chromatography, eluting with 18% EtOAc / Hexanes to 25%, 
to afford (-)-15 (14.6 mg, 52%).  The sample obtained using this synthetic route was 
spectroscopically identical to the starting material. 
[α]D26 = -83.6˚ (c=1.04, CH2Cl2). 
Experimental data from Figure 13. 
 
Alcohol (+)-25 (100 mg, 1.0 equiv., 0.3 mmol) in CH2Cl2 (2 mL) was cooled to 0°C, and tert-
butyldimethylsilyl chloride (TBSCl, 54.2 mg, 1.2 equiv., 0.36 mmol), imidazole (30.6 mg, 1.5 
equiv., 0.45 mmol), and 4-dimethylaminopyridine (DMAP, 7.3 mg, 0.05 equiv., 0.06 mmol) 
NsHN CO2Me
OH DEAD, Ph3P, THF, rt.
N
Ns
CO2Me
(-)-15
[a]D26 = -83.6°
c = 1.04, CH2Cl2
(+)-25
NsHN CO2Me
OH
TBSCl, imidazole,
DMAP, CH2Cl2,
0°C to rt, 78% NsHN CO2Me
OTBS
(+)-25 (+)-S-2
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were added sequentially.  The reaction was stirred for 2.5 h and concetrated.  Flash 
chromatography of the crude reaction mixture, eluting with 15 to 20% EtOAc/Hexanes, afforded 
silyl ether product S-2 (105.1 mg, 78% yield).  
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.9 Hz, 2H), 8.0 3(d, J = 8.9 Hz, 2H), 5.79 (d, J = 9.0 
Hz, 1H), 4.05 (ddd, J = 5.0, 7.6, 8.9 Hz, 1H), 3.63-3.57 (m, 2H), 3.54 (s, 3H), 1.91-1.75 (m, 2H), 
1.59-1.49 (m, 2H), 0.87 (s, 9H), 0.04 (s, 6H); 
13C NMR (125 MHz, CDCl3) δ 171.9, 150.2, 146.1, 128.6, 124.3, 62.2, 55.8, 52.7, 30.2, 28.1, 
26.0, 18.4, -5.3; 
HRMS (ESI) calc’d for C18H29N2O7SSi [M-H]-: 445.1465, found: 445.1459; 
[α]D27 = +21.2° (c = 1.08, CHCl3).  
 
 
Compound S-2 (50 mg, 1.0 equiv., 0.11 mmol) was dissolved in EtOAc (1 mL) at RT, and 
triethylamine (NEt3, 13.1 mg, 1.2 equiv., 0.13 mmol) in 0.5 mL EtOAc, DMAP (15.9 mg, 1.2 
equiv., 0.13 mmol), and Boc2O (48.0 mg, 2.0 equiv., 0.22 mmol) in 0.5 mL EtOAc were added 
sequentially.  The reaction was stirred for 30 min and concentrated.  Flash chromatography of 
the crude residue, eluting with 9:1 Hexanes/EtOAc, afforded N-Boc(Ns) bis-protected 
intermediate S-3 (55.3 mg, 92% yield).  
1H NMR (500 MHz, CDCl3) δ 8.36 (d, J = 8.9 Hz, 2H), 8.28 (d, J = 8.9 Hz, 2H), 5.07 (dd, J = 
5.1, 10.0 Hz, 1H), 3.74 (s, 3H), 3.71 (t, J = 6.0 Hz, 2H), 2.35-2.27 (m, 1H), 2.15-2.06 (m, 1H), 
1.76-1.65 (m, 2H), 1.30 (s, 9H), 0.90 (s, 9H), 0.06 (s, 6H);  
NsHN CO2Me
OTBS Boc2O, NEt3, DMAP, 
EtOAc, rt, 92% N CO2Me
OTBS
Boc
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13C NMR (125 MHz, CDCl3) δ 170.4, 150.5, 149.7, 145.3, 130.2, 123.8, 86.0, 62.4, 60.0, 52.8, 
29.8, 27.9, 27.0, 26.1, 18.5, -5.16; 
HRMS (ESI) calc’d for C23H38N2O9SSiNa [M+Na]+: 569.1965, found: 569.1967.  
 
 
 (+)-36.  N-Boc(Ns) bis-protected intermediate S-3 (55 mg, 1.0 equiv., 0.1 mmol) was dissolved 
in DMF (0.75 mL) at rt.  p-methoxythiophenol (42.1 mg, 3.0 equiv., 0.3 mmol) in DMF (0.5 mL) 
was added to the reaction, followed by K2CO3 (55.3 mg, 4.0 equiv., 0.4 mmol).  The resulting 
bright yellow slurry was stirred rapidly at rt for 24h, diluted with EtOAc and partitioned between 
EtOAc and sat. brine solution.  The organic layer was dried over Na2SO4 and concetrated.  Flash 
chromatography of the crude residue, eluting with 5% to 7% to 10% EtOAc/Hexanes afforded 
N-Boc protected bishomoserine derivative (+)-36 (26.2 mg, 72% yield).  
1H NMR (500 MHz, CDCl3) δ 5.18 (br d, J = 7.7 Hz, 1H), 4.29 (app q, J = 7.7 Hz, 1H), 3.73 (s, 
3H), 3.61 (t, J = 6.1 Hz, 2H), 1.90-1.83 (m, 1H), 1.75-1.67 (m, 2H), 1.60-1.52 (m, 2H), 1.43 (s, 
9H), 0.88 (s, 9H), 0.04 (s, 6H);  
13C NMR (125 MHz, CDCl3) δ 173.5, 155.5, 79.9, 62.5, 53.4, 52.3,29.2, 28.6, 28.5, 26.1, 18.5, -
5.2; 
HRMS (ESI) calc’d for C17H35NO5SiNa [M+Na]+: 384.2182, found: 384.2176; 
[α]D27 = +7.5° (c = 0.77, CHCl3).  
These data are in agreement with the literature report. 53 
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Methyl (S)-2-((tert-butoxycarbonyl)amino)hex-5-enoate (+)-35. 
Nosyl homoallylglycine methyl ester (+)-26 (150 mg, 1.0 eq, 0.46 mmol) was dissolved in 49:1 
MeCN/DMSO (3 mL) in a round bottom flask, and thiophenol (163 uL, 3.5 eq, 1.6 mmol) was 
added, followed by Cs2CO3 (596 mg, 4.0 eq, 1.83 mmol).  The rapidly stirred slurry was heated 
to 45°C for 2.5 h, when full conversion of the starting material was observed by TLC.  The crude 
reaction mixture was partitioned between EtOAc and sat. NaHCO3.  The aqueous layer was 
extracted with EtOAc (2 x 20 mL), dried over K2CO3, and concentrated onto silica for plug 
purification.  The plug was eluted first with 1:1 Hexanes/EtOAc to remove all nonpolar 
byproducts, and then 5/95/1 MeOH/CH2Cl2/NH4OH to remove the free amine, affording a crude 
product (53.8 mg, approx. 82%).   
 
Crude free amine (86.5 mg, 1.0 eq, 0.6 mmol) was dissolved in CH2Cl2 (5 mL), and to this 
solution was added Boc2O (144 mg, 1.1 eq, 0.66 mmol).  The mixture was stirred overnight at rt, 
then concentrated onto silica gel and purified by flash chromatography (15 % EtOAc/Hexanes), 
yielding (+)-35 (129.3 mg, 89%).   
Characterization data are in agreement with the literature report.54  
1H NMR (500 MHz, CDCl3) δ 5.79 (ddt, J = 6.6, 10.3, 16.9 Hz, 1H), 5.07-4.99 (m, 2H), 4.33 (q, 
J = 7.6 Hz, 1H), 3.74 (s, 3H), 2.15-2.04 (m, 2H), 1.94-1.87 (m, 1H), 1.75-1.68 (m, 1H), 1.44 (s, 
9H);  
 [α]D27 = +15.5° (c = 1.07, CH2Cl2).  
BocHN CO2Me
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1) PhSH, Cs2CO3,
MeCN/DMSO, 45°C, 82%
2) Boc2O, CH2Cl2, rt, 89%
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Methyl (R)-2-aminohept-6-enoate (-)-37. 
Nosyl bishomoallylglycine methyl ester (-)-27 (342 mg, 1.0 eq, 1.0 mmol) was dissolved in 49:1 
MeCN/DMSO (6.6 mL), and thiophenol (357	   μL, 3.5 eq, 3.5 mmol) was added, followed by 
Cs2CO3 (1.303 g, 4.0 eq, 4.0 mmol).  The rapidly stirred slurry was heated to 45 °C for 3h, when 
full conversion of starting material was observed by TLC.  The crude reaction mixture was 
partitioned between EtOAc and sat. NaHCO3.  The aqueous layer was extracted with EtOAc (2x 
50 mL), dried over K2CO3, and concentrated onto silica purification.  Flash chromatography 
eluting with 2%à5% MeOH/CH2Cl2 afforded (-)-37.  135.6 mg, 86%. 	  
1H NMR (500 MHz, Chloroform-d) δ 5.78 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.09 – 4.83 (m, 2H), 
3.71 (s, 3H), 3.44 (dd, J = 7.3, 5.5 Hz, 1H), 2.06 (q, J = 6.7 Hz, 2H), 1.79 – 1.66 (m, 1H), 1.64 – 
1.38 (m, 3H);  
13C NMR (126 MHz, Chloroform-d) δ 176.7, 138.4, 115.0, 54.5, 52.1, 34.5, 33.6, 25.1; IR (film, 
cm-1) 3386, 2860, 1737, 1641, 1438, 1197, 1172;  
HRMS (ESI) m/z calc’d for C8H16NO2 [M+H]+: 158.1181, found 158.1185;  
[α]D24 = -17.6˚ (c = 1.41, CHCl3). 
 
Methyl (S)-2-((tert-butoxycarbonyl)amino)-5-(dibenzylamino)pentanoate (+)-38. 
Nosyl amino acid (+)-28 (80 mg, 1.0 equiv., 0.156 mmol) was dissolved in 98:2 MeCN/DMSO 
(1.5 mL) in a round bottom flask. To the flask were then added thiophenol (56 uL, 3.5 equiv., 
H2N CO2Me
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H
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MeCN/DMSO, 45°C, 86%
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BocHN CO2Me
Bn2N
N
H
CO2Me
Bn2N
S
O
O
O2N
1) PhSH, Cs2CO3,
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2) Boc2O, CH2Cl2, rt, 91%
(+)-28 (+)-38
	   121 
0.547 mmol) and Cs2CO3 (204 mg, 4.0 equiv., 0.626 mmol), and the resulting slurry was heated 
to 45 °C and stirred rapidly for 6h. The reaction was recharged with additional thiophenol (56 
uL), Cs2CO3 (204 mg), and solvent (1.5 mL) and stirred overnight at 45 °C. The crude reaction 
mixture was partitioned between EtOAc and sat. NaHCO3.  The aqueous layer was extracted 
with EtOAc (2 x 50 mL), dried over K2CO3, and concentrated onto silica for purification.  Flash 
chromatography eluting with 1:1 Hexanes/EtOAc to remove nonpolar byproducts and 
thiophenol, followed by 10:1:89 MeOH/NH4OH/CH2Cl2 afforded crude free amine (35.0 mg, 
approximately 69% yield).  The crude amine was dissolved in CH2Cl2 (1 mL), and Boc2O (25.7 
mg, 1.1 equiv., 0.12 mmol) was added, and the reaction stirred overnight at RT.  Flash 
chromatography eluting with 9:1à4:1 Hexanes / EtOAc afforded (+)-38 (42.2 mg, 90% yield, 
63% yield over two steps).  
1H NMR (500 MHz, CDCl3) δ 7.36-7.23 (m, 10H), 5.18 (d, J = 7.2 Hz, 1H), 4.28-4.21 (m, 1H), 
3.70 (s, 3H), 3.60-3.51 (m, 4H), 2.47-2.39 (m, 2H), 1.80-1.50 (m, 4H), 1.44 (s, 9H);  
13C NMR (125 MHz, CDCl3) δ 173.5, 155.5, 139.6, 129.0, 128.4, 127.0, 79.9, 58.4, 53.5, 53.0, 
52.3, 30.5, 28.5, 23.0; 
HRMS (ESI) calc’d for: C25H35N2O4 [M+H]+: 427.2597, found: 427.2599;  
[α]D26 = +9.6° (c = 1.17, CHCl3). 
Experimental data from Figure 14. 
 
Tert-butyl ((4-nitrophenyl)sulfonyl)-L-leucinate (+)-39. 
NsHN CO2tBu
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1H NMR (500 MHz, CDCl3) δ 8.23 (d, J = 9.0 Hz, 2H), 7.94 (d, J = 8.8 Hz, 2H), 5.20 (s, 1H), 
4.14 – 3.52 (m, 1H), 1.84 – 1.62 (m, 1H), 1.37 (ddd, J = 8.3, 6.0, 1.7 Hz, 2H), 1.13 (s, 9H), 0.82 
(dd, J = 6.6, 1.6 Hz, 6H);  
13C NMR (126 MHz, CDCl3) δ 171.2, 150.2, 145.9, 128.8, 124.3, 82.9, 55.2, 42.5, 27.8, 24.5, 
23.0, 21.5;  
IR (film, cm-1) 3278, 3106, 2962, 2935, 2874, 1731, 1606, 1531, 1457, 1349, 1309, 1166, 1145, 
1091, 1012;  
HRMS (ESI) m/z calc’d for C16H25N2O6NaS [M+Na]+: 395.1253, found 395.1253;  
[α]D24 = +38.9˚ (c=1.16, CH2Cl2). 	  
	  
(S)-tert-butyl 4-hydroxy-4-methyl-2-(4-nitrophenylsulfonamido)pentanoate (+)-40.  
N-Nosyl-Leucine tert-butyl ester (+)-39  (186.2 mg, 1.0 eq, 0.5 mmol) was reacted with (R,R)-
Fe(PDP)(MeCN)2(SbF6)2 (116.5 mg, 0.125 mmol, 0.25 eq), AcOH (14.3 uL, 0.5 eq, 0.25 mmol), 
and H2O2 (170 uL, 2.5 mmol, 5.0 eq) in MeCN according to Procedure B.  The crude mixture 
was purified by flash chromatography on silica using 9:1 CHCl3:EtOAc.  Run 1: Recycled 1x for 
a total of 55% X and 15% RSM; Cycle 1: (+)-40 (80.1 mg, 0.205 mmol, 41%), RSM (73.1 mg, 
0.196 mmol, 39%); Cycle 2: (+)-40 (26.8 mg, 0.07 mmol, 35%), RSM (27.8 mg, 0.15 mmol, 
38%). Run 2: Recycled 1x for a total of 53% yield (+)-40 and 7% RSM; Cycle 1: (+)-40 (84.7 
mg, 0.22 mmol, 44%), RSM (47.9 mg, 0.13 mmol, 26%); Cycle 2: (+)-40 (18.3 mg, 0.05mmol, 
37%), RSM (25.7 mg, 0.07 mmol, 54%). Average overall yield: 54% with 1 recycle. 
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1H NMR (500 MHz, Chloroform-d) δ 8.35 (d, J = 8.8 Hz, 2H), 8.08 (d, J = 8.7 Hz, 2H), 5.92 (d, 
J = 7.2 Hz, 1H), 4.10 (td, J = 7.6, 4.9 Hz, 1H), 1.92 – 1.78 (m, 2H), 1.34 (s, 3H), 1.30 (s, 9H), 
1.28 (s, 3H);  
13C NMR (125 MHz, Chloroform-d) δ 170.9, 150.2, 145.8, 128.9, 124.3, 83.0, 71.2, 54.7, 44.1, 
30.7, 29.1, 27.8;  
IR (film, cm-1) 3535, 3510, 3271, 3109, 2978, 2931, 1732, 1606, 1531, 1350, 1309, 1255, 1153, 
1092, 939, 856, 739, 685615;  
HRMS (ESI) m/z calc’d for C16H25N2O7S [M+H]+: 389.1382, found 389.1383;  
[α]D27 = +20.4˚ (c=0.17, CH2Cl2). 
 
 
Tert-butyl 4-fluoro-4-methyl-2-(4-nitrophenylsulfonamido)pentanoate (+)-41.  Tert-butyl 4-
hydroxy-4-methyl-2-(4-nitrophenylsulfonamido)pentanoate (+)-40 (56.3mg, 0.145 mmol, 1 
equiv) was dissolved in dry dichloromethane (0.1 M, 1.45 mL) and cooled to -78 
°C.  Diethylamino sulfur trifluoride (DAST, 1.5 equiv, 0.218 mmol, 35.1 mg, 28.8 µL) was then 
added dropwise to the reaction mixture using a 50 µL syringe.  After one hour the cold bath was 
removed and the reaction mixture was allowed to warm to ambient temperature, and at two hours 
the progress of the reaction was checked by TLC.  A significant amount of starting material 
remained unreacted so an additional 0.25 equiv of DAST was added and allowed to stir just as 
before.  After 4 hours some starting material still remained so a final addition of DAST (0.25 
equiv.) was added.  After 6 hours the crude mixture was concentrated via rotary evaporation to a 
NsHN CO2tBu
OH
DAST (2.0 equiv.)
CH2Cl2, -78°C to rt NsHN CO2tBu
F
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minimal amount of dichloromethane and loaded directly onto a silica gel column for purification 
using dichloromethane as the eluent to afford (+)-41 (41.6mg, 0.107 mmol, 74%). 
1H NMR (500 MHz, Chloroform-d) δ 8.35 (d, J = 8.8 Hz, 2H), 8.06 (d, J = 8.6 Hz, 2H), 5.38 (d, 
J = 9.0 Hz, 1H), 4.05 (td, J = 8.4, 4.8 Hz, 1H), 1.43 (app. t, J = 21.3 Hz, 6H), 1.27 (s, 9H);  
13C NMR (125 MHz, Chloroform-d) δ 170.3, 150.3, 145.9, 128.9, 124.4, 94.8 (d, J = 167 Hz), 
83.4, 53.8 (d, J = 3.6 Hz), 43.8 (d, J = 22.6 Hz), 27.8, 27.4 (d, J = 24.4 Hz), 27.0 (d, J = 24.3 
Hz);  
IR (film, cm-1) 3282, 3107, 2981, 2933, 1736, 1606, 1531, 1351, 1151, 1093, 856, 739, 687, 615;  
HRMS (ESI) m/z calc’d for C16H23FN2O6SNa [M+Na]+: 413.1159, found 413.1160;  
[α]D27 = +24.9˚ (c=0.88, CH2Cl2). 
 
Methyl ((4-nitrophenyl)sulfonyl)-L-valinate   (+)-42. 
1H NMR (500 MHz, Chloroform-d) δ 8.35 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 5.36 (s, 
1H), 3.84 (dd, J = 10.0, 4.9 Hz, 1H), 3.52 (s, 3H), 2.28 – 1.95 (m, 1H), 0.98 (d, J = 6.8 Hz, 3H), 
0.88 (d, J = 6.9 Hz, 3H);  
13C NMR (125 MHz, Chloroform-d) δ 171.6, 150.3, 145.8, 128.7, 124.5, 61.4, 52.7, 31.8, 19.2, 
17.5;  
IR (film, cm-1) 3297, 3272, 3110, 2970, 1733, 1714, 1606, 1529, 1467, 1444, 1349, 1292, 1272, 
1174, 1139, 1090;  
HRMS (ESI) m/z calc’d for C12H17N2O6S [M+H]+: 317.0807, found 317.0811;  
[α]D25 = +33.2˚ (c=2.13, CH2Cl2). 
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(S)-methyl 3-hydroxy-3-methyl-2-(4-nitrophenylsulfonamido)butanoate (+)-43.  
N-Nosyl-valine methyl ester (+)-42 (158 mg, 1.0 eq, 0.5 mmol) was reacted with (S,S)-
Fe(PDP)(MeCN)2(SbF6)2 (116.5 mg, 0.25 eq, 0.125 mmol), AcOH (28.6 uL, 1.0 eq, 0.5 mmol), 
and H2O2 (276 uL, 9.0 eq, 4.5 mmol) according to a modified Procedure C.  The crude mixture 
was purified on silica using 2:1 CHCl3:EtOAc. Run 1: Recycled 1x for a 51% (+)-43.  Cycle1: 
(+)-43 (58.0 mg, 0.17 mmol, 36%), RSM (89.3 mg, 0.28 mmol, 57%); Cycle 2: (+)-43 (26.9 mg, 
0.081 mmol, 29%), RSM (61.4 mg, 68%). Run 2: Recycled 1x for a 50% yield (+)-43.  Cycle 1: 
(+)-43 (63.0 mg, 38%), RSM (74.0 mg, 47%). Cycle 2: (+)-43 (20.0 mg, 26%), RSM (48.0 mg, 
65%). Average: 51% with 1x recycle. 
1H NMR (500 MHz, Chloroform-d) δ 8.35 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.8 Hz, 2H), 6.19 (d, 
J = 10.2 Hz, 1H), 3.85 (d, J = 10.2 Hz, 1H), 3.48 (s, 3H), 1.31 (s, 3H),  2.57 (s, 1H), 1.25 (s, 3H);  
13C NMR (125 MHz, Chloroform-d) δ 171.0, 150.3, 145.7, 128.7, 124.4, 72.1, 63.5, 52.6, 26.9, 
26.7;  
IR (film, cm-1) 3529, 3263, 3107, 2983, 2929, 1736, 1531, 1352, 1314, 1169, 1092, 856, 737, 
617;  
HRMS (ESI) m/z calc’d for C12H17N2O7S [M+H]+: 333.0756, found 333.0756;  
[α]D27 = +12.2˚ (c=0.87, CH2Cl2). 
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Methyl (R)-3-fluoro-3-methyl-2-((4-nitrophenyl)sulfonamido)butanoate  (+)-44. 
A flame-dried round bottom flask under inert atmosphere was charged with hydroxyvaline (+)-
43 (21.9 mg, 0.066 mmol, 1.0 eq) in CH2Cl2 (2 mL) and cooled to -78°C.  DAST (17 µL, 0.13 
mmol, 2.0 eq.) was added dropwise to the solution over 1 minute.  The reaction was allowed to 
warm to room temperature and was stirred overnight.  The crude reaction mixture was 
concentrated onto silica gel and directly purified via flash chromatography using 
10%à15%à25% EtOAc/Hexanes, affording (+)-44 (11.0 mg, 50%).   
1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 8.9 Hz, 2H), 8.02 (d, J = 8.9 Hz, 2H), 5.64 (d, J = 
10.3 Hz, 1H), 4.01 (dd, J = 10.3, 17.7 Hz, 1H), 3.51 (s, 3H), 1.46 (d, J = 21.8 Hz, 3H), 1.41 (d, J 
= 21.7 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ 168.9, 150.3, 145.5, 128.7, 124.4, 94.9 (d, J = 178.3 Hz), 62.7 (d, 
J = 24.4 Hz), 52.9 (d, J = 13.1 Hz), 24.5; 
HRMS (ESI) calc’d for: C12H14N2O6FS [M-H]-: 333.0557, found: 333.0555; 
[α]D27 = +21.6° (c = 1.02, CH2Cl2).  
 
	  
Methyl (S)-2-((4-nitrophenyl)sulfonamido)pentanoate  (+)-45. 
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1H NMR (500 MHz, Chloroform-d) δ 8.35 (d, J = 8.8 Hz, 2H), 8.03 (d, J = 8.8 Hz, 2H), 5.21 (d, 
J = 9.35 Hz, 1H), 4.00 (ddd, J = 5.1, 7.8, 9.3 Hz, 1H), 3.54 (s, 3H), 1.78-1.71 (m, 1H), 1.67-1.60 
(m, 1H), 1.43-1.35 (m, 2H). 0.91, (t, J = 7.3 Hz, 3H); 
13C NMR (125 MHz, Chloroform-d) δ 172.0, 150.3, 145.8, 128.6, 124.4, 55.8, 52.8, 35.5, 18.4, 
13.5; 
IR (film, cm-1) 3262, 3108, 2947, 1729, 1606, 1523, 1442, 1432, 1346, 1305, 1226, 1205, 1166, 
1091;  
HRMS (ESI) m/z calc’d for C12H17N2O6S [M+H]+: 317.0807, found 317.0806;  
[α]D25 = +33.0˚ (c=1.18, CH2Cl2). 
 
Methyl (S)-2-((4-nitrophenyl)sulfonamido)-4-oxopentanoate  (+)-46. 
N-Nosyl-Norvaline, methyl ester (+)-45 (158 mg, 1.0 eq, 0.5 mmol) was reacted with (R,R)-
Fe(CF3PDP)(MeCN)2(SbF6)2 (169.5 mg, 0.25 eq, 0.125 mmol), AcOH (14.3 uL, 0.5 eq, 0.25 
mmol), and H2O2 (170 uL, 5.0 eq, 0.25 mmol) in MeCN according to Procedure B.  The crude 
mixture was purified via flash chromatrograpy using 4:1à3:1à2:1 Hexanes:Acetone gradient. 
Run 1: (+)-46 (75.5 mg, 0.228 mmol, 48%), RSM (50.6 mg, 0.32 mmol, 32%). Run 2: (+)-46 
(86.3 mg, 0.26 mmol, 52%), RSM (37.4 mg, 0.12 mmol, 24%). Average: 50% (+)-46, 28% 
RSM. 
1H NMR (500 MHz, Chloroform-d) δ 8.34 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 6.09 (d, 
J = 8.7 Hz, 1H), 4.16 (dt, J = 8.5, 4.1 Hz, 1H), 3.54 (s, 3H), 3.22 (dd, J = 18.4, 4.2 Hz, 1H), 3.06 
(dd, J = 18.4, 4.2 Hz, 1H), 2.17 (s, 3H);  
NsHN CO2Me
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13C NMR (126 MHz, Chloroform-d) δ 206.1, 170.5, 150.1, 145.9, 128.6, 124.3, 53.1, 51.9, 46.5, 
29.9;  
IR (film, cm-1) 3286, 3108, 2956, 2923, 1743, 1716, 1606, 1531, 1436, 1351, 1311, 1214, 1166, 
1122, 1093;  
HRMS (ESI) m/z calc’d for C12H15N2O7S [M+H]+: 331.0600, found 331.0603;  
[α]D23 = +41.6˚ (c=0.85, CH2Cl2). 
 
 
Dimethyl ((4-nitrophenyl)sulfonyl)-L-leucyl-L-glutamate (+)-47. 
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.75 Hz, 2H), 8.04 (d, J = 8.7 Hz, 2H), 6.52 (d, J = 
7.35 Hz, 1H), 5.42 (d, J = 8.95 Hz, 1H), 4.34 (td, J =5.0, 7.7 Hz, 1H), 3.84 (q, 7.45 Hz, 1H), 3.72 
(s, 3H), 3.69 (s, 3H), 2.25-2.10 (m, 2H), 2.01 (ddd, J = 2.2, 7.3, 14.4 Hz, 1H), 1.87-1.74 (m, 2H), 
1.51 (t, J = 7.15 Hz, 2H), 0.92 (d, J = 6.65 Hz, 3H), 0.89 (d, J = 6.55 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.5, 171.8, 171.3, 150.2, 146.0, 128.6, 124.4, 55.6, 52.8, 51.9, 
42.7, 29.9, 26.9, 24.4, 22.9, 21.5; 
HRMS (ESI) calc’d for: C19H28N3O9S [M+H]+: 474.1546, found: 474.1540;  
[α]D27 = +19.6° (c = 1.22, CH2Cl2).  	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Dimethyl ((S)-4-hydroxy-4-methyl-2-((4-nitrophenyl)sulfonamido)pentanoyl)-L-glutamate 
(-)-48. 
Substrate Ns-Leu-Glu(OMe)-OMe (+)-47 (236.8 mg, 1.0 equiv., 0.5 mmol) was reacted 
according to Procedure C with (R,R)-Fe(PDP)(MeCN)2(SbF6)2 (116.5 mg, 0.25 equiv., 0.125 
mmol), AcOH (143 uL, 5.0 equiv., 2.5 mmol), and H2O2 (256 uL, 9.0 equiv., 4.5 mmol), in 
MeCN at rt.  Flash chromatography eluting with 1:1 EtOAc / Hexanes to 3:1 afforded (-)-48.  
Run 1: Recycled 1x for a total yield of 72%. Cycle 1: (-)-48 (121.4 mg, 50%) and RSM (105.1 
mg, 44%). Cycle 2: (-)-48 (54.4 mg, 51%) and RSM (47.7 mg, 45%).  Total yield: 72%. Run 2: 
Recycled for a total of yield of 65%. Cycle 1: (-)-48 (126.0 mg, 51%) and RSM (88.0 mg, 37%). 
Cycle 2: (-)-48 (34 mg, 39%) and RSM (53 mg, 61%). Total yield: 65%. Average: 68%, 1x 
recycle. 
1H NMR (500 MHz, CDCl3) δ 8.36 (d, J = 8.9 Hz, 2H), 8.08 (d, J = 8.9 Hz, 2H), 7.43 (d, J = 7.7 
Hz, 1H), 6.66 (d, J = 5.4 Hz, 1H), 4.43 (td, J = 5.3, 7.9 Hz, 1H), 3.95 (q, J = 5.8 Hz, 1H), 3.73 (s, 
3H), 3.67 (s, 3H), 2.30-2.18 (m, 3H), 2.15-2.08 (m, 1H), 1.94-1.86 (m, 3H), 1.31 (s, 3H), 1.10 (s, 
3H); 
13C NMR (125 MHz, CDCl3) δ 173.1, 171.9, 171.2, 150.4, 145.0, 129.0, 124.5, 71.8, 54.6, 52.8, 
52.1, 52.0, 44.8, 30.0, 27.2; 
HRMS (ESI) calc’d for: C19H28N3O10S [M+H]+: 490.1495, found: 490.1486; 
[α]D26 = -40.6 ° (c = 1.0, CH2Cl2). 
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Dimethyl ((S)-4-fluoro-4-methyl-2-((4-nitrophenyl)sulfonamido)pentanoyl)-L-glutamate (-)-
49. 
Ns-(Hydroxy)Leu-Glu(OMe)-OMe (-)-48 (25 mg, 1.0 equiv., 0.051 mmol) was dissolved in 
CH2Cl2 and cooled to -78°C.  DAST (34 uL, 5.0 equiv., 0.26 mmol) was added dropwise to the 
stirring solution, which was allowed to warm to RT over 3.5 h.  Additional DAST (17 uL, 2.5 
equiv., 0.13 mmol) was added dropwise to the solution and the mixture stirred 1h.  The crude 
material was loaded onto silica gel and purified via flash chromatography eluting with 40% 
EtOAc/Hexanes to 50%, affording (-)-49 (17.2 mg, 69%).  
1H NMR (500 MHz, CDCl3) δ 8.36 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 4.8 
Hz, 1H), 5.78 (t, J = 6.1 Hz, 1H), 4.42 (td, J = 5.5, 7.6 Hz, 1H), 3.98-3.94 (m, 1H), 3.74 (s, 3H), 
3.69 (s, 3H), 2.32-2.17 (m, 2H), 2.15-1.88 (m, 4H), 1.41 (d, J = 22.2 Hz, 3H), 1.19 (d, J = 22.0 
Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.2, 171.5, 170.5, 150.5, 145.0, 129.0, 124.5, 96.5 (d, J = 
164.2 Hz), 54.1, 52.8, 52.2, 52.1, 43.6, 29.9, 27.2 (d, J = 24.4 Hz), 27.0, 26.6 (d, J = 24.0 Hz); 
HRMS (ESI) calc’d for: C19H26N3O9FSNa [M+Na]+: 514.1271, found: 514.1270; 
[α]D26 = -18.7° (c = 1.15, CH2Cl2). 
 
Methyl ((4-nitrophenyl)sulfonyl)-L-valyl-L-alaninate (+)-50. 
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1H NMR (500 MHz, Acetone-d6) δ 8.40 (d, J = 8.95 Hz, 2H), 8.10 (d, J = 8.95 Hz, 2H), 7.57 (d, 
J = 6.2 Hz, 1H), 6.93 (s, 1H), 4.06 (p, J = 7.2 Hz, 1H), 3.79 (d, J = 6.45 Hz, 1H), 3.61 (s, 3H), 
1.99 (dq, J = 6.8, 13.4 Hz, 1H), 1.12 (d, J = 7.3 Hz, 3H), 0.95 (d, J = 6.75 Hz, 3H), 0.92 (d, J = 
6.75 Hz, 3H); 
13C NMR (125 MHz, Acetone-d6) δ 173.2, 170.3, 150.9, 147.7, 129.5, 124.9, 62.7, 52.3, 48.6, 
32.5, 19.4, 18.2, 17.4; 
HRMS (ESI) calc’d for: C15H22N3O7S [M+H]+: 388.1178, found: 388.1171;  
[α]D27 = +37.7° (c = 1.01, CH2Cl2).  
 
Methyl ((S)-3-hydroxy-3-methyl-2-((4-nitrophenyl)sulfonamido)butanoyl)-L-alaninate (+)-
51. 
Substrate Ns-Val-Ala-OMe (+)-50 (193.7 mg, 1.0 equiv., 0.5 mmol) was reacted according to 
Procedure C with (R,R)-Fe(PDP)(MeCN)2(SbF6)2 (116.5 mg, 0.25 equiv., 0.125 mmol), AcOH 
(143 uL, 5.0 equiv., 2.5 mmol), and H2O2 (276 uL, 9.0 equiv., 4.5 mmol) in MeCN at RT.  The 
crude mixture was purified via flash chromatography eluting with gradient Hexanes/EtOAc 
2:1à3:2à1:1 to afford (+)-51.  Run 1: 106.7 mg, 53%. Run 2: 107.0 mg, 53%. Average: 53%.  
1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 8.95 Hz, 2H), 8.03 (d, J = 9.0 Hz, 2H), 6.56 (d, J = 
6.8 Hz, 1H), 5.78 (d, J = 9.15 Hz, 1H), 4.32 (p, J = 7.3 Hz, 1H), 3.73 (s, 3H), 3.64 (d, J = 9.05 
Hz, 1H), 2.94 (s, 1H), 1.39 (s, 3H), 1.23 (d, J = 7.3 Hz, 3H), 1.14 (s, 3H); 
13C NMR (125 MHz,CDCl3) δ 173.5, 168.9, 150.3, 145.5, 128.8, 124.3, 72.9, 63.6, 53.0, 48.5, 
28.1, 24.4, 17.6; 
HRMS (ESI) calc’d for: C15H22N3O8S [M+H]+: 404.1128, found: 404.1122.; 
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 [α]D25 = +13.1° (c = 0.55, MeOH).  
Experimental data from Figure 15. 
Synthesis of Peptide Substrates.   
 Substrates were generally synthesized N-to-C-terminus using standard solution phase 
peptide coupling procedures.  Representative General Procedures are provided below for the 
synthesis of tripeptide Ns-P-L-A-OMe (-)-52.  
 
General procedure for the p-Nitrosulfonyl protection of α-amino acids.  
Example: Preparation of Ns-Pro-OH S-5.  To a glass round-bottom flask with Teflon stir bar was 
added (L)-Proline (6.93 g, 1.0 equiv., 60.2 mmol) 1M Aq. NaOH (60 mL, 1M reaction 
concentration based on amino-acid).  The reaction was cooled to 0 ◦C and stirred vigorously.  To 
this was added 4-Nitrosulfonyl Chloride (20 g, 1.5 equiv., 90.2 mmol) in small portions over 1-2 
minutes.  The reaction was stirred at 0°C for 10 minutes, and was then warmed to room 
temperature.  As the reaction proceeded, the pH of the solution became more acidic.  Every 30 
minutes, the pH was taken and if pH was <7, additional 1M NaOH (approx. 1 equiv.) was added 
slowly until a pH ~ 10-12 was achieved.  This process was repeated until a basic pH is sustained 
for 45 minutes without requiring additional base.  The reaction was transferred to a separatory 
funnel.  The basic solution was extracted with EtOAc (3x) and the organic layers were combined 
and set aside.  The Aqueous solution (containing product) was then cooled to 0 ◦C and acidified 
to pH 2 with HCl (10% Aq.) via dropwise addition and vigorous stirring.  The acidic aqueous 
solution was then transferred to a separatory funnel and extracted with EtOAc (3x), making sure 
the aqueous solution retained an acidic pH (~2) prior to each extraction.  The combined organic 
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layers were then dried over MgSO4, filtered, and concentrated in vacuo to afford crude Ns-Pro-
OH S-5 in approx. 90% purity (17.9 g, 98%).  This crude material was carried forward to peptide 
coupling reactions without further purification.  
 
General Procedure for peptide coupling. 
Example: Coupling of Ns-Pro-OH S-5 to H-Leu-OMeHCl.  (L)-Leucine methyl ester 
hydrochloride (8.41 g, 1.0 equiv., 46.3 mmol) was weighed into a round-bottom flask with a stir 
bar, diluted with CH2Cl2 (500 mL, 0.1-0.2M), and cooled to 0°C in an ice bath.  To this solution 
was added Diisopropyl Ethylamine (8.06 mL, 1.0 equiv., 46.3 mmol) dropwise.  Next were 
added, in the following order: 1) Ns-Pro-OH S-5 (13.9 g, 1.0 equiv., 46.3 mmol), 2) 
Hydroxybenzotriazole (HOBt, 20% by weight H2O, 8.60 g, 1.1 equiv), and 3) 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC, 8.88 g, 1.0 equiv, 46.3 mmol) and the 
reaction was warmed to room temperature.  The reaction was then stirred overnight or until 
complete consumption of the carboxylic acid coupling partner was observed by TLC (typically: 
1% Acetic Acid in Ethyl Acetate eluent).   
The reaction contents were added to an appropriately sized separatory funnel and washed 
with a 1:1 volume each of NaHCO3 (Sat. Aq.), Citric Acid (10 wt% Aq.), and Brine.  Following 
each of the first two washes, the aqueous layer was extracted with CH2Cl2 (2 x), and the 
combined organic layers were taken on to the next wash.  The combined organic layers were 
then dried over Na2SO4, filtered, and concentrated in vacuo to provide crude Ns-Pro-Leu-OMe 
S-6 (assumed quantitative yield) which was taken on without further purification to the next step. 
The crude material can alternatively be purified via flash chromatography on silica gel to afford 
H
N OMe
O
O
NsN
EDC, HOBT,
DIPEA, CH2Cl2
0°C to RT
N
Ns
CO2H
CO2MeH2N
•HCl+
S-5 S-6
	   134 
the desired product.  (Note 1: in order to achieve a dry solid after purification, it may be 
necessary to rotovap down the pure oil from Hexanes several times to completely remove 
residual CH2Cl2, followed by placement on a high vacuum line for 24h. Note 2: in the case of 
using a free amine methyl ester in place of a hydrochloride salt, DIPEA (0.1 equiv) was used).   
 
General Procedure for methyl ester hydrolysis.   
Example:  Hydrolysis of Ns-Pro-Leu-OMe S-6. To a glass round-bottom flask with 
Teflon stir bar was added crude Ns-Pro-Leu-OMe S-6 (46.3 mmol, 1.0 equiv) in 3:1 THF:H2O 
(130 mL, 0.5 M).  The solution was cooled to 0◦C in an ice bath, and LiOH (9.71 g, 5.0 equiv., 
231.5 mmol) was added in 1 portion.  The reaction was held at 0°C for 10 minutes, and then 
warmed to room temperature and stirred for 24 hours, or until complete conversion of the methyl 
ester was observed by TLC.   
 Upon complete conversion, the reaction was cooled back down to 0°C, and acidified to a 
pH of <2 via dropwise addition of KHSO4 (10 wt% Aq.).  The solution was then diluted with 
Ethyl Acetate (~1:1 v/v) and the two layers were separated via separatory funnel.  The pH of the 
Aqueous layer was then taken, and if found to be >4/5, was re-acidified with KHSO4 (10 wt% 
Aq.) to a pH <2.  It was then extracted with Ethyl Acetate (2x), making sure to retain an acidic 
pH before extraction each time.  The organic layers were combined and washed with Water (1x) 
and Brine (1x), dried over MgSO4, filtered, and concentrated in vacuo to afford crude Ns-Pro-
Leu-OH S-7 (16.6 g, 87% over two steps). The acid materials were typically obtained in >90% 
purity and carried on crude to further peptide coupling steps, but can also be purified via flash 
chromatography on silica gel. 
LiOH-H2O,
THF/H2O, 0°C to RT
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Peptide coupling reaction – Synthesis of Ns-P-L-A-OMe (-)-52. 
Crude Ns-Pro-Leu-OH S-7 (16.6 g, 1.0 equiv., 40.1 mmol) was coupled with (L)-alanine methyl 
ester hydrochloride (5.6 g, 1.0 equiv., 40.1 mmol) using DIPEA (6.98 mL, 1.0 equiv., 40.1 
mmol), HOBt (7.45 g, 1.1 equiv., 44.1 mmol) and EDC (7.69 g, 1.0 equiv., 40.1 mmol) 
according to the General Procedure for peptide coupling. After workup, the crude material was 
purified via flash chromatography eluting with 2:1 Hexanes/Acetone to afford (-)-Ns-P-L-A-
OMe (-)-39 (15.90 g, 80% yield).   
methyl ((4-nitrophenyl)sulfonyl)-L-prolyl-L-leucyl-L-alaninate  
(Ns)Pro-Leu-Ala-OMe (Ns-P-L-A-OMe) (-)-52. 
1H NMR (500 MHz, CDCl3) δ 8.42 (d, J = 8.8 Hz, 2H), 8.11 (d, J = 8.8 Hz, 2H), 6.96 (dd, J = 
13.4, 8.2 Hz, 2H), 4.81 – 4.40 (m, 2H), 4.08 (dd, J = 8.3, 3.7 Hz, 1H), 3.73 (s, 3H), 3.67 (ddd, J 
= 10.1, 6.7, 3.9 Hz, 1H), 3.27 – 3.19 (m, 1H), 2.20 – 2.09 (m, 1H), 1.90 – 1.82 (m, 3H), 1.78 – 
1.69 (m, 1H), 1.66 – 1.57 (m, 2H), 1.39 (d, J = 7.2 Hz, 3H), 0.95 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 
6.3 Hz, 3H);  
13C NMR (125 MHz, CDCl3) δ 173.2, 171.2, 170.6, 150.8, 141.1, 129.4, 124.8, 62.6, 52.5, 52.0, 
50.4, 48.2, 40.7, 31.1, 25.2, 24.7, 23.2, 21.7, 18.1;  
IR (film, cm-1) 3394, 3302, 3105, 2958, 2873, 1743, 1658, 1531, 1454, 1352, 1165, 912, 735; 
HRMS (ESI) m/z calc’d for C21H30N4O8S [M+H]+: 499.1863, found 499.1864;  
[a]D26 = -133.7◦ (c=1.06, CH2Cl2).   
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Methyl ((2S)-5-hydroxy-1-((4-nitrophenyl)sulfonyl)pyrrolidine-2-carbonyl)-L-leucyl-L-
alaninate 53. 
Substrate Ns-Pro-Leu-Ala-OMe (-)-52 (1.496 g, 1.0 equiv., 3.0 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH.  Flash chromatography 
eluting with 2:1à3:2à1:1 EtOAc/CHCl3 afforded 53 as a mixture of hemiaminal epimers.  Run 
1: 859.4 mg, 56%. Run 2: On 2 mmol scale yielded 558.4 mg, 54%.  Average: 55%.  
1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 8.9 Hz, 2H), 8.10 (d, J = 8.8 Hz, 2H), 7.22 (d, J = 8.2 
Hz, 1H), 6.94 (d, J = 7.5 Hz, 1H), 5.68-5.63 (m, 1H), 4.56-4.42 (m, 3H), 4.22-4.10 (m, 1H), 3.73 
(s, 3H), 1.95-1.71 (m, 3H), 1.71-1.56 (m, 3H), 1.40 (d, J = 7.2 Hz, 3H), 0.94 (d, J = 6.4 Hz, 3H), 
0.90 (d, J = 6.4 Hz, 3H); 
13C NMR (125 MHz,CDCl3) δ 173.4, 171.8, 171.7, 150.7, 143.3, 128.9, 124.9, 86.3, 62.8, 52.7, 
52.4, 48.4, 40.8, 33.5, 31.1, 29.4, 25.0, 23.2, 21.7, 17.8; 
HRMS (ESI) calc’d for: C21H31N4O9S [M+H]+: 515.1812, found: 515.1806. 
 
 
 Methyl ((4-nitrophenyl)sulfonyl)-L-leucyl-L-alanyl-L-prolinate (-)-54. 
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1H NMR (500 MHz, Acetone-d6) δ 8.40 (d, J = 9.0 Hz, 2H), 8.12 (d, J = 9.0 Hz, 2H), 7.37 (d, J = 
6.8 Hz, 2H), 4.34 (dd, J = 5.0, 8.6 Hz, 1H), 4.31-4.26 (m, 1H), 4.06 (dd, J = 4.9, 10.0 Hz, 1H), 
3.63 (s, 3H), 3.61-3.57 (m, 1H), 3.52 (dt, J = 9.8, 6.8 Hz, 1H), 2.56-2.55 (m, 1H), 2.25-2.17 (m, 
1H), 2.14-2.08 (m, 2H), 2.01-1.73 (m, 2H, overlaps somewhat with residual acetone solvent), 
1.51 (ddd, J = 14.8, 10.2, 4.9 Hz, 1H), 1.44 (ddd, J = 13.9, 9.0, 5.0 Hz, 1H), 1.04 (d, J = 6.9 Hz, 
3H), 0.89 (d, J = 6.7 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H); 
13C NMR (125 MHz, Acetone-d6) δ 173.01, 171.1, 151.0, 147.8, 129.7, 125.1, 59.6, 56.3, 55.1, 
52.2, 47.4, 43.3, 25.7, 25.1, 23.4, 21.6, 17.7; 
HRMS (ESI) calc’d for: C21H31N4O8S [M+H]+: 499.1863, found: 499.1858; 
[α]D26 = -40.0°, (c = 0.97, Acetone). 
 
 (S)-5-methoxy-4-((S)-2-((S)-4-methyl-2-((4-
nitrophenyl)sulfonamido)pentanamido)propanamido)-5-oxopentanoic acid (-)-55. 
Substrate Ns-Leu-Ala-Pro-OMe (-)-54 (149.6 mg, 1.0 equiv., 0.3 mmol) was reacted according 
to General Oxidation Procedure B with (S,S)-Fe(PDP)(MeCN)2(SbF6)2 (101.7 mg, 0.25 equiv., 
0.075 mmol), AcOH (8.6 uL, 0.5 equiv., 0.15 mmol), and H2O2 (86.5 uL, 5.0 equiv., 1.5 mmol) 
in 4:1 MeCN/CH2Cl2 (to increase solubility of the substrate). Flash chromatography of the crude 
mixture eluting with gradient 0:99.5:0.5à5:94.5:0.5 MeOH/Et2O/AcOH afforded (-)-55. Run 1: 
74.1 mg, 47%. Run 2: 83.6 mg, 53%. Average: 50%. 
1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 8.7 Hz, 2H), 8.07 (d, J =8.7 Hz, 2H), 4.38 (dd, J = 
5.2, 9.0 Hz, 1H), 3.95 (q, J =7.1 Hz, 1H), 3.91 (dd, J = 9.7, 5.2 Hz, 1H), 3.69 (s, 3H), 2.35 (t, J 
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= 7.4 Hz, 2H), 2.11 (dq, J =13.4, 7.6 Hz, 1H), 1.88 (dq, J = 14.7, 8.3, 7.8 Hz, 1H), 1.70 (dq, J 
=13.0, 7.8, 6.9 Hz, 1H), 1.46 (dtd, J =17.4, 8.8, 4.1 Hz, 2H), 1.18 (d, J =7.1 Hz, 3H), 0.91 (d, J 
=6.7 Hz, 3H), 0.83 (d, J =6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 176.2, 174.6, 173.4, 173.3, 151.4, 147.8, 129.8, 125.1, 56.3, 53.0, 
52.7, 49.9, 42.9, 31.0, 30.9, 27.7, 25.4, 23.3, 21.6, 17.6; 
HRMS (ESI) calc’d for: C21H31N4O10S [M+H]+: 531.1761, found: 531.1765; 
[α]D26 = -43.2° (c = 1.01, MeOH). 
 
 
 
Methyl-(2S)-2-((2S)-2-((2S)-4-methyl-2-((2S)-1-((4-nitrophenyl)sulfonyl)-1λ4-pyrrolidine-2-
carboxamido)pentanamido)propanamido)-3-(4-
(((trifluoromethyl)sulfonyl)oxy)phenyl)propanoate (-)-56. 
1H NMR (500 MHz, CDCl3) δ 8.39 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 7.24 (d, J = 8.7 
Hz, 2H), 7.18 (d, J = 8.7 Hz, 2H), 7.14 (t, J = 6.8 Hz, 2H), 7.04 (d, J = 8.4 Hz, 1H), 4.77 (dt, J = 
7.5, 6.1 Hz, 1H), 4.56 – 4.47 (m, 1H), 4.45 (t, J = 7.2 Hz, 1H), 4.01 (dd, J = 8.8, 4.0 Hz, 1H), 
3.68 (s, 4H), 3.31 – 3.13 (m, 2H), 3.08 (dd, J = 14.0, 6.6 Hz, 1H), 2.13 – 2.04 (m, 1H), 1.98 – 
1.89 (m, 1H), 1.86 – 1.78 (m, 2H), 1.76 – 1.66 (m, 1H), 1.65 – 1.56 (m, 2H), 1.31 (d, J = 7.1 Hz, 
3H), 0.94 (d, J = 6.2 Hz, 3H), 0.91 (d, J = 6.2 Hz, 3H);  
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13C NMR (125 MHz, CDCl3) δ 172.2, 172.1, 171.5, 171.4, 150.9, 148.7, 140.7, 137.2, 131.5, 
129.5, 124.9, 121.5, 118.9 (d, J = 320.8 Hz), 62.8, 53.6, 52.7, 52.4, 50.5, 49.3, 40.4, 37.3, 31.4, 
25.4, 24.8, 23.3, 21.5, 17.2;  
IR (film, cm-1) 3386, 2958, 1741, 1658, 1531, 1502, 1421, 1352, 1250, 1217, 1167, 1142, 1109, 
1018, 910, 893, 735;  
HRMS (ESI) m/z calc’d for C31H39 F3N5O12S2 [M+H]+: 794.1989, found 794.1984;  
[a]D26 = -70.3◦ (c=1.25, CH2Cl2). 
 
Methyl (9S,12S,15S,18S)-12-isobutyl-15-methyl-9-((4-nitrophenyl)sulfonamido)-10,13,16-
trioxo-18-(4-(((trifluoromethyl)sulfonyl)oxy)benzyl)-2-oxa-5,11,14,17-tetraazanonadecan-
19-oate (+)-57. 
Substrate Ns-Pro-Leu-Ala-Tyr(OTf)-OMe (-)-56 (119.0 mg, 1.0 equiv., 0.15 mmol) was reacted 
with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, AcOH, and H2O2 according to General Oxidation 
Procedure A with the following modification: an additional round of catalyst, AcOH, and H2O2 
were added to the reaction, for a total of 4 x 5% Fe(PDP).  The crude material was purified via 
plug and subjected to a modified Reductive Amination Procedure:  The crude material was 
dissolved in MeOH (2 mL), and methoxyethylamine (27.0 mg, 6.0 equiv., 0.36 mmol) was added 
in 0.5 mL MeOH, followed by NaBH3CN (2.3 mg, 0.6 equiv., 0.036 mmol) in 0.5 mL MeOH.  
The resulting solution was stirred at 45°C for 48h, and the crude mixture was purified via flash 
chromatography eluting with MeOH/CH2Cl2 2% à4%à7%à10% MeOH/CH2Cl2 +1% 
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NH4OH, affording (+)-57.  Run 1: Recycled 1x for a total yield of 40%. Cycle 1: Product (+)-57 
(42.6 mg, 33%) and RSM (47.1 mg, 40%). Cycle 2: Product (+)-57  (9.3 mg, 18%), RSM (40%). 
Total yield: 40%.  Run 2:  Recycled 1x for a total yield of 37%. Cycle 1: Product (+)-57  (40.4 
mg, 31%) and RSM (45.0 mg, 38%). Cycle 2: Product (+)-57  (7.4 mg, 15%), RSM (35%). Total 
yield: 37%.  Average: 39% with 1x recycle.  
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 7.62 (d, J = 6.0 
Hz, 1H), 7.20 (q, J = 8.8 Hz, 1H), 4.68 (q, J = 6.5 Hz, 1H), 4.51 (p, J = 6.9 Hz, 1H), 4.27 (q, J = 
8.2 Hz, 1H), 3.96 (br s, 1H), 3.79-3.72 (m, 2H), 3.70-3.65 (m, 4H including s at 3.66, 3H), 3.36 
(s, 3H), 3.18-2.96 (m, 6H), 2.04-1.96 (m, 3H), 1.73-1.62 (m, 1H), 1.61-1.52 (m, 2H), 1.37-1.33 
(m, 1H), 1.30 (d, J = 7.05 Hz, 3H), 0.84 (d, J = 6.55 Hz, 3H), 0.72 (d, J = 6.5 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 172.9, 172.6, 171.4, 170.7, 150.2, 148.7, 145.2, 136.8, 131.3, 
128.8, 124.5, 121.6, 118.8 (q, J = 320.8 Hz), 67.6, 59.1, 55.4, 53.7, 53.1, 52.6, 49.0, 48.2, 47.7, 
40.6, 37.2, 30.7, 25.0, 22.9, 22.3, 21.4, 17.9; 
HRMS (ESI) calc’d for: C34H48N6O13F3S2 [M-H2O]+: 869.2673, found: 869.2657;  
[α]D25 = +13.1° (c = 0.55, MeOH).  
 
 
Methyl (S)-2-((S)-2-((S)-2-((2S,5R)-5-(2-hydroxynaphthalen-1-yl)-1-((4-
nitrophenyl)sulfonyl)pyrrolidine-2-carboxamido)-4-methylpentanamido)propanamido)-3-
(4-(((trifluoromethyl)sulfonyl)oxy)phenyl)propanoate (-)-58. 
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Substrate Ns-Pro-Leu-Ala-Tyr(OTf)-OMe (-)-56 (396.6 mg, 1.0 equiv., 0.5 mmol) was reacted 
with Fe(PDP), AcOH, and H2O2 according to Procedure A with the following modification: an 
additional round of catalyst, AcOH, and H2O2 were added to the reaction, for a total of 4 x 5% 
Fe(PDP).  The crude material was purified via silica plug and subjected to the Standard Arylation 
Procedure (see above) using 2-naphthol (72 mg, 1.0 equiv., 0.5 mmol) and BF3-OEt2 (126 µL, 
2.0 equiv., 1.0 mmol) in CH2Cl2 (3 mL).  Flash chromatography of the crude reaction mixture 
eluting with gradient Et2O/EtOAc 6:1à4:1à3:1 afforded (-)-58. Run 1: 150.2 mg, 32%. Run 2: 
180.0 mg, 38%. Average: 35%.  The diastereoselectivity of the addition was assigned based on 
analogy to (-)-19.  
1H NMR (500 MHz, CDCl3) δ 8.16-8.12 (m, 2H), 8.09 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 
1H), 7.62-7.56 (m, 5H), 7.50 (t, J = 8.7 Hz, 1H), 7.45 (d, J = 8.7 Hz, 2H), 7.36-7.30 (m, 3H), 
6.74 (d, J = 8.8 Hz, 1H), 5.74 (dd, J = 6.1, 10. Hz, 1H), 5.01 (d, J = 8.9 Hz, 1H), 4.73 (td, J =7.6, 
5.9 Hz, 1H), 4.68-4.64 (m, 1H), 4.45 (p, J =7.1 Hz, 1H), 3.66 (s, 3H), 3.22 (dd, J = 5.8, 14.0 Hz, 
1H), 3.12 (dd, J = 7.6, 13.9 Hz, 1H), 2.52-2.43 (m, 2H), 2.32-2.25 (m, 1H), 2.22-2.15 (m, 1H), 
1.87-1.79 (m, 1H), 1.73-1.63 (m, 2H), 1,30 (d, J = 7.1 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H), 0.98 (d, 
J = 6.6 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 174.5, 172.7, 172.1, 171.7, 154.5, 150.6, 149.1, 143.8, 138.5, 
133.6, 132.0, 130.4, 129.6, 129.2, 127.2, 123.8, 123.3, 121.8, 120.5, 118.0, 133.5, 110.4, 62.5, 
60.1, 53.9, 52.3, 49.4, 41.7, 37.2, 30.8, 25.2, 23.4, 21.8, 18.2; 
HRMS (ESI) calc’d for: C41H45N5O13F3S2 [M+H]+: 936.2407, found: 936.2404;  
[α]D24 = -33.5° (c = 0.93, CHCl3).  
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Methyl ((4-nitrophenyl)sulfonyl)-L-alanyl-L-prolyl-L-alaninate (-)-59. 
Isolated as a 13:1 mixture of apparent rotamers. 
1H NMR (500 MHz, CDCl3) Major: δ 8.33 (d, J = 8.6 Hz, 2H), 8.05 (d, J = 8.6 Hz, 2H), 6.82 (d, 
J = 7.3 Hz, 1H), 6.46 (d, J = 8.8 Hz, 1H), 4.45 (p, J = 7.2 Hz, 1H), 4.27-4.18 (m, 2H), 3.71 (s, 
3H), 1.03 (dq, J = 4.4, 8.4 Hz, 1H), 3.48-3.38 (m, 1H), 2.20-2.08 (m, 2H), 1.32 (d, J = 3.2 Hz, 
3H), 1.31 (d, J = 2.9 Hz, 3H); 
Minor (only non-overlapping peaks listed): δ 3.75 (s, 3H), 1.46 (d, δ 7.2 Hz, 3H), 1.27 (d, δ 6.9 
Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.3, 170.8, 170.3, 150.2, 146.6, 128.4, 124.4, 60.0, 52.6, 50.6, 
48.3, 47.3, 28.1, 25.1, 19.4, 18.2; 
HRMS (ESI) calc’d for: C18H24N4O8NaS [M+Na]+: 479.1213, found: 479.1209; 
[α]D25 = -52.9° (c = 2.88, CH2Cl2).  
 
 
Methyl ((S)-5-(benzylamino)-2-((S)-2-((4-
nitrophenyl)sulfonamido)propanamido)pentanoyl)-L-alaninate (-)-61. 
Ns-A-P-A-OMe (-)-59 (136.9 mg, 1.0 equiv., 0.3 mmol) was reacted according to Procedure A 
with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH.  Immediately after completion of the 
oxidation, without any purification, the solution was diluted with CH2Cl2 (2 mL), and  
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benzylamine (48.2 mg, 1.5 equiv., 0.45 mmol) was added in CH2Cl2 (1 mL), followed by sodium 
triacetoxyborohydride (STAB, 190.7 mg, 3.0 equiv., 0.9 mmol).  The mixture was allowed to 
warm to RT and was stirred overnight, concentrated onto silica gel, and purified via flash 
chromatography eluting with MeOH/CH2Cl2 5%à7%à10%à12%, to afford (-)-61.  Run 1: 
82.6 mg, 49% yield; Run 2: 77.5 mg, 46% yield. Average: 48% (69% per step). 
1H NMR (500 MHz, Methanol-d4) δ 8.40 (d, J = 8.95 Hz, 2H), 8.11 (d, J = 8.95 Hz, 2H), 7.51-
7.41 (m, 5H), 4.37 (q, J = 7.3 Hz, 1H), 4.26 (dd, J = 5.75, 7.45 Hz, 1H), 4.19 (s, 2H), 3.94 (q, J = 
7.0 Hz, 1H), 3.70 (s, 3H), 3.05 (t, J = 7.85 Hz, 2H), 1.89-1.75 (m, 3H), 1.70-1.63 (m, 1H), 1.38 
(d, J = 7.35 Hz, 3H), 1.24 (d, J = 7.05 Hz, 3H); 
13C NMR (125 MHz, Methanol-d4) δ 174.6, 174.2, 172.9, 151.5, 147.6, 133.2, 130.9, 130.5, 
130.2, 129.6, 125.4, 53.7, 53.4, 52.9, 52.4, 49.9, 48.1, 30.3, 23.4, 19.1, 17.2; 
HRMS (ESI) calc’d for: C25H34N5O8S [M+H]+: 564.2128, found: 564.2128; 
[α]D24 = -49.3° (c = 1.3, MeOH). 
 
 
Methyl ((S)-5-hydroxy-2-((S)-2-((4-nitrophenyl)sulfonamido)propanamido)pentanoyl)-L-
alaninate (-)-62. 
Ns-A-P-A-OMe (-)-59 (136.9 mg, 1.0 equiv., 0.3 mmol) was reacted according to Procedure A 
with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH.  Immediately after completion of the 
oxidation, without any purification, the solution was diluted with EtOH (2 mL) and, still at 0°C, 
sodium borohydride (56.7 mg, 5.0 equiv., 1.5 mmol) was added.  The solution was allowed to 
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warm to RT and stirred for 3h.  The solution was concentrated onto silica gel and purified via 
flash chromatography, eluting with MeOH/EtOAc 0% to 1% to 3% to afford (-)-62.  Run 1: 47.2 
mg, 33%; Run 2: 46.1 mg, 32%. Average: 33% (57% per step). 
1H NMR (500 MHz, Methanol-d4) δ 8.39 (d, J = 8.9 Hz, 2H), 8.08 (d, J = 8.9 Hz, 2H), 4.34 (q, J 
= 7.3 Hz, 1H), 4.10 (dd, J = 5.7, 8.2 Hz, 1H), 3.96 (q, J = 7.1 Hz, 1H), 3.69 (s, 3H), 3.53 (t, J = 
6.3 Hz, 2H), 1.83-1.76 (m, 1H), 1.62-1.44 (m, 3H), 1.36 (d, J = 7.3 Hz, 3H), 1.27 (d, J = 7.1 Hz, 
3H); 
13C NMR (125 MHz, Methanol-d4) δ 174.4, 173.8, 173.6, 151.5, 147.7, 129.6, 125.3, 62.3, 54.0, 
53.6, 52.7, 49.4, 29.8, 29.6, 19.6, 17.2; 
HRMS (ESI) calc’d for: C18H27N4O9S [M+H]+: 475.1499, found: 475.1483; 
[α]D26 = -54.0° (c = 1.0, MeOH).  
 
(S)-5-(((S)-1-methoxy-1-oxopropan-2-yl)amino)-4-((S)-2-((4-
nitrophenyl)sulfonamido)propanamido)-5-oxopentanoic acid (-)-60. 
Ns-A-P-A-OMe (-)-59 (228.2 mg, 1.0 equiv., 0.5 mmol) was subjected to General Oxidation 
Procedure B with (S,S)Fe(CF3PDP) (169.5 mg, 0.25 equiv., 0.125 mmol), AcOH (14.3 µL, 0.5 
equiv., 0.25 mmol) and H2O2 (170 µL, 5.0 equiv., 2.5 mmol) in MeCN at RT.  The crude 
reaction mixture was concentrated onto silica gel and purified via flash chromatography, eluting 
with Et2O/EtOAc/MeOH/AcOH 97.5/0/2/0.5à92/5/2/0.5, to afford (-)-60.  Run 1: 151.5 mg, 
62%; Run 2: 149.8 mg, 61%.  Average: 62%.  
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1H NMR (500 MHz, Methanol-d4) δ  8.39 (d, J = 8.8 Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 4.34 (q, J 
= 7.3 Hz, 1H), 4.15 (dd, J = 5.8, 8.05 Hz, 1H), 3.97 (q, J = 7.1 Hz, 1H), 3.67 (s, 3H), 2.32-2.24 
(m, 2H), 2.03-1.96 (m, 1H), 1.83-1.76 (m, 1H), 1.36 (d, J = 7.35 Hz, 3H), 1.27 (d, J = 7.15 Hz, 
3H); 
13C NMR (125 MHz, Methanol-d4) δ 176.4, 174.4, 173.8, 173.0, 151.5, 147.7, 129.6, 125.3, 
53.6, 53.4, 52.7, 30.8, 28.5, 19.6, 17.1; 
HRMS (ESI) calc’d for: C18H25N4O10S [M+H]+: 489.1291, found: 489.1274; 
[α]D26 = -48.0° (c = 1.1, MeOH).  
 
 
 
Methyl N-(tert-butoxycarbonyl)-N-((4-nitrophenyl)sulfonyl)-L-alanyl-L-prolyl-L-leucinate 
(-)-63. 
Note: The N-terminal Boc group was installed on this substrate to obviate N-terminal-to-proline 
cyclization events during the Fe(PDP) oxidation when Ns-Ala-Pro-Leu-OMe was employed. 
1H NMR (500 MHz, CDCl3) δ 8.37 (d, J = 8.8 Hz, 2H), 8.21 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 7.6 
Hz, 1H), 5.23 (q, J = 6.9 Hz, 1H), 4.55-4.48 (m, 2H), 3.71 (s, 3H), 3.69-3.67 (m, 1H), 3.64-3.54 
(m, 1H), 2.33-2.28 (m, 1H), 2.24-2.14 (m, 1H), 2.03-1.98 (m, 1H), 1.69-1.61-1.51 (m, 7H), 1.34 
(s, 9H), 0.92 (d, J = 6.2 Hz, 3H), 0.90 (d, J = 6.1 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.4, 171.0, 168.5, 150.5, 150.0, 145.3, 130.0, 124.0, 86.1, 61.0, 
55.7, 52.4, 51.1, 47.7, 41.4, 28.0, 27.6, 25.6, 24.9, 22.9, 22.1, 17.3; 
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HRMS (ESI) calc’d for: C26H39N4O10S [M+H]+: 599.2387, found: 599.2404; 
[α]D24 = -56.8° (c = 1.11, MeOH).  
 
(S)-4-((S)-2-((N-(tert-butoxycarbonyl)-4-nitrophenyl)sulfonamido)propanamido)-5-(((S)-1-
methoxy-4-methyl-1-oxopentan-2-yl)amino)-5-oxopentanoic acid (-)-64. 
Substrate Ns(Boc)-Ala-Pro-Leu-OMe (-)-63 (179.6mg, 1.0 equiv., 0.3 mmol) was reacted 
according to General Oxidation Procedure B with (S,S)-Fe(CF3PDP)(MeCN)2(SbF6)2 (101.7 
mg, 0.25 equiv., 0.075 mmol), AcOH (8.6 µL, 0.5 equiv., 0.15 mmol), and H2O2 (86.5 µL, 5.0 
equiv., 1.5 mmol) in MeCN at RT.  The crude reaction mixture was concentrated onto silica gel 
and purified via flash chromatography, eluting with MeOH / CH2Cl2 2%à3%à4%à5% to 
afford (-)-64.  Run 1: 104.1 mg, 55%; Run 2: 108.5 mg, 58% yield. Average: 57% yield. 
1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 9.0 Hz, 2H), 8.31 (d, J = 9.0 Hz, 2H), 7.15 (d, J = 7.4 
Hz, 1H), 7.04 (d, J = 8.2 Hz, 1H), 5.21 (q, J = 6.8 Hz, 1H), 4.80 (q, J = 7.4 Hz, 1H), 4.51-4.47 
(m, 1H), 3.69 (s, 3H), 2.59-2.45 (m, 2H), 2.21-2.16 (m, 1H), 2.00-1.93 (m, 1H), 1.77 (d, J = 6.9 
Hz, 3H), 1.66-1.55 (m, 2H), 1.28 (s, 9H), 0.89 (d, J = 5.9 Hz, 3H), 0.87 (d, J = 5.7 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 176.2, 172.8, 171.1, 170.2, 150.5, 149.8, 145.2, 130.0, 123.9, 
86.1, 56.4, 52.4, 51.2, 40.5, 29.8, 28.0, 27.8, 24.88, 22.8, 21.8, 16.9; 
HRMS (ESI) calc’d for: C26H39N4O12S [M+H]+: 631.2285, found: 631.2289; 
[α]D26 = -11.4 ° (c = 1.1, MeOH) 
 
Experimental data from Figure 16. 
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Methyl ((2S,5R)-5-(2-hydroxyphenyl)-1-((4-nitrophenyl)sulfonyl)pyrrolidine-2-carbonyl)-L-
leucyl-L-alaninate (+)-65. 
Substrate Ns-P-L-A-OMe (-)-52 (498.6 mg, 1.0 equiv., 1.0 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH, and the crude reaction 
mixture was passed through a plug of silica (40 mL) with EtOAc (250 mL) and concentrated.  
The crude residue was then subjected to the General 2-Step Oxidation / Arylation Procedure, 
using Phenol (188 mg, 2.0 mmol) and BF3OEt2 (502 uL, 4.0 mmol) in CH2Cl2 (10 mL).  The 
crude reaction mixture was concentrated onto silica gel and purified via flash chromatography, 
eluting with 3:1à2:1à1:1 Hexanes / EtOAc, affording (+)-65 (217.4 mg, 37 % yield over 2 
steps, 61% per step).  
1H NMR (500 MHz, Chloroform-d) δ 8.69 (s, 1H), 8.05 (d, J = 8.9 Hz, 2H), 7.91 (d, J = 8.7 Hz, 
1H), 7.61 (d, J = 8.9 Hz, 2H), 7.09 (dd, J = 7.6, 1.7 Hz, 1H), 7.05 – 6.97 (m, 2H), 6.79 (td, J = 
7.4, 1.2 Hz, 1H), 6.39 (dd, J = 8.2, 1.2 Hz, 1H), 4.88 (dd, J = 10.2, 1.4 Hz, 1H), 4.72 (td, J = 8.7, 
6.0 Hz, 1H), 4.66 (dd, J = 11.3, 5.9 Hz, 1H), 4.56 (p, J = 7.2 Hz, 1H), 3.76 (s, 3H), 2.60 – 2.42 
(m, 1H), 2.28 (tdd, J = 12.8, 10.0, 6.6 Hz, 1H), 2.18 – 2.08 (m, 2H), 1.86 – 1.67 (m, 3H), 1.42 (d, 
J = 7.2 Hz, 3H), 1.01 (d, J = 6.0 Hz, 3H), 0.98 (d, J = 6.0 Hz, 3H);  
13C NMR (126 MHz, Chloroform-d) δ 173.7, 173.0, 172.0, 154.7, 149.9, 143.6, 131.1, 130.1, 
129.1, 123.4, 122.0, 120.0, 117.6, 66.3, 62.4, 52.7, 52.1, 48.5, 41.4, 31.1, 29.8, 24.9, 23.1, 22.1, 
18.0;  
IR (film, cm-1) 3294, 3103, 2958, 2873, 1745, 1651, 1531, 1458, 1350, 1161;  
N
H
N N
H
OMe
ONs
O
O
OH
	   148 
HRMS (ESI) m/z calc’d for C27H35N4O9S [M+H]+: 591.2125, found 591.2119;  
[α]D25 = +43.1˚ (c=1.01, CH2Cl2). 
 
 
(S)-5-(((S)-1-(((S)-1-methoxy-1-oxopropan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-
4-((4-nitrophenyl)sulfonamido)-5-oxopentanoic acid  (Ns-Glu-Leu-Ala-OMe) (-)-66. 
Substrate Ns-Pro-Leu-Ala-OMe (-)-52 (149.6 mg, 1.0 equiv., 0.3 mmol) was reacted according 
to General Oxidation Procedure B with (S,S)-Fe(CF3PDP)(MeCN)2(SbF6)2 (101.7 mg, 0.25 
equiv., 0.075 mmol), AcOH (8.6 uL, 0.5 equiv., 0.15 mmol), and H2O2 (86.5 uL, 5.0 equiv., 1.5 
mmol) in MeCN at RT. The crude material was purified via flash chromatography eluting with 
gradient MeOH/CH2Cl2 3%à10%, affording (-)-66.  Run 1: 57.3 mg, 36%. Run 2: 58.8 mg, 
37%.  Average: 37%.  
1H NMR (500 MHz, Methanol-d4) δ .838 (d, J = 8.8 Hz, 2H), 8.07 (d, J = 8.8 Hz, 2H), 4.33 (q, J 
= 7.3 Hz, 1H), 4.15 (dd, J = 5.3, 9.6 Hz, 1H), 3.90 (dd, J = 5.2, 8.9 Hz, 1H), 3.68 (s, 3H), 2.35-
2.28 (m, 2H), 1.99-1.94 (m, 1H), 1.83-1.76 (m, 1H), 1.53-1.44 (m, 4H), 1.36 (d, J = 7.3 Hz, 3H), 
0.88 (d, J = 6.3 Hz, 3H), 0.79 (d, J = 6.3 Hz, 3H); 
13C NMR (125 MHz, Methanol-d4) δ 174.4, 174.1, 172.7, 151.4, 147.7, 129.7, 125.3, 57.4, 52.7, 
41.9, 30.1, 25.6, 23.3, 22.0, 17.2; 
HRMS (ESI) calc’d for: C21H31N4O10S [M+H]+: 531.1761, found: 531.1748; 
[α]D27 = -305.2° (c = 0.94, CH2Cl2).  
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Marfey’s Reagent Analysis of Ns-Glu-Leu-Ala-OMe. 
Marfey’s reagent (FDAA) analysis was performed on Ns-E-L-A-OMe (-)-66 according to a 
literature procedure.55, 56 A sample of approx. 0.1mg of purified peptide was hydrolyzed by 
treatment with 2 mL of 6N HCl and heating to 120°C for 24h in a sealed tube.  The hydrolysate 
was dried under N2.  To a total of 1 µmol of amino acids in an eppendorf tube, 1.44 µmol of a 
1% solution of Marfey’s reagent (FDAA, N-(5-fluoro-2,4-dinitrophenyl)-D-Alaninamide) and 8 
µmol of a 1 M solution of NaHCO3 were added.  The reaction mixture was heated at 40°C for 1 
h and then cooled to RT.  The reaction was quenched by adding 8 µmol of 2 M HCl and diluted 
with 0.2 mL MeOH.  Standards (L-Ala, D-ala, L-Leu, D-Leu, L-Glu, D-Glu) were treated with 
the identical procedure. 
Samples were analyzed by RP-HPLC on a C-18 column with detection at 340 nm.  
Acetonitrile/water containing 0.1% formic acid was used as the mobile phase with a linear 
gradient elution mode (MeCN, 10-60%, 60 min).  The retention times were compared to 
authentic FDAA adduct samples prepared from individual samples of D- and L-amino acids. 
Retention times for FDAA adduct standards: L-Glu: 20.125; D-Glu: 23.959; L-Ala: 24.678; D-
Ala: 27.675; L-Leu: 35.351; D-Leu: 39.368.  No D-amino acids were observed for the samples 
of Ns-Glu(OH)-Leu-Ala-OMe that were tested, indicating no epimerization of the residues.  
 
Methyl ((S)-2-((4-nitrophenyl)sulfonamido)hex-5-enoyl)-L-leucyl-L-alaninate (-)-67. 
 Ns-P-L-A-OMe (-)-52 (249.3 mg, 0.5 mmol, 1.0 equiv.) was reacted according to Procedure A 
with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH. The crude reaction mixture was plugged 
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through silica gel, concentrated, and then added as a solution in THF to a solution of Wittig 
reagent at 0°C (prepared prior to the reaction using the Wittig reagent preparation above). Flash 
chromatography of the crude reaction mixture eluting with gradient Hexanes/EtOAc 3:2à1:1 
afforded (-)-67.  Run 1: 85.8 mg, 33%.  Run 2: 81.2 mg, 32%. Average: 33% (57% per step).  
1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 8.8 Hz, 2H), 8.05 (d, J = 8.8 Hz, 2H), 6.33 (d, J = 7.2 
Hz, 1H), 6.15 (d, J = 8.4 Hz, 1H), 5.76 – 5.64 (m, 1H), 5.60 (d, J = 8.2 Hz, 1H), 5.06 – 4.96 (m, 
2H), 4.52 (p, J = 7.3 Hz, 1H), 4.28 (td, J = 8.5, 5.7 Hz, 1H), 3.78 (td, J = 8.1, 5.2 Hz, 1H), 3.75 
(s, 3H), 2.10 (hept, J = 7.2, 6.5 Hz, 2H), 1.82 (dq, J = 13.5, 6.8 Hz, 1H), 1.70 (dq, J = 14.6, 8.1 
Hz, 1H), 1.54 – 1.49 (m, 1H), 1.38 (d, J = 7.2 Hz, 3H), 1.36 – 1.29 (m, 2H), 0.85 (d, J = 6.3 Hz, 
3H), 0.81 (d, J = 6.3 Hz, 3H);  
13C NMR (126 MHz, Acetone-d6) δ 173.6 , 172.3 , 171.0 , 151.0 , 147.7 , 138.3, 129.6, 125.2, 
115.8, 57.18 , 52.37 , 52.02 , 48.81 , 42.15 , 34.20 , 25.18 , 23.35 , 22.07 , 17.71;  
IR (film, cm-1)  3359, 3261, 3124, 2925, 1737, 1643, 1525, 1349, 1266, 1091;  
HRMS (ESI) m/z calc’d for C22H33N4O8S [M+H]+: 513.2019, found: 513.2010;  
[α]D24 = -9.3˚ (c = 1.02, CH2Cl2). 
	  
Methyl ((S)-5-(dibenzylamino)-2-((4-nitrophenyl)sulfonamido)pentanoyl)-L-leucyl-L-
alaninate (-)-68. 
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Ns-P-L-A-OMe (-)-52 (249.3 mg, 0.5 mmol, 1.0 equiv.) was reacted according to Procedure A 
with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH, and the crude reaction mixture was 
passed through a plug of silica (40 mL) with EtOAc (250 mL) and concentrated.  The crude 
residue was dissolved in CH2Cl2 and reacted with dibenzylamine (98.6 mg, 0.5 mmol, 1.0 equiv.) 
and sodium triacetoxyborohydride (317.9  mg, 1.5 mmol, 3.0 equiv.) according to the General 
Procedure for Reductive Amination.  Flash chromatography eluting with 2:1 CHCl3/EtOAc 
afforded (-)-68. Run 1: 134.0 mg, 39%; Run 2: 119.9 mg, 35%; Avg: 37% (61% per step).	  
1H NMR (500 MHz, CDCl3) δ 8.26 (d, J = 8.8 Hz, 2H), 7.93 (d, J = 8.8 Hz, 2H), 7.35-7.33 (m, 
8H), 7.30-7.25 (m, 2H), 6.84 (d, J = 7.6 Hz, 1H), 6.42 (d, J = 8.7 Hz, 1H), 4.54 (p, J = 7.2 Hz, 
1H), 4.40-4.35 (m, 1H), 3.73 (s, 3H), 3.60 (d, J = 14.0 Hz, 2H), 3.53 (dd, J = 4.4, 8.1 Hz, 1H), 
3.45 (d, J = 13.6 Hz, 2H), 2.43-2.32 (m, 2H), 1.72-1.64 (m, 1H), 1.61-1.47 (m, 4H), 1.35 (d, J = 
7.3 Hz, 3H), 1.32-1.28 (m, 2H), 0.82 (d, J = 6.3 Hz, 3H), 0.77 (d, J = 5.9 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.2, 171.1, 170.8, 150.1, 145.5, 138.6, 129.4, 128.7, 128.5, 
127.4, 124.3, 60.5, 58.3, 52.6, 51.7, 51.5, 48.2, 41.4, 31.2, 24.8, 22.8, 22.3, 21.9, 18.2, 14.3; 
HRMS (ESI) calc’d for: C35H46N5O8S [M+H]+: 696.3067, found: 696.3072; 
[α]D26 = -27.1° (c = 1.04, CHCl3).   
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Methyl ((S)-5-(benzylamino)-2-((4-nitrophenyl)sulfonamido)pentanoyl)-L-leucyl-L-
alaninate (+)-69. 
Ns-P-L-A-OMe (-)-52 (249.3 mg, 0.5 mmol, 1.0 equiv.) was reacted according to Procedure A 
with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH, and the crude reaction mixture was 
passed through a plug of silica (40 mL) with EtOAc (250 mL) and concentrated.  The crude 
residue was dissolved in CH2Cl2 and reacted with benzylamine (53.6 mg, 0.5 mmol, 1.0 equiv.) 
and sodium triacetoxyborohydride (317.9  mg, 1.5 mmol, 3.0 equiv.) according to the General 
Procedure for Reductive Amination.  Flash chromatography eluting with MeOH/CH2Cl2 
5%à10% afforded (+)-69. Run 1: 152.1 mg, 50%; Run 2: 144.0 mg, 48%; Average: 49% (70% 
per step). 
1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 8.45 Hz, 2H), 7.99 (d, J = 8.55 Hz, 2H), 7.96 (m, 1H), 
7.44-7.41 (m, 2H), 7.39-7.32 (m, 3H), 7.04 (d, J = 7.4 Hz, 1H), 4.43 (p, J = 7.2 Hz, 1H), 4.26-
4.21 (m, 1H), 4.01-3.92 (m, 3H), 3.66 (s, 3H), 2.92-2.87 (m, 1H), 2.81-2.75 (m, 1H), 1.90-1.85 
(m, 2H), 1.79-1.67 (m, 2H), 1.53-1.37 (m, 3H), 1.31 (d, J = 7.25 Hz, 3H), 0.81 (d, J = 6.4 Hz, 
3H), 0.71 (d, J = 6.35 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.4, 171.9, 170.8, 150.1, 145.6, 129.6, 129.1, 129.0, 128.7, 
124.4, 55.7, 52.3, 52.5, 52.3, 48.2, 46.7, 40.7, 31.2, 24.8, 23.1, 22.9, 21.6, 18.0; 
HRMS (ESI) calc’d for: C28H40N5O8S [M+H]+: 606.2598, found: 606.2599; 
[α]D25 = +7.4° (c = 1.11, CHCl3).  
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Methyl ((S)-5-morpholino-2-((4-nitrophenyl)sulfonamido)pentanoyl)-L-leucyl-L-alaninate 
(-)-70. 
Ns-P-L-A-OMe (-)-52 (249.3 mg, 0.5 mmol, 1.0 equiv.) was reacted according to Procedure A 
with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH, and the crude reaction mixture was 
passed through a plug of silica (40 mL) with EtOAc (250 mL) and concentrated.  The crude 
residue was dissolved in CH2Cl2 and reacted with morpholine (43.6 mg, 0.5 mmol, 1.0 equiv.) 
and sodium triacetoxyborohydride (317.9 mg, 1.5 mmol, 3.0 equiv.) according to the General 
Procedure for Reductive Amination.  Flash chromatography eluting with MeOH/CH2Cl2 
5%à7% afforded (-)-70.  Run 1: 129.5 mg, 44%; Run 2: 137.9 mg, 47%; Avg: 46% (68% per 
step). 
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 8.8 Hz, 2H), 8.04 (d, J = 8.8 Hz, 2H), 7.20 (d, J = 7.0 
Hz, 1H), 6.83 (d, J = 7.5 Hz, 1H), 4.49 (p, J = 7.2 Hz, 1H), 4.38-4.33 (m, 1H), 3.89-3.79 (m, 
5H), 3.71 (s, 3H), 2.68-2.57 (m, 2H), 2.56-2.42 (m, 3H), 2.41-2.30 (m, 1H), 2.13-2.06 (m, 1H), 
1.66-1.52 (m, 4H), 1.48-1.38 (m, 2H), 1.35 (d, J = 7.2 Hz, 3H), 0.87 (d, J = 6.4 Hz, 3H), 0.82 (d, 
J = 6.3 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.1, 171.3, 170.6, 150.1, 146.0, 128.5, 124.5, 66.0, 58.1, 55.8, 
53.6, 53.1, 52.6, 51.9, 48.1, 41.4, 31.8, 25.0, 22.9, 21.9, 20.9, 18.1; 
HRMS (ESI) calc’d for: C25H40N5O9S [M+H]+: 586.2547, found: 586.2549; 
[α]D26 = -45.6° (c = 0.96, CHCl3).	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Methyl ((S)-2-((4-nitrophenyl)sulfonamido)-5-(4-(pyridin-2-yl)piperazin-1-yl)pentanoyl)-L-
leucyl-L-alaninate (-)-71. 
Ns-P-L-A-OMe (-)-52 (249.3 mg, 0.5 mmol, 1.0 equiv.) was reacted according to Procedure A 
with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH, and the crude reaction mixture was 
passed through a plug of silica (40 mL) with EtOAc (250 mL) and concentrated.  The crude 
residue was dissolved in CH2Cl2 and reacted with 1-(2-pyridyl)piperazine (81.6 mg, 0.5 mmol, 
1.0 equiv.) and sodium triacetoxyborohydride (317.9  mg, 1.5 mmol, 3.0 equiv.) according to the 
General Procedure for Reductive Amination..  Flash chromatography (MeOH / CH2Cl2 
5%à7%) afforded (-)-71.  Run 1: 163.0 mg, 49%; Run 2: 149.1 mg, 45%; Average: 47% (69% 
per step). 
1H NMR (500 MHz, CDCl3) δ 8.31 (d, J = 8.8 Hz, 2H), 8.19 (d, J = 4.8 Hz, 1H), 8.04 (d, J = 8.7 
Hz, 2H), 7.52-7.49 (m, 1H), 6.83 (d, J = 7.4 Hz, 1H), 6.68-6.65 (m, 2H), 4.51 (p, 7.3 Hz, 1H), 
4.42-4.38 (m, 1H), 3.88 (m, 1H), 3.75-3.66 (m, 6H, including s at 3.72, 3H), 2.80-2.71 (m, 2H), 
2.68-2.59 (m, 2H), 2.57-2.48 (m, 1H), 2.45-2.36 (m, 1H), 2.23-2.13 (m, 1H), 1.70-1.44 (m, 6H), 
1.36 (d, J = 7.3 Hz, 3H), 0.91 (d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.2 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.2, 171.2, 170.6, 159.1, 150.1, 148.1, 145.8, 137.8, 128.6, 
124.5, 114.1, 109.9, 107.4, 57.7, 55.9, 52.6, 52.0, 48.1, 44.4, 41.4, 31.7, 25.1, 23.0, 21.8, 21.3, 
18.2, 14.3; 
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HRMS (ESI) calc’d for: C30H44N7O8S [M+H]+: 662.2972, found: 662.2963; 
[α]D26 = -16.2° (c = 1.10, CHCl3). 
 	  
Methyl ((S)-5-hydroxy-2-((4-nitrophenyl)sulfonamido)pentanoyl)-L-leucyl-L-alaninate (-)-
72. 
Substrate Ns-Pro-Leu-Ala-OMe (-)-52 (149.6 g, 1.0 equiv., 0.5 mmol) was reacted according to 
Procedure A with (S,S)-Fe(PDP)(MeCN)2(SbF6)2, H2O2, and AcOH, and the crude reaction 
mixture was passed through a plug of silica (40 mL) with EtOAc (250 mL) and concentrated.  
The crude residue was dissolved in CH2Cl2/ EtOH (1:1, 10 mL) and cooled to 0°C.  To this 
stirring solution was added sodium borohydride (19 mg, 0.5 mmol, 1.0 equiv.), which caused the 
solution to gently bubble.  The reaction was allowed to warm to RT and concentrated onto silica 
gel for purification.  Flash chromatography (1:1 CHCl3/EtOAc à 100% EtOAc) afforded (-)-72. 
Run 1: 91.4 mg, 35%; Run 2: 96.9 mg, 38%; Average: 37% (61% per step).   
1H NMR (500 MHz, Methanol-d4) δ 8.37 (d, J = 8.8 Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 4.32 (q, J 
= 7.3 Hz, 1H), 4.11 (dd, J = 5.3, 9.5 Hz, 1H), 3.88 (dd, J = 5.5 8.3 Hz, 1H), 3.68 (s, 3H), 3.52 (t, 
J = 6.1 Hz, 2H), 1.79-1.72 (m, 1H), 1.64-1.36 (m, 5H), 1.34 (d, J = 7.3 Hz, 3H), 0.88 (d, J = 6.4 
Hz, 3H), 0.79 (d, J = 6.3 Hz, 3H); 
13C NMR (125 MHz, Methanol-d4) δ 174.4, 1741, 173.0, 151.4, 147.9, 129.7, 125.3, 62.1, 57.6, 
52.7, 52.6, 42.0, 31.2, 29.5, 25.6, 23.2, 22.1, 17.2; 
HRMS (ESI) calc’d for: C21H33N4O9S [M+H]+: 517.1968, found: 517.1960;  
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[α]D27 = -39.7 ° (c = 1.17, MeOH). 
 
Figure 19. Synthesis of Macrocycle (-)-73 
 
 
Methyl ((2S,5R)-1-((4-nitrophenyl)sulfonyl)-5-(2-(pent-4-en-1-yloxy)phenyl)pyrrolidine-2-
carbonyl)-L-leucyl-L-alaninate S-8. 
Phenol-Adduct (+)-65 (655.3 mg, 1.0 equiv., 1.12 mmol) and 5-bromo-1-pentene (0.79 mL, 6.0 
equiv., 6.6 mmol) in DMF (5 mL), were cooled to 0°C.  Then K2CO3 (1.55 g, 10 equiv., 11.2 
mmol) was added to the reaction and the resulting suspension stirred rapidly at 0°C for 2h, then 
gradually allowed to warm to RT and stirred for 22h. The reaction mixture was partitioned 
between EtOAc and sat. aq. NaHCO3 solution, the layers separated and the organic layer washed 
once with additional sat. aq. NaHCO3, dried over Na2SO4, and concentrated onto silica gel for 
purification.  Flash chromatography on silica gel, eluting with 2:1 to 1:1 Hexanes / EtOAc 
afforded S-8 (550.2 mg, 0.84 mmol, 75%).  
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1H NMR (500 MHz, Chloroform-d) δ 8.34 (d, J = 8.8 Hz, 2H), 8.08 (d, J = 8.8 Hz, 2H), 7.37 (d, 
J = 7.6 Hz, 1H), 7.20 (t, J = 7.0 Hz, 1H), 7.12 (d, J = 8.5 Hz, 1H), 6.84 (dt, J = 14.5, 7.3 Hz, 3H), 
5.89 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.20 (t, J = 7.1 Hz, 1H), 5.13 – 5.02 (m, 2H), 4.66 – 4.55 
(m, 2H), 4.37 – 4.31 (m, 1H), 4.12 – 3.98 (m, 2H), 3.77 (s, 3H), 2.27 (q, J = 6.6 Hz, 3H), 2.18 – 
2.08 (m, 1H), 1.95 (p, J = 6.9 Hz, 2H), 1.91-1.78 (m, 4H), 1.75 – 1.66 (m, 1H), 1.42 (d, J = 7.2 
Hz, 3H), 1.02 (dd, J = 6.4, 3.1 Hz, 6H);  
13C NMR (126 MHz, Chloroform-d) δ 173.3, 171.3, 170.7, 155.4, 150.4, 141.8, 137.5, 129.6, 
128.9, 128.8, 127.1, 124.2, 120.5, 115.6, 111.3, 67.3, 64.0, 60.3, 52.5, 52.3, 48.1, 41.3, 34.1, 
30.3, 28.9, 28.5, 25.0, 23.3, 21.7, 18.2;  
IR (film, cm-1) 3284, 3079, 2954, 2873, 2252, 1739, 1666, 1604, 155, 1535, 1492, 1454, 1351, 
1288, 1240, 1207, 1170, 1093, 1054, 1010, 912, 856, 736;  
HRMS (ESI) m/z calc’d for C32H42N4O9S [M+H]+: 659.2751, found 659.2746;  
[α]D29 = +24.1˚ (c=1.14, CH2Cl2). 
 
 
 
 
methyl N-((2S,5R)-1-((4-nitrophenyl)sulfonyl)-5-(2-(pent-4-en-1-yloxy)phenyl)pyrrolidine-
2-carbonyl)-L-leucyl-L-alanyl-O-(pent-4-en-1-yl)-L-serinate  
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To a solution of peptide S-8 (380 mg, 1.0 equiv., 0.577 mmol) in 3:1 THF/H2O (5.8 mL) at 0°C 
was added LiOH-H2O (121 mg, 5.0 equiv., 2.89 mmol).  The resulting solution was allowed to 
gradually warm to RT while stirring overnight. The solution was quenched by paritioning 
between EtOAc and 1M KHSO4; the layers were separated and the aqueous layer was extracted 
with EtOAc (3 x 20 mL).  Combined organics were dried over Na2SO4 and concentrated, 
yielding crude free acid (213.7 mg, 0.332 mmol, approx. 58%) which was taken on without 
further purification.  The crude acid (213.7 mg, 1.0 equiv., 0.332 mmol) was dissolved in 1:1 
CH2Cl2 / DMF and cooled to 0°C.  To this stirring solution were added HATU (176.7 mg, 1.4 
equiv., 0.465 mmol), pentenyl-serine-OMe (88.9 mg, 1.2 equiv., 0.398 mmol), and N-
methylmorpholine (109.5 uL, 3.0 equiv., 0.996 mmol).  The reaction was stirred overnight and 
gradually allowed to warm to RT.  Flash chromatography of the crude reaction mixture, eluting 
with 3:1 to 2:1 hexanes / acetone, afforded S-9 (275.5 mg, 0.32 mmol, 97%). 
1H NMR (500 MHz, Chloroform-d) δ 8.34 (d, J = 8.8 Hz, 2H), 8.11 (d, J = 8.8 Hz, 2H), 7.38 
(dd, J = 7.6, 1.7 Hz, 1H), 7.24 – 7.19 (m, 1H), 7.13 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 7.6 Hz, 1H), 
6.86 (dd, J = 13.2, 7.7 Hz, 2H), 6.73 (d, J = 8.2 Hz, 1H), 5.89 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 
5.79 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.19 (t, J = 7.0 Hz, 1H), 5.13 – 4.92 (m, 4H), 4.76 – 4.66 
(m, 1H), 4.57 (dt, J = 14.5, 6.6 Hz, 2H), 4.30 (dd, J = 7.5, 4.7 Hz, 1H), 4.12 – 3.96 (m, 2H), 3.88 
(dd, J = 9.6, 3.4 Hz, 1H), 3.77 (s, 3H), 3.65 (dd, J = 9.6, 3.4 Hz, 1H), 3.51-3.45 (m, 1H), 3.42 
(dt, J = 9.5, 6.5 Hz, 1H), 2.27 (q, J = 6.6 Hz, 3H), 2.07 (q, J = 6.9 Hz, 3H), 1.96 (q, J = 6.8 Hz, 
2H), 1.91 – 1.76 (m, 4H), 1.67 – 1.60 (m, 3H), 1.43 (d, J = 7.1 Hz, 3H), 1.02 (t, J = 6.0 Hz, 6H);  
13C NMR (126 MHz, Chloroform-d) δ 172.1, 171.5, 170.8, 170.7, 155.5, 150.5, 141.8, 138.1, 
137.5, 129.7, 129.0, 128.8, 127.1, 124.3, 120.6, 115.7, 115.0, 111.4, 70.9, 70.2, 67.4, 64.1, 60.2, 
52.8, 52.7, 52.4, 48.9, 41.4, 34.2, 30.3, 30.2, 28.9, 28.6, 28.6, 25.1, 23.4, 21.7, 18.5;  
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IR (film, cm-1) 3307, 3102, 2952, 2871, 1745, 1643, 1604, 1531, 1494, 1454, 1349, 1311, 1290, 
1243, 1211, 1162, 1106, 1054, 1010, 914, 854;  
HRMS (ESI) m/z calc’d for C40H56N5O11S [M+H]+: 814.3697, found 814.3702;  
[α]D25 = +16.8˚ (c=0.97, CH2Cl2). 
 
Diene S-9 (47 mg, 1.0 equiv., 0.0577 mmol) was dissolved in CH2Cl2 (11.5 mL, [diene] = 0.005 
M), and to this solution was added Benzylidene-bis(tricyclohexylphosphine)dichlororuthenium 
(Grubb’s I catalyst) (9.5 mg, 0.2 equiv., 0.0115 mmol).  The resulting solution was heated to 
reflux overnight, then concentrated onto silica gel for purification.  Flash chromatography, 
eluting with 3:1à2:1 Hexanes / Acetone, afforded alkene macrocycle S-10 (23.5 mg, 0.03 
mmol, 52%), which was taken on to the next step. 
 
 
 
 (12R,15S,14R,17S,20S)-20-isobutyl-14,17-dimethyl-11-((4-nitrophenyl)sulfonyl)-3,12-dioxa-
15,18,21-triaza-1(2,5)-pyrrolidina-2(1,2)-benzenacyclodocosaphane-16,19,22-trione (-)-73. 
To nosyl-amine containing macrocycle S-10 (70.6 mg, 1.0 equiv., 0.0898 mmol) in 98:2 MeCN / 
DMSO was added thiophenol (99.0 mg, 10.0 equiv., 0.898 mmol), and Cs2CO3 (438.9 mg, 15.0 
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equiv., 1.347 mmol).  The resulting slurry was stirred rapidly and heated to 45°C for 4h.  The 
reaction was poured into sat. aq. NaHCO3 and extracted with EtOAc (3 x 20 mL).  The combined 
organics were dried over K2CO3 and concentrated onto silica gel for purification.  Flash 
chromatography, eluting with 5% to 10% MeOH / CH2Cl2 afforded free amine intermediate S-11 
(40.2 mg, 0.067 mmol, 75%).  Free amine intermediate S-11 was dissolved in MeOH (6 mL), 
and to this solution was added 5% Pd/C (20.1 mg, 50 wt% relative to substrate).  Two balloons 
of H2 gas were bubbled through the resulting slurry and a third full balloon left static to maintain 
H2 atmosphere, as the mixture was stirred at RT overnight.  The crude mixture was passed 
through a plug of Celite with MeOH to remove Pd/C, and then concentrated onto silica gel for 
purification.  Flash chromatography, eluting with 3% MeOH / CH2Cl2 afforded (-)-73 (42.0 mg, 
0.067 mmol, 99% from S-11).  
1H NMR (500 MHz, Chloroform-d) δ 8.18 (s, 1H), 7.31 – 7.19 (m, 2H), 7.06 (d, J = 8.1 Hz, 1H), 
6.98 – 6.86 (m, 2H), 6.63 (s, 1H), 4.73 (td, J = 7.3, 6.0, 3.5 Hz, 1H), 4.56 – 4.44 (m, 2H), 4.28 
(dt, J = 10.3, 5.5 Hz, 1H), 4.12 (d, J = 5.5 Hz, 1H), 4.07 (t, J = 5.7 Hz, 2H), 3.86 (dd, J = 10.2, 
6.0 Hz, 1H), 3.72 (s, 3H), 3.63 (dd, J = 10.3, 3.5 Hz, 1H), 3.42 (t, J = 6.2 Hz, 2H), 2.41 – 2.29 
(m, 1H), 2.25 – 2.16 (m, 1H), 2.15 – 1.97 (m, 2H), 1.91-1.77 (m, 2H), 1.72 – 1.60 (m, 1H), 1.60 
– 1.22 (m, 16H), 0.87 (dd, J = 6.1, 4.4 Hz, 6H);  
13C NMR (126 MHz, Chloroform-d) δ 176.5, 172.1, 170.6, 157.1, 129.9, 129.0, 121.0, 111.7, 
71.3, 69.9, 68.5, 66.0, 59.5, 53.0, 52.8, 52.7, 48.9, 40.4, 29.6, 29.5, 29.2, 29.04, 29.02, 28.8, 26.6, 
25.7, 25.0, 23.2, 21.7, 17.3 (2 peaks overlapping or obscured); 
IR (film, cm-1) 3295, 3054, 2933, 2859, 1747, 1658, 1602, 1523, 1454, 1386, 1369, 1241, 1162, 
1118, 1051;  
HRMS (ESI) m/z calc’d for C32H51N4O7 [M+H]+: 603.3758, found 603.3749;  
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[α]D25 = -29.6˚ (c=1.28, CH2Cl2). 
 
 
Figure 20. Synthesis of Macrocycle (-)-74 
 
 
Methyl N5-(but-3-en-1-yl)-N2-((4-nitrophenyl)sulfonyl)-L-glutaminyl-L-leucyl-L-alaninate	    
Acid (-)-66 (500 mg, 0.94 mmol, 1.0 equiv.) was dissolved in DMF (2.3 mL, 0.4 M) at RT.  3-
Butenylamine hydrochloride (500 mg, 4.71 mmol, 5.0 equiv.), DIPEA (0.82 mL, 4.71 mmol, 5.0 
equiv.), HOBt (238.1 mg, 1.41 mmol, 1.5 equiv.), and EDC (180.2 mg, 0.94 mmol, 1.0 equiv.) 
were added sequentially to the reaction, and stirred at 45°C for 48 h.  The crude mixture was then 
concentrated via rotary evaporation at 60°C to remove DMF solvent by several additions of 
toluene as an azeotrope, and purified via flash chromatography (MeOH / CH2Cl2 3%à5%) to 
afford S-12 (355.1 mg, 0.61 mmol, 65%).   
1H NMR (500 MHz, Acetone-d6) δ 8.43 (d, J = 8.7 Hz, 2H), 8.13 (d, J = 8.7 Hz, 2H), 7.65 (d, J 
= 8.5 Hz, 1H), 7.62 (d, J = 7.3 Hz, 1H), 7.30 (br s, 1H), 5.81 (ddt, J = 6.8, 10.3, 17.1 Hz, 1H), 
5.07 (dd, J = 1.6, 17.2 Hz, 1H), 5.01-4.98 (m, 1H), 4.38 (p, J = 7.3 Hz, 1H), 4.33-4.28 (m, 1H), 
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3.93 (dd, J = 6.0, 7.7 Hz, 1H), 3.65 (s, 3H), 3.31-3.18 (m, 2H), 2.31-2.18 (m, 4H), 1.97-1.84 (m, 
2H), 1.58-1.52 (m, 1H), .50-1.39 (m, 2H), 1.32 (d, J = 7.3 Hz, 3H), 0.84 (d, J = 6.4 Hz, 3H), 0.76 
(d, J = 6.4 Hz, 3H); 
13C NMR (125 MHz, Acetone-d6) δ 173.7, 173.2, 172.6, 171.0, 151.0, 147.4, 136.9, 129.6, 
125.3, 116.8, 57.5, 52.4, 48.9, 42.0, 39.6, 34.7, 32.5, 25.3, 23.5, 22.0, 17.7; 
HRMS (ESI) calc’d for: C25H38N5O9S [M+H]+: 584.2390, found: 584.2388; 
[α]D26 = +2.8° (c = 1.12, DMF).  
 
 
Methyl N5-(but-3-en-1-yl)-N2-(tert-butoxycarbonyl)-L-glutaminyl-L-leucyl-L-alaninate  
Nosyl tripeptide S-12 (351.4 mg, 0.6 mmol, 1.0 equiv.) was dissolved in DMF (6 mL, 0.1 M).  p-
Methoxyphenylthiol (221 µL, 1.8 mmol, 3.0 equiv.) was added, followed by K2CO3 (332 mg, 2.4 
mmol, 4.0 equiv.).  The reaction was stirred at RT for approx. 3.5 h, and diluted with CH2Cl2 (15 
mL).  Boc2O (655 mg, 3.0 mmol, 5.0 equiv.) was added to the mixture and was stirred overnight.  
The crude reaction mixture was partitioned between CH2Cl2 and H2O.  The aqueous layer was 
extracted with CH2Cl2 (3 x 20 mL) and combined organic layers were washed with brine (3 x 20 
mL), dried over Na2SO4, and concentrated.  Residual DMF was removed via rotary evaporation 
at 60°C with several additions of toluene as an azeotrope.  The crude residue was purified via 
flash chromatography (0%à5% MeOH / CH2Cl2) to afford S-13 (263.1 mg, 0.53 mmol, 88%).   
1H NMR (500 MHz, CDCl3) δ 6.95 (d, J = 7.0 Hz, 1H), 6.90 (d, J = 7.9 Hz, 1H), 6.28 (t, J = 4.6 
Hz, 1H), 5.77 (ddt, J = 6.8, 10.2, 17.0 Hz, 1H), 5.68 (d, J = 6.1 Hz, 1H), 5.17-5.05 (m, 2H), 4.53 
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(p, J = 7.3 Hz, 1H), 4.48-4.41 (m, 1H), 4.10 (q, J = 6.7 Hz, 1H), 3.73 (s, 3H), 2.35-2.23 (m, 4H), 
2.06-1.99 (m, 2H), 1.73-1.63 (m, 2H), 1.59-1.52 (m, 1H), 1.42 (s, 9H), 1.39 (d, J = 7.2 Hz, 3H), 
0.93 (d, J = 6.2 Hz, 3H), 0.90 (d, J = 6.1 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.3, 172.7, 172.0, 171.9, 156.0, 135.5, 117.4, 80.2, 54.1, 52.6, 
52.1, 48.2, 40.9, 38.7, 33.8, 32.9, 28.6, 28.4, 24.8, 23.1, 21.8, 18.2; 
HRMS (ESI) calc’d for: C24H42N4O7Na [M+Na]+: 521.2951, found: 521.2952;  
[α]D26 = -47.3° (c = 0.9, MeOH).  
 
Methyl (6S,9S,12S,15R)-6-(3-(but-3-en-1-ylamino)-3-oxopropyl)-9-isobutyl-2,2,12-
trimethyl-4,7,10,13-tetraoxo-15-(pent-4-en-1-yl)-3-oxa-5,8,11,14-tetraazahexadecan-16-oate  
Tripeptide S-13 (263 mg, 0.53 mmol, 1.0 equiv.) was dissolved in 3:1 THF/H2O and cooled to 
0°C.  LiOH-H2O (111 mg, 2.64 mmol, 5.0 equiv.) was added and the reaction was stirred 
overnight and warmed to RT.  The crude reaction mixture was partitioned between EtOAc and 
1M KHSO4, and the aqueous layer was extracted with EtOAc (3 x 20 mL) and concentrated.  
The crude carboxylic acid material was dissolved in 1:1 DMF / CH2Cl2 (5.3 mL, 0.1 M) and 
HATU (281.4 mg, 0.74 mmol, 1.4 equiv.), D-bishomoallylglycine methyl ester (83 mg, 0.53 
mmol, 1.0 equiv.), and N-methylmorpholine (174 uL, 1.58 mmol, 3.0 equiv.) were added 
sequentially.  The reaction was stirred overnight at RT.  The reaction was concentrated via rotary 
evaporation at 60°C with several additions of toluene as an azeotrope to remove residual DMF, 
and the residue was purified via flash chromatography (1%à3% MeOH / CH2Cl2) to afford 
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diene S-14 (226.2 mg, 0.37 mmol, 69% over two steps), with a minor HATU-derived impurity 
(1-hydroxy-7-azabenzotriazole).   
1H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 7.05 Hz, 1H), 7.01 (d, J = 7.5 Hz, 1H), 6.88 (d, J = 
5.85 Hz, 1H), 6.27 (br s, 1H), 6.22 (d, J = 5.1 Hz, 1H), 5.80-5.71 (m, 2H), 5.11-5.06 (m, 2H), 
5.01-4.92 (m, 2H), 4.50-4.46 (m, 2H), 4.30-4.27 (m, 1H), 4.05 (q, J = 6.6 Hz, 1H), 3.69 (s, 3H), 
3.38-3.26 (m, 2H), 2.39-2.24 (m, 4H) 2.10-1.96 (m, 4H), 1.88-1.80 (m, 1H), 1.76-1.63 (m, 3H), 
1.58-1.52 (m, 1H), 1.47-1.44 (m, 2H), 1.42 (s, 9H), 1.39 (d, J =7.2 Hz, 3H), 0.93 (d, J = 6.2 Hz, 
3H), 0.89 (d, J = 6.1 Hz, 3H). (Additional resonances corresponding to minor HATU derived 
impurity, 1-hydroxy-7-azabenzotriazole: 8.68 (d, J = 3.8 Hz), 8.34 (d, J = 8.2 Hz)); 
13C NMR (125 MHz, MeOH-d4) δ 175.0, 174.9, 174.6, 173.9, 157.9, 139.2, 136.7, 117.0, 115.5, 
80.8, 55.7, 53.7, 52.7, 50.5, 41.6, 40.0, 34.8, 34.2, 33.3, 32.0, 28.9, 28.7, 26.0, 25.8, 23.5, 21.8, 
18.2.  2 peaks obscured or overlapping. (Additional resonances corresponding to minor HATU 
derived impurity, 1-hydroxy-7-azabenzotriazole: 152.0, 129.9, 122.1); 
HRMS (ESI) calc’d for: C31H54N5O8 [M+H]+: 624.3972, found: 624.3964; 
[α]D26 = -68.6° (c = 1.07, CH2Cl2).  
 
Diene S-14 (75 mg, 0.12 mmol, 1.0 equiv.) was dissolved in CH2Cl2 (25 mL, 0.0047 M) in a 
round-bottomed flask under N2 atmosphere.  To this solution was added Ti(OiPr)4 (36 µL, 0.12 
mmol, 1.0 equiv.), and the colorless solution turned a light yellow.  The mixture was stirred for 
30 min, then Grubbs I catalyst (29.6 mg, 0.036 mmol, 0.3 equiv.) was added in 1 mL of CH2Cl2.  
The flask was fitted with a water-cooled condenser and an N2 inlet, and heated to gentle reflux 
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for 3h.  The reaction was cooled to RT and purified via flash chromatography (25% Acetone / 
Hexanes to 60%) to afford alkene-containing macrocycle S-15 (53.9 mg, 0.082 mmol, 68%) as 
an inconsequential ~1:1 E/Z isomer mixture, which was taken through to the next step. 
 
Methyl (3S,6S,9S,21R)-9-((tert-butoxycarbonyl)amino)-6-isobutyl-3-methyl-2,5,8,12-
tetraoxo-1,4,7,13-tetraazacyclohenicosane-21-carboxylate (-)-74. 
Alkene-containing macrocycle S-15 (53.9 mg, 0.09 mmol, 1.0 equiv.) was dissolved in MeOH 
(5mL).  5%Pd/C (25 mg, 50% wt) was added to the solution.  H2 was bubbled through the 
solution (2 balloons, ~ 20 min), and a third balloon was added to maintain H2 atmosphere.  The 
H2 balloon was recharged after 8h and the reaction stirred overnight.  The crude mixture was 
purified by eluting through a plug of Celite with MeOH, and concentrated to afford 
hydrogenated product (-)-74 (44.0 mg, 0.074 mmol, 82%).   
1H NMR (500 MHz, CDCl3) δ 7.52-7.45 (m, 1H), 7.06-7.00 (m, 1H), 6.84 (d, J = 7.6 Hz, 1H), 
6.76 (d, J = 6.1 Hz, 1H), 5.30 (d, J = 6.65 Hz, 1H), 4.57-4.52 (m, 1H), 4.50-4.42 (m, 2H), 4.09-
4.04 (m, 1H), 3.73 (s, 3H), 3.35-3.24 (m, 2H), 2.30-2.08 (m, 4H), 2.07-1.80 (m, 5H), 1.78-1.42 
(m, 9H), 1.41 (s, 9H), 1.35 (d, J = 7.2 Hz, 3H), 0.96 (d J = 6.1 Hz, 3H), 0.89 (d, J = 5.95 Hz, 
3H); 
13C NMR (125 MHz, CDCl3) δ 173.4, 173.0, 172.8, 172.3, 171.9, 155.7, 80.4, 53.5, 52.6, 52.4, 
52.0, 49.8, 41.0, 39.6, 32.1, 31.7, 28.4, 27.8, 25.8, 24.9, 23.5, 23.1, 21.4, 17.7 (3 peaks 
overlapping or obscured); 
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HRMS (ESI) calc’d for: C29H52N5O8 [M+H]+: 598.3816, found: 598.3820; 
[α]D27 = -40.3° (c = 0.51, MeOH).  
 
Figure 21. Synthesis of Macrocycle (-)-75 
 
 
Tripeptide Ns-Hag-Leu-Ala-OMe (-)-67 (613.2 mg, 1.20 mmol, 1.0 equiv.) was dissolved in 3:1 
THF / H2O (7 mL) and cooled to 0°C.  To this was added LiOH-H2O (250.9 mg, 5.98 mmol, 5.0 
equiv.), and the reaction was stirred overnight, allowing it to warm to RT. The crude reaction 
mixture was partitioned between EtOAc and 1M KHSO4 (100 mL each) and the aqueous layer 
extracted with EtOAc (3 x 30 mL).  A precipitate formed in the organic layer, and the combined 
organics (including the precipitate) were concentrated without further purification.  The crude 
acid obtained from the hydrolysis was dissolved in 1:1 DMF / CH2Cl2 (12 mL), and HATU 
(638.8 mg, 1.68 mmol, 1.4 equiv.), D-allylglycine methyl ester hydrochloride (238.2 mg, 1.44 
mmol, 1.2 equiv.) and N-methylmorpholine were added sequentially to the reaction.  The 
solution turned from a light yellow color to dark red.  The reaction was stirred at RT for 8h, and 
the crude reaction mixture was plugged through a pad of silica (approx. 50 mL dry volume) with 
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10% MeOH / DCM (1 L).  The plug eluent was diluted to a total volume of approx. 1.5 L with 
CH2Cl2 to prevent precipitation of product, transferred to a 2L separatory funnel, and washed 
with sat. NaHCO3 solution (500 mL), with further dilution by CH2Cl2 (300 mL).  The combined 
organics were diluted to a volume of ~2 L, and split into two 1 L portions.  Each organic portion 
was washed with 1M HCl (300 mL), dried over Na2SO4, and concentrated.  Residual DMF was 
removed via rotary evaporation at 60°C with several additions of toluene as an azeotrope, to 
afford diene S-16 (683.3 mg, 1.13 mmol, 94%).  This highly insoluble diene was characterized 
by 1H NMR and HRMS and then carried on to further steps. 
1H NMR (500 MHz, Acetone-d6) δ 8.43 (d, J = 8.8 Hz, 2H), 8.17 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 
7.3 Hz, 1H), 7.42 (d, J = 7.1 Hz, 1H), 7.37 (d, J = 7.3 Hz, 1H), 5.76 (dddd, J = 2.8, 6.9, 9.9, 16.9 
Hz, 2H), 5.17-5.02 (m, 2H), 5.00-4.86 (m, 2H), 4.47 (td, J = 5.4, 7.9 Hz, 1H), 4.38 (p, J = 7.1 
Hz, 1H), 4.23-4.19 (m, 1H), 3.96 (dd, J = 5.1, 8.5 Hz, 1H), 3.68 (s, 3H), 2.54 (dt, J = 6.1, 12.5 
Hz, 1H), 2.46 (dt, J = 7.5, 14.2 Hz, 1H), 2.20-2.11 (m, 1H), 1.89-1.79 (m, 1H), 1.72 (ddt, J = 5.5, 
9.3, 18.9 Hz, 1H), 1.54-1.40 (m, 3H), 1.27 (d, J = 7.1 Hz, 3H), 0.83 (d, J = 6.2 Hz, 3H), 0.75 (d, 
J = 6.2 Hz, 3H); 
HRMS (ESI) calc’d for C27H40N5O9S [M+H]+: 610.2547, found: 610.2540.  
 
 
Diene S-16 (357 mg, 0.586 mmol, 1.0 equiv.) was dissolved in 98:2 MeCN / DMSO (10 mL).  
To this solution was added thiophenol (209 uL, 2.05 mmol, 3.5 equiv.), followed by Cs2CO3 
(762 mg, 2.34 mmol, 4.0 equiv.).  The reaction was stirred rapidly and heated to 45°C for 3.5 h.  
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The reaction was partitioned between EtOAc and sat. NaHCO3 solution.   The aqueous layer was 
extracted with EtOAc (3 x 25 mL), and combined organics were dried over K2CO3 and 
concentrated.  The crude residue was purified via flash chromatography (MeOH / CH2Cl2 
1%à5%) to afford crude free amine S-17 (165.1 mg, 0.387 mmol, 66%).    
 
Crude free amine S-17 was dissolved in CH2Cl2 (15 mL), and Boc2O was added in 2 mL of 
CH2Cl2.  The reaction was stirred at RT overnight, and concentrated.  The crude residue was 
purified via flash chromatography (2% MeOH / CH2Cl2) to afford Boc protected diene S-18 
(183.1 mg, 0.348 mmol, 90%).   
Methyl (6S,9S,12S,15R)-15-allyl-6-(but-3-en-1-yl)-9-isobutyl-2,2,12-trimethyl-4,7,10,13-
tetraoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-oate S-18 
1H NMR (500 MHz, CDCl3) δ 6.87 (d, J = 6.3 Hz, 1H), 6.76 (d, J = 7.2 Hz, 1H), 6.45 (d, J = 7.0 
Hz, 1H), 5.83-5.68 (m, 2H), 5.16-5.02 (m, 4H), 5.00-4.91 (m, 1H), 4.60 (q, J = 7.3 Hz, 1H), 4.48 
(p J = 7.2 Hz, 1H), 4.40-4.31 (m, 1H), 4.06 (q, J = 6.2 Hz, 1H), 3.72 (s, 3H), 2.61 (dt, J = 6.3, 
12.7 Hz, 1H), 2.52 (dt, J = 7.1, 14.2 Hz, 1H), 2.14 (q, J = 7.3 Hz, 2H), 1.94 (dq, J = 7.5, 13.7 Hz, 
1H), 1.75-1.63 (m, 6H), 1.45 (s, 9H), 1.39 (d, J = 7.1 Hz, 1H), 0.95 (d, J = 6.4 Hz, 1H), 0.92 (J = 
6.3 Hz, 1H); 
13C NMR (125 MHz, CDCl3) δ 172.5, 172.1, 171.8, 156.0, 137.2, 132.5, 119.1, 115.9, 80.3, 54.5, 
52.4, 52.1, 51.9, 48.9, 41.5, 36.6, 31.7, 29.9, 28.4, 24.9, 23.1, 22.1, 18.8; 
HRMS (ESI) calc’d for C26H45N4O7+ [M+H]+: 525.3288, found: 525.3286; 
 [a]D23 = -50.7° (c 0.99, CHCl3). 
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A flame dried flask under Ar atmosphere was charged with diene S-18 (47.2 mg, 0.090 
mmol, 1.0 equiv.) in CH2Cl2 (17 mL).  To this mixture was added Grubbs I catalyst (14.8 mg, 
0.018 mmol, 0.2 equiv.) in 3 mL CH2Cl2 (total volume ~20 mL, [diene] ~ 0.0048M).  The flask 
was fitted with a water-cooled condenser with an Ar inlet, and the reaction was heated to gentle 
reflux for 2h. The reaction was recharged with Grubbs I catalyst (7.4 mg, 0.009 mmol, 0.1 
equiv.) in 2 mL CH2Cl2 through the top of the condenser, and refluxed for 2 h.  The crude 
reaction mixture was purified via flash chromatography (2% MeOH / CH2Cl2 to 3%) to afford 
alkene-containing macrocycle S-19 as an inconsequential ~1:1 E/Z isomer mixture (31.0 mg, 
0.062 mmol, 69%).  Note: in some cases it was observed that tricyclohexyl phosphine oxide (a 
byproduct of the Grubbs catalyst) elutes with the desired product.  This impurity may be 
removed by passing the material through a silica plug with EtOAc.   
 
Alkene-containing macrocycle S-19 (31.0mg, 1.0 equiv., 0.062 mmol,) was dissolved in MeOH 
(5 mL), and 5% Pd/C (15.5 mg, 50% wt) was added.  The flask was capped with a rubber septum 
and H2 was bubbled through the solution (2 large balloons, ~20 min), with a third H2 balloon 
kept over the solution to maintain hydrogen atmosphere.  The solution was stirred overnight, and 
the crude reaction mixture was plugged through a pad of Celite with MeOH to afford 
hydrogenated product (-)-75 (20.8 mg, 0.056 mmol, 90%).   
Methyl (2S,5S,8R,14S)-14-((tert-butoxycarbonyl)amino)-2-isobutyl-5-methyl-3,6,15-trioxo-
1,4,7-triazacyclopentadecane-8-carboxylate (-)-75. 
1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 6.5 Hz, 1H), 6.69 (d, J = 7.4 
Hz, 1H), 5.75 (d, J = 7.8 Hz, 1H), 4.52 (q, J = 7.6 Hz, 1H), 4.46-4.37 (m, 1H), 4.15-4.05 (m, 
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2H), 3.72 (s, 3H), 1.83-1.64 (m, 5H), 1.60 (d, J = 7.3 Hz, 3H), 1.41 (s, 9H), 1.35-1.20 (m, 8H), 
0.94 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 6.3 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.6, 172.9, 172.54, 172.47, 155.6, 79.9, 54.2, 53.8, 52.53, 
52.49, 52.4, 41.1, 31.8, 30.6, 29.8, 28.5, 26.9, 24.9, 23.0, 22.2, 16.6 (1 peak overlapping or 
obscured); 
HRMS (ESI) calc’d for: C24H43N4O7 [M+H]+: 499.3132, found: 499.3133; 
[α]D26 = -18.9° (c = 0.98, CH2Cl2).  
 
 
(D)-Allylglycine methyl ester hydrochloride (495.3 mg, 1.0 equiv., 3.0 mmol) and Boc-Alanine 
(567.6 mg, 1.0 equiv., 3.0 mmol) were reacted with DIPEA (0.52 mL, 1.0 equiv., 3.0 mmol), 
HOBt (557.3 mg, 1.1 equiv., 3.3 mmol), and EDC (575.1 mg, 1.0 equiv., 3.0 mmol) in CH2Cl2 
(30 mL) according to the General Peptide Coupling Procedure to afford crude S-20.   
Boc Deprotection Procedure. Crude S-20 was dissolved in CH2Cl2 (3 mL) at room temperature, 
and trifluoroacetic acid (3 mL, 1.0 M) was added.  The reaction was monitored by TLC and 
when full conversion of the starting material was observed, the reaction was diluted with CH2Cl2 
(10 mL) and concentrated via rotary evaporation to remove residual trifluoroacetic acid.  Further 
CH2Cl2 (10 mL) was added and the mixture concentrated again.  This dilution / rotary 
evaporation procedure was repeated three more times, and the resulting residue was placed under 
high vacuum for 30 min, affording crude S-20-salt.  
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Crude S-20-salt (assumed 3.0 mmol, 1.0 equiv.) was reacted with Boc-Proline (775.1 mg, 1.2 
equiv., 3.6 mmol), DIPEA (1.4 mL, 2.0 equiv., 6.0 mmol), HOBt (557.3 mg, 1.1 equiv., 3.3 
mmol), and EDC (575.1 mg, 1.0 equiv., 3.0 mmol) in CH2Cl2 according to the General Peptide 
Coupling Procedure to afford crude S-21.  Crude S-21 was then deprotected with trifluoroacetic 
acid in CH2Cl2 according to the Boc Deprotection Procedure (above), affording crude S-21-salt.   
 
Crude S-21-salt (assumed 3.0 mmol, 1.0 equiv.) was reacted with Boc-Alanine (851.4 mg, 1.5 
equiv., 4.5 mmol), DIPEA (2.3 mL, 4.5 equiv., 13.5 mmol), HOBt (835.9 mg, 1.65 equiv., 4.95 
mmol), and EDC (862.7 mg, 1.5 equiv., 4.5 mmol) in CH2Cl2 according to the General Peptide 
Coupling Procedure.  The crude material was concentrated onto silica gel for purification.  Flash 
chromatography, eluting with 3:1à2:1à3:2 CH2Cl2/Acetone, afforded tetrapeptide Boc-Ala-
Pro-Ala-(D)-Allyglycine-OMe (-)-63 (846.2 mg, 1.8 mmol, 60% over 5 steps).   
 
Methyl (R)-2-((S)-2-((S)-1-((tert-butoxycarbonyl)-L-alanyl)pyrrolidine-2-
carboxamido)propanamido)pent-4-enoate  (Boc-Ala-Pro-Ala-(D)-Allyglycine-OMe) (-)-S-
22. 
1H NMR (500 MHz, CDCl3) δ 7.06 (d, J = 7.4 Hz, 1H), 6.87 (d, J = 7.7 Hz, 1H), 5.72-5.60 (m, 
1H), 5.35 (d, J = 7.9 Hz, 1H), 5.14-5.06 (m, 2H), 4.64-4.57 (m, 1H), 4.53 (dd, J = 3.7, 7.7 Hz, 
1H), 4.49-4.40 (m, 2H), 3.71 (s, 3H), 3.70-3.65 (m, 1H), 3.59-3.54 (m, 1H), 2.62-2.54 (m, 1H), 
N
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2.51-2.46 (m, 1H), 2.23-2.17 (m, 1H), 2.13-1.96 (m, 3H), 1.41 (s, 9H), 1.34 (d, J = 6.9 Hz, 3H), 
1.32 (d, J = 7.1 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 173.3, 172.1, 171.8, 171.2, 155.4, 132.3, 119.2, 79.9, 60.3, 52.5, 
51.8, 48.9, 48.2, 47.4, 36.4, 28.5, 27.9, 25.3, 18.5, 17.9; 
HRMS (ESI) calc’d for: C22H37N4O7 [M+H]+: 469.2662, found: 469.2640; 
[α]D25 = -52.5° (c = 1.09, CH2Cl2).  
 
 
Methyl (R)-2-((S)-2-((S)-1-(((S)-2-((4-nitrophenyl)sulfonamido)hex-5-enoyl)-L-
alanyl)pyrrolidine-2-carboxamido)propanamido)pent-4-enoate (-)-76. 
Preparation of Ns-Homoallylglycine-OH:  Ns-Homoallyglycine methyl ester (+)-26 (273.6 mg, 
1.0 equiv., 0.83 mmol) was dissolved in 3:1 THF/H2O (2 mL) and cooled to 0°C.  Then, lithium 
hydroxide hydrate (175 mg, 5.0 equiv., 4.17 mmol) was added to the stirring solution.  The 
solution was warmed to RT and stirred for 12h, then partitioned between EtOAc and 1M 
KHSO4.  The aqueous layer was extracted with EtOAc (5 x 20 mL) and combined organics were 
dried over Na2SO4 and concentrated to afford 26-seco acid a crude yellow solid, which was used 
without further purification. 
Preparation of tetrapeptide coupling partner and coupling: In a separate flask, Boc-Ala-Pro-
Ala-(D)-allylglycine-OMe (-)-S-22 (374.9 mg, 1.0 equiv., 0.8 mmol) was dissolved in CH2Cl2 (1 
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mL), and trifluoroacetic acid (1 mL) was added dropwise to the mixture.  The resulting solution 
was stirred at RT for 12h, then concentrated by addition of CH2Cl2 and subsequent rotary 
evaporation, which was repeated 5 times to remove residual trifluoroacetic acid.  The resulting 
clear gum of S-22-salt was dissolved in CH2Cl2 (2 mL), added to a solution containing crude 26-
seco acid (previously prepared, approx.. 0.8 mmol) in 8:1 CH2Cl2/DMF (9 mL) and cooled to 
0°C.  N-methylmorpholine (0.93 mL, approx. 9 equiv., 8.4 mmol) was added dropwise to the 
stirring solution, followed by HATU (456.3 mg, 1.5 equiv, 1.2 mmol), and the solution was 
stirred at 0°C for 1h, then warmed to RT and stirred overnight.  The reaction was partitioned 
between EtOAc and 1M HCl, the aqueous layer extracted with EtOAc (1 x 20 mL), and 
combined organics were washed with brine (3 x 20 mL), dried over Na2SO4, and concentrated.  
Purification via flash chromatography, eluting with 3%à4% MeOH / CH2Cl2, afforded (-)-76 
(475.2 mg, 89%).  
1H NMR (500 MHz, CDCl3) δ 8.27 (d, J = 8.6 Hz, 2H), 8.01 (d, J = 8.7 Hz, 2H), 7.50 (d, J = 6.7 
Hz, 1H), 7.30 (d, J = 6.8 Hz, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H), 5.66 (dq, J = 
7.0, 17.0 Hz, 2H), 5.09 (d, J = 12.1 Hz, 2H), 4.98-4.88 (m, 2H), 4.67 (q, J = 6.8 Hz, 1H), 4.56-
4.46 (m, 3H), 3.99 (q, J = 8.5 Hz, 1H), 3.72 (s, 3H), 3.65-3.45 (m, 2H), 2.59 (dt, J = 6.0, 12.6 
Hz, 1H), 2.48 (dt, J = 6.9, 14.0 Hz, 1H), 2.17-2.07 (m, 4H), 2.03-1.92 (m, 2H), 1.77-1.60 (m, 
2H), 1.30 (d, J = 7.0 Hz, 3H), 1.09 (d, J = 6.7 Hz, 3H); 
13C NMR (125 MHz, CDCl3) δ 172.3, 172.2, 171.4, 171.2, 170.0, 150.0, 146.2, 136.5, 132.1, 
128.6, 124.3, 119.4, 116.1, 60.4, 56.6, 52.6, 51.8, 48.8, 47.4, 47.1, 36.6, 33.3, 29.4, 28.8, 25.1, 
18.4, 18.2; 
HRMS (ESI) calc’d for: C29H41N6O10S [M+H]+: 665.2605, found: 665.2621; 
[α]D26 = -86.9° (c = 0.52, MeOH).  
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Methyl (3S,6R,12S,15S,20aS)-3,15-dimethyl-12-((4-nitrophenyl)sulfonamido)-1,4,13,16-
tetraoxoicosahydropyrrolo[1,2-d][1,4,7,10]tetraazacyclooctadecine-6-carboxylate (-)-77. 
A round bottom flask was charged with diene (-)-76 (200 mg, 1.0 equiv., 0.3 mmol) in CH2Cl2 
(57.5 mL) and equipped with an N2 inlet.  Then, Hoveyda-Grubbs-II catalyst (9.5 mg, 0.05 
equiv., 0.015 mmol) in CH2Cl2 (5 mL) was added to the flask, the flask equipped with a water-
cooled condenser with N2 inlet, and heated to gentle reflux for 4h.  The green solution was 
concentrated onto silica gel and purified via flash chromatography, eluting with 2:1 CH2Cl2 / 
Acetone to 1:1, affording the crude cyclized product S-23 (117.4 mg, 61%).  The crude cyclized 
product S-23 (117.4 mg, 1.0 equiv., 0.18 mmol) was dissolved in 1:1 CH2Cl2 / DMSO (4 mL) 
and cooled to 0°C.  Freshly prepared dipotassium azodicarboxylate57 (KO2CN=NCO2K, 713 mg, 
20.0 equiv., 3.67 mmol) was added in one portion, followed by dropwise addition of AcOH (0.42 
mL, 40.0 equiv., 7.35 mmol), and the solution was allowed to warm to rt and stirred for 12h.  
The reaction was again cooled to 0°C and recharged with dipotassium azodicarboxylate and 
AcOH equivalent amounts to previous), and warmed to RT and stirred for 48h.  The crude 
yellow mixture was poured into 20 mL of brine and stirred for 10 min until the solution was clear 
and colorless, then extracted with EtOAc (3 x 20 mL), dried over Na2SO4, and concentrated.  
The crude residue was redissolved in CH2Cl2 / DMSO and resubjected to dipotassium 
azodicarboxylate and AcOH, and worked up as described above.  The resulting crude liquid was 
dissolved in EtOAc and washed with brine (5 x 15 mL), dried over Na2SO4, and concentrated.  
N
H
N
NH
HN
O
O
NsHN
O O
CO2Me
N
H
N
NH
HN
O
O
NsHN
O O
CO2Me
N
H
N
NH
HN
O
O
NsHN
OO
CO2Me
Hoveyda-Grubbs II
DCM, reflux,
61% (crude)
KO2CNNCO2K,
AcOH,
DCM / DMSO
54%
(-)-76 S-23 (-)-77
	   175 
The crude mixture was purified via PTLC, eluting 2x with 2:1 CH2Cl2 / Acetone, to afford (-)-77 
as an apparent ~4:1 mixture of conformers (62.0 mg, 54%).  
1H NMR (500 MHz, CDCl3) Major conformer: δ 8.33 (d, J = 8.9 Hz, 2H), 8.03 (d, J = 8.9 Hz, 
2H), 7.60 (d, J = 8.5 Hz, 1H), 6.60 (d, J = 8.3 Hz, 1H), 6.26 (d, J = 8.8 Hz, 1H), 5.59 (d, J =9.0 
Hz, 1H), 4.72 (dt, J = 5.5, 8.5 Hz, 1H), 4.60-4.49 (m, 2H), 4.29 (dd, J = 9.4, 7.8 Hz, 1H), 3.88-
3.83 (m, 1H), 3.79 (s, 3H), 3.77-3.71 (m, 1H), 3.57-3.52 (m, 1H), 2.44-2.38 (m, 1H), 2.02-1.73 
(m, 8H), 1.72-1.52 (m, 3H), 1.40 (d, J = 7.3 Hz, 3H), 1.37 (d, J = 7.3 Hz, 3H), 1.27-1.19 (m, 
2H); 
Minor conformer (only clearly visible, non-overlapping peaks are listed): δ 8.27 (d, J = 8.9 Hz), 
8.08 (d, J = 8.7 Hz), 7.99 (d, 8.9 Hz), 7.49 (d, J = 8.9 Hz), 6.99-6.93 (m), 4.45-4.38 (m), 4.07-
3.91 (m), 3.72 (s)1,48 (d, J = 7.0 Hz); 
13C NMR (125 MHz, CDCl3) δ 176.0, 173.2, 171.7, 170.3, 150.1, 146.7, 128.4, 124.3, 109.9, 
63.3, 55.9, 52.5, 51.4, 48.7, 47.9, 47.7, 32.9, 30.7, 29.4, 26.2, 25.8, 23.5, 22.9, 18.1, 16.3; 
HRMS (ESI) calc’d for: C27H39N6O10S [M+H]+: 639.2448, found: 639.2459; 
[α]D25 = -46.9° (c = 0.98, CHCl3).  
 
Methyl (2S,5S,8S,11R,17S)-5-(3-(dibenzylamino)propyl)-2,8-dimethyl-17-((4-
nitrophenyl)sulfonamido)-3,6,9,18-tetraoxo-1,4,7,10-tetraazacyclooctadecane-11-
carboxylate (-)-78. 
The reaction was performed using a modified Procedure A, employing and additional iterative 
addition of catalyst, AcOH, and H2O2.  Prior to beginning the reaction, a stock solution of (S,S)-
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Fe(PDP)(MeCN)2(SbF6)2 (9.0mg)  and AcOH (11 µL) in MeCN (200 µL) was prepared.  Four 
vials of H2O2 (4.2 µL, 1.9 equiv., 0.074 mmol) in 350 µL MeCN were prepared and cooled to 
0°C.  Then, macrocyclic pentapeptide (-)-77 (25 mg, 1.0 equiv., 0.039 mmol) was dissolved in 
MeCN (0.2 mL) in a 2-dram vial, and cooled to 0°C.  Catalyst / AcOH stock solution (42 µL) 
was added, followed by dropwise addition of one H2O2 solution over 2-3 minutes, and the 
reaction was allowed to stir for 10 min.  The addition of catalyst / AcOH followed by H2O2 
solution dropwise and stirring for 10 min was iterated three more times, amounting to a total 
addition of catalyst (4 x [1.8 mg, 0.05 equiv., 0.0020 mmol]), AcOH (4 x [2.2 µL, 1.0 equiv., 
0.039 mmol]), and H2O2 (4 x [4.2 µL, 1.9 equiv., 0.074 mmol]).  Immediately after the 
completion of the oxidation, the reaction was diluted with MeOH (1 mL) and dibenzylamine 
(46.2 mg, 6.0 equiv., 0.234 mmol) in MeOH (1 mL) was added, followed by sodium 
cyanoborohydride (14.7 mg, 6.0 equiv., 0.234 mmol).  The vial was capped and heated to 45°C 
for 48h.  The crude reaction mixture was purified via PTLC eluting 2x with 3:2 CH2Cl2 / 
Acetone to afford (-)-78 (10.2 mg, 31% yield, 56% per step).  
1H NMR (500 MHz, Acetone-d6) δ 8.40 (d, J = 8.8 Hz, 2H), 8.10 (d, J = 8.8 Hz, 2H), 7.80-7.61 
(m, 2H), 7.50-7.40 (m, 2H), 7.37 (d, J = 7.6 Hz, 4H), 7.30 (t, J = 7.5 Hz, 4H), 7.22 (t, J = 7.2 Hz, 
2H), 4.29-4.21 (m, 1H), 4.13-3.99 (m, 3H), 3.96 (t, J = 7.0 Hz, 1H), 3.61 (s, 3H), 3.51 (s, 4H), 
3.35-3.26 (m, 2H), 2.45-2.38 (m, 2H), 1.86-1.73 (m, 4H), 1.66-1.54 (m, 4H), 1.50-1.36 (m, 4H), 
1.33 (d, J = 7.2 Hz, 3H), 1.19 (d, J = 7.2 Hz, 3H); 
13C NMR (125 MHz, Acetone-d6) δ 173.4, 172.9, 172.5, 172.2, 171.4, 151.0, 148.0, 140.9, 
129.8, 129.6, 129.1, 127.8, 125.1, 77.4, 58.8, 57.6, 56.1, 54.8, 53.7, 53.5, 52.3, 51.7, 50.2, 34.6, 
31.5, 28.7, 25.4, 23.5, 17.9 (1 peak overlapping or obscured); 
HRMS (ESI) calc’d for: C41H54N7O10S [M+H]+: 836.3653, found: 836.3652; 
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[α]D26 = -27.4° (c = 0.79, MeOH).  
 
X-Ray Crystal Structure Data for 2-Naphthol-Proline Adduct (-)-19. 
 
Crystal data and structure refinement for 1478941. 
Identification code  1478941 
Empirical formula  C28 H26 N2 O7 S 
Formula weight  534.57 
Temperature  193(2) K 
Wavelength  0.71073 ≈ 
Crystal system  Orthorhombic 
Space group  P 21 21 21  
Unit cell dimensions a = 6.1126(9) ≈ α= 90∞. 
 b = 11.1682(16) ≈ β= 90∞. 
 c = 37.608(5) ≈ γ = 90∞. 
Volume 2567.4(6) ≈3 
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Z 4 
Density (calculated) 1.383 Mg/m3 
Absorption coefficient 0.177 mm-1 
F(000) 1120 
Crystal size 0.298 x 0.26 x 0.183 mm3 
Theta range for data collection 1.90 to 25.33∞. 
Index ranges -7<=h<=7, -13<=k<=13, -45<=l<=45 
Reflections collected 28189 
Independent reflections 4703 [R(int) = 0.0362] 
Completeness to theta = 25.33∞ 100.0 %  
Absorption correction Integration 
Max. and min. transmission 0.9821 and 0.9512 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4703 / 0 / 350 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0290, wR2 = 0.0701 
R indices (all data) R1 = 0.0326, wR2 = 0.0725 
Absolute structure parameter -0.06(6) 
Largest diff. peak and hole 0.132 and -0.240 e.≈-3 
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X-Ray Crystal Data for Indole-Proline Adduct (+)-23. 
 
 
Crystal data and structure refinement for 1478940. 
Identification code  1478940 
Empirical formula  C26 H23 N3 O8 S2 
Formula weight  569.59 
Temperature  183(2) K 
Wavelength  0.71073 ≈ 
Crystal system  Orthorhombic 
Space group  P 21 21 21  
Unit cell dimensions a = 9.8392(11) ≈ α= 90∞. 
 b = 10.6710(12) ≈ β= 90∞. 
 c = 24.909(3) ≈ γ = 90∞. 
Volume 2615.3(5) ≈3 
Z 4 
Density (calculated) 1.447 Mg/m3 
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Absorption coefficient 0.259 mm-1 
F(000) 1184 
Crystal size 0.38 x 0.359 x 0.262 mm3 
Theta range for data collection 2.08 to 25.35∞. 
Index ranges -11<=h<=11, -12<=k<=12, -30<=l<=30 
Reflections collected 28691 
Independent reflections 4790 [R(int) = 0.0356] 
Completeness to theta = 25.35∞ 99.9 %  
Absorption correction Integration 
Max. and min. transmission 0.9591 and 0.9253 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4790 / 331 / 435 
Goodness-of-fit on F2 1.050 
Final R indices [I>2sigma(I)] R1 = 0.0261, wR2 = 0.0668 
R indices (all data) R1 = 0.0276, wR2 = 0.0682 
Absolute structure parameter -0.03(4) 
Largest diff. peak and hole 0.135 and -0.322 e.≈-3 
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X-Ray Crystal Data for Benzothiophene-Proline Adduct (+)-24. 
 
 
Crystal data and structure refinement for 1478939. 
Identification code  1478939 
Empirical formula  C21 H20 N2 O6 S2 
Formula weight  460.51 
Temperature  100(2) K 
Wavelength  0.71073 ≈ 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 7.9013(3) ≈ α= 90∞. 
 b = 13.6408(6) ≈ β= 90∞. 
 c = 18.8526(8) ≈ γ = 90∞. 
Volume 2031.93(15) ≈3 
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Z 4 
Density (calculated) 1.505 Mg/m3 
Absorption coefficient 0.306 mm-1 
F(000) 960 
Crystal size 0.395 x 0.278 x 0.062 mm3 
Theta range for data collection 2.161 to 27.200∞. 
Index ranges -10<=h<=10, -17<=k<=17, -11<=l<=24 
Reflections collected 18166 
Independent reflections 4518 [R(int) = 0.0375] 
Completeness to theta = 25.242∞ 99.8 %  
Absorption correction Integration 
Max. and min. transmission 1.0000 and 0.9040 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4518 / 0 / 282 
Goodness-of-fit on F2 1.030 
Final R indices [I>2sigma(I)] R1 = 0.0286, wR2 = 0.0696 
R indices (all data) R1 = 0.0317, wR2 = 0.0718 
Absolute structure parameter 0.01(3) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.303 and -0.259 e.≈-3 	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